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T
he beneficial effects of modern 
health care are greatly dependent 
on medical technology. For an es-
timated 98% of all hospital admis-
sions in the Netherlands, medical technology is 
used.[1] In the past decades, the technical de-
velopments have advanced and consequent-
ly, life expectancy and quality of life have in-
creased. For example, cardiac implantable 
electronic devices have prolonged the lives of 
many patients worldwide because conduction 
disorders, atrial and ventricular fibrillation and 
subsequent heart failure can be treated by im-
plantation of increasingly sophisticated pace-
makers, ICD’s and CRT-devices.[2-3] However, 
recent major incidents of deficient medical 
devices – mainly concerning implants – have 
illustrated that patient safety and trust in medi-
cal devices can be seriously affected by failures 
and recalls.[4] Consequently, there is a need to 
detect potential failures and complications as 
early as possible.
Patient safety became an issue after the pub-
lication of the Institute of Medicine report To 
Err Is Human; Building a safer health system 
in 1999[5]. This report addressed the effects of 
medical errors and their causes. The report led 
to several patient safety initiatives and compa-
rable studies worldwide, among which in the 
Netherlands.[6-7] Where many studies focused 
on medical and medication errors, two Dutch 
studies also included adverse events related to 
the use of medical technology.[1, 8] These stud-
ies concluded that for 2.7-2.9% of all hospital 
admissions medical technology related injuries 
occurred. Placing of implants contributed rela-
tively mostly to health care related injuries and 
included infections, bleeding and perforations. 
However, as product failures or long-term inju-
ries following implantation were not included, 
the actual percentage of implant related inju-
ries is expected to be higher.[1]
Device failures and related complications may 
not become apparent until the post-market-
ing phase, as was the case for many major 
incidents in the past. Examples are the met-
al-on-metal hip implants, Björk Shiley heart 
valves, the Sprint Fidelis leads from Medtronic 
and Riata leads from St. Jude.[9-13] Advisories 
and recalls of implants have major impact on 
the life of involved patients. If surgery is need-
ed for replacing a defective implant, the risks 
of such surgery must be weighed against the 
risks of occurrence of device failure. In case a 
failure is life threatening, patients may have to 
live with a constant fear that their implant stops 
functioning.[14-16] which was illustrated by the 
problems with the Björk Shiley heart valve. A 
particular type of this heart valve appeared to 
have a risk of device fracture, leading to death 
in two thirds of the cases. The valve was re-
called and class actions by worried patients 
and family of deceased patients followed.[12, 17] 
Even if there are no failures, medical devices 
and particularly implants are never without 
risk. Device related injuries are not necessar-
ily caused by device failures alone. Insufficient 
training of health care professionals, insufficient 
evidence based application of technologies 
and even negligence may contribute to compli-
cations and injuries.[18] Regarding the problems 
with the use of transvaginal mesh, incidents 
were at least partly also a consequence of 
the conduct of medical professionals; the im-
plants were quickly incorporated into clinical 
practice without proper clinical evaluation by 
the field and insufficient consideration of alter-
native treatments.[19-21] Additionally, underlying 
co-morbidity and patient related factors such 
as age, predisposition to allergies and level of 
physical activity may also influence efficacy, 
effectiveness, and complication rates of device 
therapies. All these factors should be included 
in the decision-making process for the best ap-
plicable treatment and the expected positive 
effects must be carefully balanced against pos-
sible failures and complications of devices.
Regardless of the cause of major device related 
incidents and failures, they have made the pub-
lic, media, politics, and regulatory authorities to 
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question the rigor of existing medical devices 
legislation and its ability to sufficiently protect 
patients. This discussion intensified after the 
problems with PIP breast implants emerged, 
where the manufacturer fraudulently used in-
dustrial silicone instead of medical grade sili-
cone in their implants for several years while 
misleading the notified body during audits of 
the production process.[4, 22-25] 
Market entry
In this context, a comparison with the US leg-
islation is often made in favor of the US as it 
would be stricter and more protective for pa-
tients.[4, 24, 26] However, also in the US several 
major problems with implants have occurred, for 
example the insulation failures with Medtronic 
Sprint Fidelis leads and St. Jude’s Riata leads, 
the problems with metal-on-metal hip implants, 
and with transvaginal pelvic floor mesh.[9, 10, 19] 
Due to the nature of medical devices and par-
ticularly implants, exhaustive clinical trials are 
not always possible and even in cases where 
clinical trials have been performed, failures and 
device related complications may not become 
apparent until after the devices have been used 
in a larger population and for a longer period 
of time.[27] Therefore, and contrary to pharma-
ceuticals, medical devices regulation puts more 
focus on post-market surveillance than on the 
pre-market approval regulations.
Medical devices are allowed on the European 
market when they comply with the essential 
requirements as laid down in the European 
Directives on medical devices and active im-
plantable medical devices.[28-29] By applying the 
CE-mark to a device, the manufacturer claims 
such compliance. This Conformité Europeène 
marking is the device’s passport which grants 
it access to all 28 Member States of the Euro-
pean Union and the European countries which 
are not Member States, but have implemented 
this legislation. These are the European Free 
Trade Associations (EFTA), comprising of Nor-
way, Switzerland, Liechtenstein and Iceland.[30]
The medical devices directives seek harmoni-
zation of legislation across Europe in order to 
facilitate trade, while also setting a standard for 
safe and effective devices.[28-29, 31] In achieving a 
risk lever that is as low as possible, the essen-
tial requirements primarily focus on a safe de-
vice design. Any residual risks need to be miti-
gated preferably by alarms on the device itself 
and if this is not possible as is the case for sev-
eral implants, they should be mentioned in the 
instructions for use. As part of the risk analysis, 
a manufacturer is required to identify all risks of 
normal use and of any reasonably foreseeable 
misuse of the device. This risk analysis must 
be continuously updated, also in the post-mar-
keting phase. A trusted third party, the notified 
body, assesses the conformity of a device 
with the essential requirements. This process 
entails the assessment of the technical docu-
mentation that needs to be available for each 
device, audits of the production facilities and 
audits of the quality management system. In 
the post-marketing phase, manufacturers need 
to inform their notified body – but also relevant 
European competent authorities – of incidents, 
field safety corrective actions and relevant in-
formation emerging from the post-marketing 
surveillance activities. The Directives will be 
replaced by a single regulation which entered 
into force in May 2017 and will be fully appli-
cable in 2020.[32] Contrary to the Directives, the 
regulation is applicable in all European coun-
tries without the need for implementation in na-
tional legislation. Important changes are more 
requirements regarding robust clinical evidence 
before and more rigorous post-marketing sur-
veillance after market entry of a device.
In essence, the EU regulatory system does not 
differ to a great extent from that in the US; both 
systems have a market entry route via demon-
stration of equivalency with existing, similar de-
vices and a pre-market approval route for high 
risk devices.[31, 33-34] Implants such as pacemak-
ers and artificial hip prostheses are regarded 
as high risk medical devices and belong to the 
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group of most strictly regulated products, which 
have to follow a thorough pre-market approv-
al or conformity assessment procedure. In the 
USA, a pre-market approval by the Food and 
Drug Administration (FDA) is necessary, al-
though (minor) changes to a product already on 
the market may be approved via less extensive 
supplemental procedures.[35] In Europe, confor-
mity to the essential requirements needs to be 
proven and in the case of high risk devices such 
as pacemakers and hip prostheses, an assess-
ment of conformity with full design examination 
by a notified body is necessary. Providing clinical 
evidence is part of both procedures, but the type 
of information that is considered acceptable 
as clinical evidence differs.[30] The fact that in 
the US the pre-market approval assessment is 
performed by the governmental FDA, whereas 
in the EU conformity assessment is performed 
by notified bodies is an important difference be-
tween both systems. However, notified bodies 
oversee all high-risk devices, whereas high-risk 
devices that are allowed on the US market by 
equivalency via the 510(k) procedure are not as-
sessed by the FDA.[31, 33-34]
During the market authorization process, a man-
ufacturer must provide proof of conformity with 
the essential requirements. This proof is partial-
ly based on clinical data, which can either be 
(1) a critical appraisal of scientific literature of a 
device to which equivalence has been demon-
strated, (2) the results of a clinical investigation 
or (3) a combination of both.[34] However, not all 
defects, failures and complications can be iden-
tified during such studies. Bench testing may not 
always be comparable to use in actual patients 
and clinical studies usually include only a lim-
ited number of participants. Furthermore, after 
marketing, the population in which the implant 
is actually used could significantly differ from the 
study population. Consequently, rare events and 
complications may only emerge after the device 
has been marketed and used in several thou-
sands of patients. Therefore, post-market sur-
veillance (PMS) is necessary for the evaluation 
of device performance in real-life.[27] Manufactur-
ers are legally obliged to ‘institute and keep up 
to date a systematic procedure to review experi-
ence gained from devices in the post-production 
phase, and to implement appropriate means to 
apply any necessary corrective action’. Unfor-
tunately, legislation does not define how this 
should be done.[4, 34, 36] However, information for 
post-marketing surveillance can come from dif-
ferent sources. One used by all manufacturers 
is the collection and analysis of complaints and 
incident reports. However, this passive form of 
data collection is prone to underreporting and 
should be complemented with activities such as 
post-market clinical follow-up studies, enquiries, 
user panels and other pro-active sources. 
Post-market phase
Post-market information is also relevant to the 
competent authorities overseeing the field of 
medical devices and its legislation.  In case a 
device poses an unacceptable risk for patient 
safety, and is insufficiently addressed by the 
manufacturer, competent authorities can take 
measures such as requiring the manufacturer 
to take corrective actions or perform a recall. 
If a device should be removed from the mar-
ket, the involved notified body can withdraw the 
CE-certificate.[30, 34] Ultimately, legislation allows 
competent authorities to remove a device from 
the market if the risk is severe and other mea-
sures are not sufficient or appropriate.[28-29, 34] 
Additionally, depending on national legislation 
authorities may impose fines, as is the case for 
France, the United Kingdom and the Nether-
lands.[37-39]
Competent authorities rely on several, most-
ly external, sources of information on device 
safety. These are their own market surveillance 
activities such as inspections of manufacturers 
and studies on products or product groups. The 
latter are generally based on technical files of 
products, literature studies and/or biocompat-
ibility studies. Such activities may differ be-
tween competent authorities. 
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In general, clinical trials with devices are the 
responsibility of manufacturers as part of the 
pre-market authorization and post-market clin-
ical follow-up processes. Other sources of in-
formation are the obligatory vigilance reports 
by manufacturers and depending on national 
legislation, mandatory and/or voluntary reports 
by health care professionals, and reports by 
patients.[34] Therefore, it is important that health 
care professionals realize that they have a role 
in reporting negative trends or experience with 
structurally deficient devices to manufacturers 
and competent authorities. Detection of device 
problems as early as possible is of paramount 
importance for authorities. Following incidents 
with metal-on-metal hip implants and transvag-
inal mesh, the Dutch competent authority ad-
vised to establish a register where patients can 
report adverse events and unwanted side-ef-
fects.[13, 21] Such a system has been established 
and started in July 2017, with a focus on report-
ing of events related to implants.[40]
Despite current initiatives, the availability of 
comprehensive registries that may be useful 
for information on device performance is lim-
ited to date and those that are available are 
often not accessible to manufacturers or com-
petent authorities. Registers can provide data 
on long term safety, performance, and reliabil-
ity and allow early identification of problems, 
which has been proven for the metal-on-metal 
hip implants in the past.[4] For the studies de-
scribed in this thesis, existing registries have 
been used; a utilization register on pacemak-
ers and a national hospital discharge records 
database. These databases are some of the 
few long-term registries that are available. Fur-
thermore, data were used from a prospective 
population-based cohort study with up to 25 
years of follow-up. Below, these databases are 
described in short.
CPPR-SPRN
The Netherlands Pacemaker Registry Foun-
dation (CPPR-SPRN) was established in 1982 
and the computerised Central Pacemaker Pa-
tients Registration was started. The aims of the 
registry were to get an overview of: 1) patient 
and implant characteristics; 2) trends in types 
of pacemakers and leads; and 3) the annual 
number of implants per clinic and nationwide. 
Furthermore, the objectives of the registry 
were to inform the participating clinics and re-
cipients about quality issues with pacemakers 
and leads, to exchange information with other 
European countries, and to increase indirect 
patient care by furnishing information to clinics 
about pacemakers implanted elsewhere and 
to patients about pacemaker centers in other 
countries.[41-43] 
Cardiologists and pacemaker technicians 
were requested to register the data on the 
patient, device and leads on the pacemaker 
card. Each recipient of a pacemaker was reg-
istered in the database. Data on symptoms, 
indication and diagnosis, brand of pacemaker 
and leads, type, follow-up visits, explantation, 
hospital transfer and death were registered 
according to European Registry Guidelines 
established in 1982 and later. When CP-
PR-SPRN ended its registration activities 
in December 2007, data on 174,405 first im-
plantations and replacements, with 204,920 
leads, had been recorded for 136,342 pa-
tients for 25 years.[41-43] 
Until 1989, data were centrally registered 
by sending a carbon copy of the pacemaker 
card to the registry. From 1989 onwards, dig-
italised registration was used with automatic 
communication between the central registra-
tion computer and the local computer of the 
implanting centre. During the daily conver-
sions into the database, multiple checks were 
performed on: missing data, conformation 
with already stored information and plausibil-
ity.[41] Additionally, the data were periodically 
returned to the clinics for correction purpos-
es. A validation process in order to obtain 
better insight into the quality of the database 
was performed in 1997.[42]
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National hospital discharge 
records database
The nationwide electronic database with hos-
pital discharge records in The Netherlands 
(Landelijke Medische Registratie, LMR) cov-
ered admissions in all general and university 
medical centers.[44] The database included, 
among others, demographics, date of admis-
sion and discharge, main intervention (cod-
ed), type of medical specialist (coded), and 
the main and up to 9 secondary diagnoses at 
discharge, based on the International Classifi-
cation of Diseases, 8th Revision, Clinical Modi-
fication (ICD-9-CM) coding system.[45] Registra-
tion of the main diagnosis was mandatory, the 
others were optional. Characteristics of all hos-
pitalizations, polyclinical visits excluded, were 
registered by medical doctors on the basis of 
hospital discharge letters and coded by profes-
sional code clerks. The coding was indepen-
dent of reimbursement of hospital or specialist. 
All diagnoses were submitted in the same for-
mat, mostly electronically. 
The purpose of the registry was to provide 
medical-administrative information regarding 
hospital care in the Netherlands to support gov-
ernmental and hospital policy. Additionally, it 
could provide bench-mark information to hospi-
tals and medical specialists. The data was also 
available for scientific research. Unfortunately, 
the LMR-registry has been replaced by a new 
registry in 2006 which encompasses a sys-
tem of ‘diagnosis-therapy combinations’ [diag-
nose-behandelcombinatie (DBC)]. The DBCs 
lack relevant epidemiologic information such 
as a coded diagnosis. Furthermore, the choice 
for a DBC may depend on reimbursement, and 
could therefore introduce the possibility of diag-
nostic information bias.[44, 46] 
The Rotterdam Study
The Rotterdam Study (RS) is a large prospec-
tive population based cohort study on the oc-
currence and determinants of disease and 
disability in older persons. The study started in 
1990, consisting of a cohort of inhabitants of 
Ommoord, a suburb of Rotterdam, who were 
55 years or older and lived in Ommoord for at 
least one year. Initially, the study started with 
7983 persons (78% of 10,215 invitees). In 2000 
and 2006 two more cohorts were added, the 
latter also included all inhabitants aged 45-
54 years. The overall response figure for all 
three cohorts at baseline was 72% (14,926 of 
20,744 eligible subjects). In February 2016, a 
fourth cohort was started. The participants of 
the study are followed for a variety of diseases 
that are frequent in the elderly, such as cardio-
vascular, locomotor, respiratory, neurological 
and psychiatric diseases. Additionally, pharma-
co-epidemiologic studies, and genomics, epi-
genetics, metabolomics and other biomarker 
studies were performed. The purpose of these 
epidemiologic studies was to gain insight in the 
etiology, prevention and prediction of disorders 
and diseases.[47] Medical implants are not reg-
istered in this study, but for several studies de-
scribed in this thesis, the data were used for 
validation purposes. 
Aim and outline of this thesis
The aim of this thesis was to gain more in-
sight into the use of medical registries as a 
source of information on complications and 
failures of implants. For this purpose, we 
used two databases; the Central Pacemaker 
Patients Registration (CPPR-SPRN) contain-
ing all first pacemaker implantations and their 
replacements between January 1984 and 
December 2007, and the National Hospital 
Discharge Records Database (LMR) contain-
ing all hospital admissions and discharges 
from 2000-2005.
Part I contains studies based on the CP-
PR-SPRN registry. In chapter 2.1 we first de-
scribe the utilization of cardiac pacemakers in 
the Netherlands over a 20-year period. Sec-
ondly, we assessed the number and reasons of 
explantations, and the service time of the pace-
maker generators (chapter 2.2). In this study, 
General introduction14 Chapter 1
we used the Rotterdam Study to validate the 
mortality data as registered in the CPPR-SPRN 
registry. Thirdly, in chapter 2.3 we analyzed the 
trends in service time of pacemaker leads, 
and the number and reasons for explantation. 
In part II we investigated the usability of the 
LMR registry for analysis of several clinical in-
terventions using implants. First, in chapter 3.1 
we analyzed the complications after hip arthro-
plasty, both after injury and for elective reasons. 
We have reviewed whether re-admissions due 
to complications are associated with hospital 
procedure volume. Furthermore, we have in
vestigated the incidence of and treatments for 
subarachnoid hemorrhage (SAH), a devastat-
ing disorder which is caused by rupture of an 
intracranial aneurysm in the majority of cases 
(chapter 3.2). Finally, in chapter 3.3 we stud-
ied three invasive procedures for treatment of 
trigeminal neuralgia (TGN). We assessed the 
frequency of use and the failure of these treat-
ments. In chapter 4 we reflect on our main find-
ings and discuss the use of registries as source 
of information on implant performance. Chap-
ter 5 contains a summary in both English and 
chapter 6 a summary in Dutch.
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Abstract
Background 
The implantation of cardiac pacemakers has become a well-established therapy for conduction 
disorders and sinus node dysfunction. In many countries pacemaker registries have been initiated 
in order to collect information on patient characteristics, trends in numbers and the types of pace-
makers used, to identify problematic devices, and for safety monitoring. 
Methods 
For this utilisation study the Central Pacemaker Patients Registration (CPPR) from the Nether-
lands Pacemaker Registry Foundation (CPPR-SPRN) containing data collected for more than 20 
years was used. 
Results 
During this period, nearly 97,000 first pacemakers were implanted. Analyses show an increase in 
the rate of implanted devices. The change in pacemaker type from VVI to DDD, followed by biven-
tricular stimulation, is reflected by the number of simultaneously implanted leads, which is partly a 
consequence of cardiac resynchronisation therapy. 
Conclusion 
Our data demonstrate that indications for implantation and type of pacemaker are comparable 
with other European countries. 
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A 
dvantages of cardiac pacing have 
been established in the past de-
cades for conventional indications 
such as conduction disorders, and 
with new applications for treatment of arrhyth-
mias and heart failure being added, clinical inves-
tigation is ongoing. Implantation of cardiac pace-
makers has prolonged the lives and improved the 
quality of life of many patients.[1-3] Despite these 
advantages, implantation of devices is also inev-
itably associated with complications and may be 
prone to product defects. This was illustrated by 
several major cases and recalls in the past, such 
as the Accufix leads for cardiac pacemakers.[4-7] 
In many countries device registries were ini-
tiated by individual cardiologists or national 
societies in order to gain insight into patient 
characteristics, trends in numbers and the 
types of pacemakers used, to inform partici-
pating centres about problematic devices, and 
to exchange information between countries.
[8-10] However, most of these registries were 
restricted to a limited number of hospitals or 
geographical areas. In the Netherlands, reg-
istration with the intention to record every 
pacemaker implanted in Dutch hospitals was 
initiated in 1982. This registry, maintained by 
the Netherlands Pacemaker Registry Founda-
tion (SPRN), was kept until 2008 after which 
the Netherlands Society of Cardiology started 
a new registration: the Dutch ICD and Pace-
maker Registration (DIPR), which was recently 
integrated into the overarching National Cardio-
vascular Data Registry (NCDR). 
The objective of the current analysis was to 
study changes in the utilisation of cardiac pace-
makers for new implantations over a period of 
more than 20 years in a country with the nearly 
nationwide pacemaker registry CPPR-SPRN.
Methods
Setting
Data were retrieved from the Central Pace-
maker Patients Registration (CPPR) from the 
Netherlands Pacemaker Registry Foundation 
(CPPR-SPRN). In 1982, CPPR-SPRN was es-
tablished and the computerised Central Pace-
maker Patients Registration was started. The 
aims of the registry were to get an overview 
of: 1) patient and implant characteristics; 2) 
trends in types of pacemakers and leads; and 
3) the annual number of implants per clinic and 
nationwide. Furthermore, the objectives of the 
registry were to inform the participating clinics 
and recipients about quality issues with pace-
makers and leads, to exchange information 
with other European countries, and to increase 
indirect patient care by furnishing information 
to clinics about pacemakers implanted else-
where and to patients about pacemaker cen-
tres in other countries.
Cardiologists and pacemaker technicians were 
requested to register data on the patient, de-
vice and leads on the pacemaker card. Each 
recipient of a pacemaker was registered in the 
database. Data on symptoms, indication and di-
agnosis, brand of pacemaker and leads, type, 
follow-up visits, explantation, hospital transfer 
and death were registered according to Euro-
pean Registry Guidelines established in 1982 
and later. When CPPR-SPRN ended its reg-
istration activities in December 2007, data on 
174,405 first implantations and replacements, 
with 204,920 leads, had been recorded for 
136,342 patients during 25 years.[8] 
Monitoring and validation of data
Until 1989, data were centrally registered by 
sending a carbon copy of the pacemaker card 
to the registry. From 1989 onwards, digitalised 
registration was used with automatic commu-
nication between the central registration com-
puter and the local computer of the implanting 
centre. During the daily conversions into the 
database, multiple checks were performed on: 
missing data, conformation with already stored 
information and plausibility.[11] Additionally, the 
data were periodically returned to the clinics for 
correction purposes. A validation process in or-
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Womena Mena p-value for differenceb
All fi rst 
implantations
Total number of first implantations 45,661 (47,1) 51,164 (52.8) <0.001c 96,900
Mean age, years (SD) 74.6 (12.6) 71.4 (13.2) <0.001 72.9 (13.0)
Median age, years 77.0 74.0 75.0
Age ≥60 years, n (%)  41,457 (90.8) 43,637 (85.3) <0.001 85,165 (87.9)
Age ≥80 years, n (%)  17,489 (38.3)  12,208 (23.9) <0.001 31,569 (32.6)
ECG, n (%):
   Sick sinus syndrome 20,166 (44.2) 20,847 (40.7) <0.001 41,026 (42.3)
   Heart block 17,612 (38.6) 20,050 (39.2) 0.049 37,682 (38.9)
   Bundle branch block 1537 (3.4) 2582 (5.0) <0.001 4121 (4.3)
   Normal sinus rhythm 
     (with or without abnormal EPS) or not documented 940 (2.1) 1164 (2.3) 0.021 2104 (2.2)
   Other 541 (1.2) 691 (1.4) 0.022 1232 (1.3)
   Unknown/uncoded/unspecified 4865 (10.7) 5830 (11.4) <0.001 10,735 (11.1)
Symptoms, n (%):
   Syncope 13,004 (28.5) 14,651 (28.6) 0.592 27,672 (28.6)
   Dizzy spells 12,749 (27.9) 12,973 (25.4) <0.001 25,728 (26.6)
   Bradycardia 9,485 (20.8) 10,908 (21.3) 0.037 20,398 (21.1)
   Dyspnoea/heart failure 2396 (5.2) 3064 (6.0) <0.001 5462 (5.6)
   None/prophylactic 751 (1.6) 1132 (2.2) <0.001 1884 (1.9)
   Tachycardia 866 (1.9) 876 (1.7) 0.031 1743 (1.8)
   Other 215 (0.5) 267 (0.5) 0.260 483 (0.5)
   Unknown/uncoded/unspecified 6195 (13.6) 7293 (14.3) 0.002 13,530 (14.0)
Aetiology, n (%):
   Conduction tissue disease 5219 (11.4) 5401 (10.6) n.c. 10,623 (11.0)
   Ischaemic 2100 (4.6) 2718 (5.3) n.c. 4818 (5.0)
   Therapy induced 1603 (3.5) 1978 (3.9) n.c. 3583 (3.7)
   Cardiomyopathy 1170 (2.6) 1400 (2.7) n.c. 2572 (2.7)
   Post myocardial infarction 716 (1.6) 1528 (3.0) n.c. 2244 (2.3)
   Congenital 394 (0.9) 348 (0.7) n.c. 742 (0.8)
   Other 182 (0.4) 446 (0.9) n.c. 628 (0.6)
   Unknown/uncoded/unspecified, n (%) 34,277 (75.1) 37,345 (73.0) n.c. 71,690 (74.0)
Table 1. Baseline characteristics of the patients at implantation of first pacemaker
EPS: electrophysiological study
a For 75 patients the sex is unknown, for 38 males and 22 females age is unknown
b P-value was not calculated for aetiology because of large proportion of missing data (n.c.)
c For 1995-2005
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der to obtain better insight into the quality of the 
database was performed in 1997.[12]
Cohort 
Based on the available data, an inception co-
hort of patients was formed containing all first 
implanted pacemakers during the period 1 Jan-
uary 1984 until 1 January 2006. A total of 353 
implantations were excluded because of incon-
sistencies in the registered data, such as a new 
implantation being registered after the sup-
posed date of death of a patient, or the same 
pacemaker registered more than once with dif-
ferent explantation dates, leaving 96,900 first 
implantations for analysis.
At the start of the registration in 1984, 120 hos-
pitals participated, some of which were sub 
locations of the same hospital but participated 
independently. During the study period several 
locations and/or hospitals merged and the reg-
istry was continued under one account, leaving 
101 participants in the registry. General popula-
tion data were obtained from Statistics Nether-
lands (CBS, www.cbs.nl/en-GB/). 
Analysis
We computed straightforward descriptive sta-
tistics for the aetiology, pacemaker types, and 
the prevalences of symptoms and ECG char-
acteristics as percentages of all first implan-
tations. For implantation rates, we calculated 
Poisson intervals. For the comparison of nor-
mally distributed continuous determinants, we 
used independent samples T-tests while cate-
gorical determinants were compared with chi-
square statistics. All statistical analyses were 
performed in IBM SPSS Statistics version 20.0 
(IBM Corp., Somers, New York, USA). 
Results
Between 1 January 1984 and 1 January 2006, 
96,900 first pacemakers were implanted (Ta-
ble 1). This corresponds to an average number 
of implantations of more than 4600 devices per 
year, varying from a total of 3236 first implan-
tations in 1984 (225 implants per million inhab-
itants) to 6901 first implantations in 2005 (423 
implants per million inhabitants). 
One hospital performed nearly 4000 first im-
plantations during the study period, which is 
approximately 4% of the total number of first 
implantations. One hospital implanted more 
than 2600 first pacemakers (2.7%), 5 hospi-
tals implanted between 1900 and 2500 pace-
makers each (2-2.5%), another 36 hospitals 
Figure 1. Number of first implantations per 1000 inhabitants per province. 1984 and 1985 excluded to create equal 
time periods, additionally no population data are available for these years for Flevoland.
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implanted between 900 and 1900 pacemakers 
each (1-2%). All other hospitals each implanted 
less than 1% of the total number of first pace-
makers. Eight of these hospitals did not partic-
ipate in the registration until the early 1990s. 
Six hospitals did not start until the late 1990s 
or early 2000s. Two hospitals implanted less 
than 10 first pacemakers per year. Most pace-
makers per 1000 inhabitants were implanted 
in the province of Groningen, followed by the 
provinces of Overijssel and Limburg (Figure 1 
and Table 2). 
The cohort comprised 52.8% men (n=51,164). 
Starting in 1995 the number of implantations 
in men was significantly higher than in women 
(p<0.001) in each following year. In the period 
before 1995 the number of implants in men was 
only significantly higher in the years 1985, 1986 
and 1992 (Table 1 and Figure 2). Mean age for 
the total cohort was 72.9 years (SD 13.0). The 
mean age at first implantation increased from 
71.1 in 1984 to 72.3 in 2005 for men (mean dif-
ference 1.2 years, p=0.003) and from 72.8 to 
75.1 for women (mean difference 2.3 years, 
p<0.001). The majority of the patients were 
over 60 years of age (87.9%) and pacemakers 
were most often implanted in the age group 
of 60 to 80-year-olds. The percentage of first 
implantations in octogenarians and nonage-
narians is constant over the years. However, 
first implantations in these groups have been 
increasing since 2002. The most common in-
dications were sick sinus syndrome (n=41,026; 
42.3%) and heart block (n=37,682; 38.9%). This 
did not change over the years (Figure 3). The 
number of pacemaker implantations for both 
Figure 2. Number of first implantations per 100,000 inhabitants by sex 
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sick sinus syndrome and bundle branch block 
significantly differed between men and women 
(p<0.001). All baseline characteristics are pro-
vided in Table 1.
Pacemakers of 18 different manufacturers 
were implanted between 1984 and 2005. The 
ventricular pacing and sensing (VVI) and du-
al-chamber pacing and sensing, rate response 
(DDDR) types were the most commonly used 
pacemakers: 34.3% and 23.1%, respectively 
(Table 3). The other types, ventricular pacing 
and sensing, rate response (VVIR, 15.2%) 
and dual-chamber pacing and sensing (DDD, 
16.1%), were used less often. However, during 
the early 1990s implantation of pacemaker 
types changed markedly from a mainly VVI 
type (single chamber systems) to a DDDR type 
(dual chamber systems) as depicted in Figure 4. 
At least 138,225 leads were implanted with the 
96,900 first pacemakers. In two thirds of the 
cases the leads were placed in the ventricle. 
For 1024 implantations (1%) no leads were reg-
istered. For 83% of these implantations the type 
of pacemaker was also not registered. More 
than 80% of these pacemakers were implanted 
during the last 5 years of the study period.
Additionally, after the introduction of cardi-
ac resynchronisation therapy (CRT) around 
1995[13], the use of biventricular pacing in-
creased between 2000 and 2005. This change 
of pacemaker type is also reflected by the 
number of first implantations with three leads 
(n=1269), 914 (72.3%) of which for the indica-
tion dyspnoea/heart failure and 65 (5.1%) for 
Figure 3. Indication for first pacemaker implantation, adjusted for number of implantations per year. BBB = bundle 
branch block; SSS = sick sinus syndrome; normal sinus rhythm with or without abnormal electrophysiological study
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bradycardia. The other first implantations with 
three leads were for various other indications
(n=96, 7.6%) and unknown, uncoded or un-
specified indications (n=190, 15.0%).
Discussion
In the Netherlands, the SPRN registry was 
operational for more than 20 years to collect 
pacemaker implantations with nearly com-
plete nationwide coverage; almost 97,000 pa-
tients received a pacemaker for the first time 
between 1984 and 2006. The registry showed 
that the number of implanted pacemakers has 
increased steadily over the past few decades. 
This increase continued in later years (2003-
2012).[14] 
The number of first implantations per million 
Dutch inhabitants was below the European 
average: 314, 294, and 532 implantations per 
million inhabitants in 2001, 2005, and 2009,
respectively, compared with an average of 390, 
475, and 552 implantations per million inhabi-
tants in Europe.[15-17] Stofmeel and colleagues[18] 
also reported that the Netherlands had a 
smaller number of implantations compared 
with other European countries over the period 
1984-1997. This may be a consequence of re-
luctance to use pacemakers for indications for 
which there was limited evidence at that time, 
such as asymptomatic total AV-block or asymp-
tomatic second-degree AV-block, type Wencke-
bach, or syncope which is not proven to be a 
consequence of a total AV-block in patients with 
a bifascicular or trifascicular block and other 
causes for syncope cannot be excluded. At that 
time, there was no agreement for those indica-
tions (class 2 indications), as was formulated in 
Figure 4. Type of pacemaker at first implantation
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the 1999 Dutch pacing guidelines.[18,19] 
The difference in implantation rates between 
provinces does not seem to be related to differ-
ences in the age of the population. Some prov-
inces with a higher implantation rate have a 
younger population than provinces with a lower 
implantation rate. In some provinces one or two 
hospitals are responsible for more than half of 
the implantations performed in that province. 
These hospitals could be ‘hot spots’ that treat 
patients from a wider area than the province 
alone. When done on a regular basis, pace-
maker implantation is safe. However, operator 
volume appears to count when it comes to 
quality of care. A concentration of procedures 
in centres where cardiologists implant at least 
50 devices per year has therefore been sug-
gested previously.[20]
Sick sinus syndrome and heart block were the 
major indications for pacemaker implantation. 
Sick sinus syndrome was significantly pre-
dominant in women. This could be attributed 
to the fact sick sinus syndrome occurs more 
often in female than in male individuals.[21] 
The indications for pacemaker implantations 
found in our study are in line with the major in-
dications in other European countries. During 
the early 1990s physiological pacing and the 
use of adaptive pacing frequencies with dual 
chamber systems (DDD(R)) were increasingly 
used compared with single chamber systems 
(VVI(R)). From the more recent World Society 
of Arrhythmias (WSA) surveys it appeared that 
indeed virtually all countries had increased 
percentages of DDDR pacemaker implanta-
tions.[15-17, 22] A modest increase of implantation 
for bundle branch block is visible over the pe-
riod 2000 to 2005, especially in men. This may 
be explained in part by the increased use of 
biventricular pacemakers for cardiac resyn-
chronisation therapy. CRT devices with ICD 
function (CRT-D) were not registered in this 
database and are therefore not included in the 
current analysis. Internationally, an increase 
of non-bradyarrhythmic indications for cardiac 
pacing was projected, however remained a mi-
nor indication with approximately 5% or less in 
most countries.[15-17, 22] In the Netherlands this 
percentage remained less than 5% for a long 
time, but started increasing in the early 2000s. 
Limitations
An important limitation of the data is that reg-
istration lies in many hands, which facilitates 
registration errors such as typographical er-
rors and duplicate registrations of patients 
transferred to another hospital. We removed 
these duplicates whenever possible. Howev-
er, some may have been overlooked due to 
unavailability of highly detailed patient-related 
data needed to distinguish duplicate records. 
Nevertheless, 99% of all implantations are 
registered[12, 18] and the data provide useful 
information; therefore, errors are expected 
to be random with regard to indication and 
pacemaker properties. In contrast to the ECG 
data and symptoms, information on aetiology 
is absent in most cases. However, in cardi-
ology practice it appears to be very difficult 
to establish the precise cause of cardiac or 
non-cardiac disease that elicits rhythm or con-
Pacemaker type n (%)
VVI 33,241 (34.3)
VVIR 14,704 (15.2)
DDD 15,636 (16.1)
DDDR 22,424 (23.1)
AAI 1500 (1.4)
AAIR 1350 (1.4)
VDD 2677 (2.8)
VDDR 1123 (1.2)
Biventricular pacing 1269 (1.3)
Unknown 2,976 (3.1)
Table 3. Type of first pacemakers 
implanted in the period 1984-2005 
in the Netherlands (n=96,900)
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duction disturbances. Additionally, the type of 
pacemaker was registered at baseline, but the 
actual setting could have been changed after 
implantation or during follow-up.
Conclusion
Maintaining a registry for implantable devices can 
serve many purposes. It provides insight into the 
patient population, trends regarding devices used 
and perhaps even more important: tracking and 
tracing of products in case of failures and recalls. 
Over the years the SPRN registry has provided 
input for several of these purposes, the most 
important being the tracking and tracing of pa-
tients in case of recalled devices. As some risks 
of implantable devices will only become apparent 
during the actual clinical use after marketing of 
the device, implant registries can serve a purpose
in identifying those risks as well. 
In conclusion, analysis of the SPRN database 
has shown that the frequency of first implanta-
tion of pacemakers has steadily increased in the 
Netherlands and that trends in indications for 
implantation and pacemaker type are in line with 
other European countries. 
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Abstract
Background 
After decades of experience and strongly improved technology, service time of pacemaker gen-
erators is expected to increase. To test this hypothesis, we conducted a retrospective review of a 
large cohort of patients with a pacemaker.
Methods 
We reviewed data collected between 1984 and 2006 in the first national Dutch pacemaker reg-
istry. This registry covered 96% of all generators implanted. We analysed the time of and reason 
for explantation of pacemaker generators. A 7-year follow-up interval after first implantation and 
following replacements was used to analyse changes over time.
Results 
During 22 years of data collection, nearly 97,000 first pacemaker generators were implanted. A 
total of 27,937 (22.4%) generators were explanted within a mean of 6.3 (SD 3.3) years. Reasons 
for approximately 60% of these explantations were end of life of the pacemaker generator or 
elective system change. Complications or failures, such as infections and recalls, accounted for 
approximately 20% of the explantations. For the remaining 20%, the reasons for explantation had 
not been registered. 
Conclusion 
Despite progress in technology, a substantial proportion of pacemaker generators is explanted be-
fore its expected service time, with one in five generators being replaced due to technical failures, 
infections or other complications. Furthermore, the time interval between pacemaker implantation 
and explantation due to normal ‘end of life’ (battery EOL) decreased. Infections continue to rank 
highly as a cause for pacing system replacement, despite all current preventive measures. 
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C
hronic stimulation of the heart with 
pacemakers for bradycardia and 
other indications has been applied 
worldwide in increasing numbers.[1-2] 
In the Netherlands, 3236 first pacemakers were 
implanted in 1984 (225 implants per million in-
habitants),[3] while 10,389 pacemakers were 
implanted in 2011 (468/million inhabitants).[4]
Pacing devices have become technically more 
sophisticated to enable more options for sens-
ing, pacing and monitoring, as well as sustain-
ability for simultaneous use of other devices 
and techniques such as magnetic resonance 
imaging. At the same time, the devices got 
substantially smaller.[5-7] These developments 
required a more robust design of the device, IT 
facilities, and increased lifespan of the battery. 
The incremental need of remote monitoring to 
support an intense technical follow-up to opti-
mise the care of the individual pacemaker re-
cipient, also required technical innovations. 
Because previous surveys showed a substan-
tial complication rate,[5,6,8,9] we aimed to inves-
tigate trends in the duration of service time or 
longevity of pacemaker generators after first 
implantation and re-implantation. For this pur-
pose, the reasons for replacement of pacemak-
ers were studied. We anticipated that because 
of growing experience, guidelines and cluster-
ing of treatment facilities, service time of the 
devices would increase, and complication rates 
would gradually diminish over several decades.
Patients and Methods
Setting
Data were retrieved from the Central Pacemak-
er Patients Registration (CPPR) from the Neth-
erlands Pacemaker Registry Foundation (CP-
PR-SPRN). The registry has been described 
in detail elsewhere.[3, 10] In brief: in 1982, CP-
PR-SPRN was established and the computer-
ised registration began. Cardiologists and allied 
professionals were invited to voluntarily register 
data of each patient, pacemaker generator, and 
leads on the former European pacemaker card. 
Data on symptoms, indication and diagnosis, 
brand of pacemaker and leads, type, follow-up 
visits, explantation, hospital transfer and death 
were registered according to European Regis-
try Guidelines established in 1982 and later. 
Monitoring and validation of data
Until 1989, data was registered centrally; a 
carbon copy of the European pacemaker card 
had to be sent to the registry. From 1989 on-
wards, a digitalised registration was used with 
automatic communication between the central 
registration computer and the local computer 
of the implanting centre. During daily conver-
sions into the database, multiple checks were 
performed on missing data, conformation with 
already stored information and plausibility.[11] 
Additionally, the data was periodically returned 
to the clinics for correction purposes. A vali-
dation process to obtain better insight into the 
quality of the database was performed in 1997. 
When the central registry was compared with 
patient files of participating hospitals and sales 
data from manufacturers, 95.7% of pacemaker 
generators could be retrieved.[12]
Cohort and outcome definition
Patients admitted for implantation of the first 
pacemaker between 1 January 1984 and 1 
January 2006 were included in this nationwide 
cohort study. A total of 452 implantations were 
excluded because of inconsistencies in the 
registered data, e.g. a new implantation was 
registered after the supposed date of death of 
a patient, or the same pacemaker was regis-
tered more than once with different explanta-
tion dates. This resulted in a cohort with 96,900 
patients having a first pacemaker implanted 
between January 1984 and January 2006, fol-
lowed by 27,937 explantations (of which 27,659 
replacement procedures) until January 2008. 
The years 2006 and 2007 were used for fol-
low-up only. Additionally, for part of the analy-
ses, the cohort was subdivided into three strata 
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with 7 years of follow-up after each implanta-
tion, leaving 66,223 patients who received a 
first pacemaker between January 1984 and 
January 2001.
Exposure
The primary interest was the number of pace-
maker replacements or explantations and the 
reasons for these interventions. In this study 
‘service time’ is defined as the time between 
pacemaker implantation and replacement or 
removal of the generator. 
Analysis
Analyses of explantations and replacements 
were performed on 1) the entire cohort of pa-
tients (n=96,900) having first and re-implan-
tations during the study period irrespective of 
available duration of follow-up, and 2) on three 
strata (n=66,223 patients) to identify changes 
over time. Each implantation in these strata 
was followed for a maximum of 7 years or un-
til explantation, whichever came first. For this 
purpose, first and re-implantations during the 
years 1984-2000 could be used, while data 
from 2001-2007 were used for follow-up only. 
We chose a 7-year follow-up period because 
the mean duration of follow-up for explanted 
pacemaker generators falls within this time in-
terval, as also observed by Hauser et al.[13] Fur-
thermore, with 66,223 first implantations during 
1984-2000, two thirds of the cohort would re-
main available for analysis. P-values were cal-
culated with chi-square analysis and indepen-
dent samples t test.
Sensitivity analysis
To estimate the proportion of deaths that was 
(voluntarily) registered in SPRN, we performed 
a sensitivity analysis by looking up patients 
from the Rotterdam Study, a large prospective 
cohort study on inhabitants of the Ommoord 
area in Rotterdam,[14] in the SPRN database. 
First, we investigated on basis of gender and 
date of birth whether a participant from the 
Rotterdam Study was registered in SPRN. Sub-
sequently, we validated each retrieval by using 
the pacemaker implant date. The date of death 
is registered for each participant of the Rotter-
dam Study.
Results 
Between 1 January 1984 and 1 January 2006, 
96,900 patients received a first pacemaker. Ap-
proximately 53% of the patients were men and 
the mean age at time of first implantation was 
72.9 years (SD 13.0). Baseline characteristics 
are provided in Table 1.
Pacemaker generator replacements 
and removals
During the study period, 22,134 patients 
(22.8%) had at least one pacemaker genera-
tor replacement or removal and 4350 patients 
(4.5%) had more than one. In total, 27,937 pace-
maker generators were replaced or removed 
(22.4% of total number of implants), including 
332 pacemaker generators that were coded 
as a removal without replacement, although it 
appeared that some of these patients did re-
ceive a new pacemaker after several weeks 
to months (Table 1). The mean duration of fol-
low-up to pacemaker generator replacement or 
removal (service time) during the whole study 
period was 6.3 (SD 3.3) years. Approximate-
ly 60% of the explantations occurred within 7 
years after implantation, 30.6% within 5 years 
and 16.8% within 3 years (Table 1). 
Approximately 19% of the pacemaker genera-
tors were replaced or removed following device 
failure or complications and in 20% the rea-
son for explantation was not available (Table 
2). Analysis of pacing systems stratified for the 
period in which a pacemaker was implanted 
and followed for a maximum of 7 years shows 
that the percentage of explantations within 7 
years due to infection lies between 4.0-4.5% for 
pacemaker generators and did not significantly 
change over time. The percentage of recalled 
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pacemaker generators within 7 years of implan-
tation increased during the study period, where-
as the percentage of device failures significantly 
decreased towards the end of the study period 
from 3.9% to 1.8% of the pacemaker generator 
replacements (p≤0.001; Table 2).
A total of 50.4% of pacemaker generators were 
explanted because of normal ‘end of life’ of the 
generator (Table 2). For these generators, the 
service time varied widely. When compared 
to the number of explantations within differ-
ent periods of follow-up, 38.4% of the gen-
erators was explanted for normal ‘end of life’ 
within <7 years, 20.5% <5 years, and 6.6% 
<3 years. These percentages increased over 
time (Table 2). 
Dual chamber systems were significantly more 
often explanted for normal ‘end of life’ <5 years 
and <7 years and technical reasons than sin-
gle chamber systems (Table 3). Overall, dual 
chamber systems were significantly more of-
ten explanted than single chamber systems 
(p≤0.001; Table 3). 
Sensitivity analysis
A total of 258 participants of the Rotterdam Study 
Explantation of pacemaker generators within 7 years of follow-up, stratifi ed for implantation perioda
n (% of explanted pacemakers):
All pacemakers 
explanted during 
study periodb 
1984-1990 1991-1995 1996-2000 1984-2007
Device failure 
(sensing, programming, output, rate, connector) 126 (3.9) 151 (3.4) 105 (1.8)
c 509 (1.8)
Recall 32 (1.0) 174 (3.9)c 270 (4.7) 583 (2.1)
Infection 149 (4.6) 176 (3.9) 248 (4.3) 884 (3.2)
Other complication 
(mechanical protrusion, erosion, wound pain) 31 (1.0) 31 (0.7) 39 (0.7) 153 (0.5)
Elective for system change 319 (9.9) 450 (10.0) 554 (9.6) 2775 (9.9)
System change – Haemodynamic reasons 90 (2.8) 261 (5.8)c 398 (6.9) 1513 (5.4)
System change – Electrode problem 182 (5.6) 325 (7.2) 178 (3.1)c 1003 (3.6)
System change – other reasons 37 (1.1) 53 (1.2) 61 (1.1) 214 (0.8)
Normal ‘end of life’, of which: 908 (28.1) 1800 (40.1)c 2678 (46.6)c 14,077 (50.4)
<7 years, n (% of all explantations <7 yearsd) 908 (28.1) 1800 (40.1)c 2678 (46.6)c 6349 (38.4)
<5 years, n (% of all explantations <5 yearsd) 202 (11.9) 393 (19.9)c 587 (23.9) 1759 (20.5)
<3 years, n (% of all explantations <3 yearsd) 29 (3.1) 48 (5.1) 87 (7.3) 307 (6.6)
Premature ‘end of life’ 77 (2.4) 140 (3.1) 126 (2.2) 520 (1.9)
Reason uncoded, unknown or unspecified  1282 (39.6) 928 (20.7)c 1088 (18.9) 5706 (20.4)
Total 3233 (100.0) 4489 (100.0) 5745 (100.0) 27,937 (100.0)
Table 2. Reasons for pacemaker generator replacements in the nationwide 
CPPR-SPRN database, the Netherlands 1984-2007
a For each stratum, the duration of follow-up was maximised at 7 years. Hence, the years 2001-2007 were used for 
follow-up only. Consequently, numbers of the first three columns do not add up to the numbers in the fourth column
b Regardless duration of follow-up
c Significantly different compared to previous time interval (p=0.001)
d See Table 1
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were found in the SPRN database. During the 
study period, 148 (57.4%) died. Of these deaths, 
60 (40.5%) were also registered in SPRN. We 
consider 92% of these registrations to be accu-
rate (within 3 months from the registered date 
of death in the Rotterdam Study). Age at death 
and implanted pacemaker type did not statis-
tically significantly differ between the group of 
patients registered as deceased and the group 
of patients not registered as deceased in SPRN 
(p=0.56 and p=0.90, respectively).
Discussion
Our results show that 22% of pacemaker gen-
erators were replaced or removed at least once 
between 1984 and 2008. Approximately one in 
five pacemaker generators were explanted due 
to technical failures or complications during 
20 years of follow-up. Complication and failure 
rates for pacemaker generators did not improve 
during at least the first 15 years of the regis-
try. Furthermore, we found that explantation of 
pacemaker generators for normal ‘end of life’ 
occurred at a decreasing follow-up time. The 
explantation rate found in the Danish Pace-
maker Registry, which covers the same period, 
compares to ours.[15]
‘Normal service time’ of pacemaker generators 
includes the lifespan of the pacemaker gener-
ator in terms of the longevity of the battery and 
of the electronic components. Time intervals 
between pacemaker implantation and removal 
vary from a mean of 6.8 years for dual cham-
ber devices and 9.7 years for single chamber 
devices in one study[16] and 7.3 years found in 
studies on several types and brands of devic-
es.[13,17] Kindermann et al. found a median time 
interval to battery depletion of 8.2 years.[18] 
However, cohort size, study duration, number 
of participating hospitals and number and type 
of different pacemakers differed between these 
studies and differed compared to ours. 
More ancillary functions and operational al-
gorithms than standard pacing, sensing and 
communicating with the programmer, require 
VVI/VVIR DDD/DDDR
  n % n % p-value
Number of first implantations of this pacemaker typea 47,945 49.5 38,060 39.3  -
Number of explantations of first pacemaker of this type 4391 9.2 5861 15.4 <0.001
Reason for explantation      
Recall 141 3.2 209 3.6 0.328
Complication 226 5.1 350 6.0 0.073
Failure 161 3.7 154 2.6 0.003
Premature end of life 123 2.8 164 2.8 0.993
Normal end of life   <7 years 1302 29.7 2716 46.3 <0.001
<5 years 273 6.2 690 11.8 <0.001
<3 years 53 1.2 46 0.8 0.408
Table 3. Comparison of specific replacement or explantation reasons between 
first pacemakers with NASPE codes VVI/VVIR and DDD/DDDR in the nationwide 
CPPR-SPRN database, the Netherlands 1984-2007 
NASPE North American Society of Pacing and Electrophysiology
a % compared to all first pacemaker implantations between 1 January 1984 and 1 January 2006, n=96,900
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more battery capacity and may thus affect 
service time. This may cause newer models 
to offer shorter service time than expected.
[17,19] Hauser et al. restricted service time to 
the battery life time ending with the appear-
ance of the elective replacement indicator, 
considering a longevity of >3 years after 
implant as a minimal requirement.[13] They 
found that the average pulse generator was 
implanted for 7.3 years (SD 3.1). The almost 
twofold increase of the most frequently reg-
istered reason for pacemaker generator re-
placement in our study – normal ‘end of life’ –
suggests that battery longevity did not im-
prove during at least the first 15 years of the 
study. This underscores the need for longer 
service time of pacemaker generators by new 
battery technology that permits pacing for at 
least 10 years. A longer ‘normal service time’ 
of pacemaker generators would be more than 
welcome because replacement of pacemak-
ers exposes patients to the risk of device in-
fection.
Nearly one in five pacemaker generators was 
explanted following a complication or failure 
in our study. A review of reports submitted 
to the FDA and analysis of device registries 
published in literature show that pacemaker 
generator failures included acute or premature 
battery depletion, connector malfunctions, 
electrical problems such as short circuit, in-
appropriate high-current drains, or hermet-
ic seal abnormalities. Such complications 
sometimes cause major clinical events.[5,6,13]
Similar technical failures also emerged in our 
registry: premature ‘end of life’, electrode prob-
lems, recalls and device failures accounted for 
more than 9% of the replacements of pace-
maker generators in our study. Furthermore, 
the percentage of explantations following 
a recall increased over time in parallel with 
medical device regulation and post-market-
ing surveillance. Nevertheless, studies have 
shown that, despite increasing complexity 
of the components of pacemaker generators 
over the past decades, the overall replace-
ment rate for technical failures dropped.[5,6]
However, technical defects may remain unno-
ticed despite regular follow-up, as a previous 
study implies.[20] This post-mortem study of 
pacemaker generators demonstrated that in 
3.8% of patients, deceased after an average 
of 4 years of pacing, a life-threatening techni-
cal failure was present and in 3.0% a poten-
tially life-threatening technical failure which 
may have caused their death.[20] The sensitivi-
ty analysis on the Rotterdam Study sub cohort 
showed that 50% the patients died within 3 
years after implantation of the last registered 
pacemaker. We cannot rule out that a propor-
tion of these patients died following pacemak-
er malfunction.
Limitations
In nearly 20% of the pacemaker generator re-
placements, the reason and time for replace-
ment or removal remained unknown. Miss-
ing data could be ascribed to the voluntary 
participation in the registration; some hos-
pitals (<5%) did not register data or did not 
register during the entire study period. Data 
were provided by each participating hospital 
individually. This may have led to differences 
in interpretation of the requested informa-
tion. Relevant variables such as information 
on comorbidity, medication use, and cardiac 
function were not recorded at all. This pre-
cluded us from adjusting for potential clinical 
confounders. Furthermore, the registry did 
not include information on pacemaker set-
ting, pacing threshold and lead impedance. 
These factors are known to influence battery 
longevity.[17,18] 
Finally, detailed information on the proportion 
of patients that may have been lost to follow-up 
is unknown. Information on date of death was 
voluntarily registered and in 10% of the re-
ported deaths no date of death was provided. 
Sensitivity analysis showed that approximately 
60% of the deaths could be missing. 
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Conclusions 
A substantial proportion of pacemaker gener-
ators is explanted before its expected service 
time, with one in five generators being replaced 
due to technical failures, infections or compli-
cations. Furthermore, the time interval between 
pacemaker implantation and explantation due 
to normal ‘end of life’ decreased. Our obser-
vations underscore the need to program only 
features of the pacemaker generator that have 
proven clinical benefit to avoid reductions of the 
service time of the device. The results of our 
study indicate that a continued highly detailed 
registry to identify risk factors for premature re-
placement is needed to maximise the service 
time of pacemakers. 
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Appendix
We also performed a time-to-event analysis. 
For this analysis, the implanted pacemakers 
were divided into groups based on the type of 
generator that was registered at implantation: 
mono-chamber systems (AAI(R) or VVI(R)), 
dual-chamber systems (DDD(R) or VDD(R)), 
and cardiac resynchronization devices (CRT). 
Patients were followed for 7 years after the 
first pacemaker implantation until either one 
of the following events occurred: replacement/
explantation, loss to follow-up, death that was 
reported to CPPR-SPRN, or end of follow-up, 
whichever came first. The 7-year follow-up in-
terval after first and possibly successive pace-
maker implantations was chosen to determine 
an assumed longevity (standard “end of life”) of 
pacemaker generators of 5 years. 
Cumulative incidence curves for pacemaker 
generator implants were estimated with com-
peting risks analysis with death as a compet-
ing event.[21] Because deceased patients are 
no longer at risk for explantation, they cannot 
be considered as censored as the assumption 
that the censoring mechanism is independent 
of the probability of the outcome of interest (i.e. 
explantation), is no longer met.[22] We calculat-
ed proportional hazard ratios for sex, age, ECG 
indication and pacemaker type on the risk of 
explantation during 7 years of follow-up using 
Cox regression adapted for competing risk of 
death free from explantation [SAS 9.4, SAS In-
stitute Inc., Cary, NC, USA].
Adjusted for age, gender and indication the 
analysis showed that AAIR, VDD and DDDR-
types had a higher probability of explanta-
tion or replacement than the reference group 
VVI-pacemakers (table A1, indication not 
shown). This outcome is most likely explained 
because VVI(R) implantation is in general a 
less complex procedure than AAI(R), VDD(R) 
and DDD(R). However, VVI(R) pacemakers are 
more often implanted in older individuals and 
patients with more extensive comorbidity.[23] 
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Table A1 (continued on next page). Hazard ratios for explantation <7 years of 
follow-up after first implantation, adjusted for the competing risk of death in the 
nation-wide CPPR-SPRN database, the Netherlands 1984-2007
Values in bold font are significant
1984-1990 1991-1995
n (%) n (%)
Number of first 
implantations 23,870 19,659
Number of 
explantations 2918 (12.2) 3413 (17.4)
Number of 
deaths 6689 (28.0) 5319 (27.1)
n (%) Crude HR  (95% CI)
Adjusted HR
  (95% CI) n  (%)
Crude HR 
(95% CI)
Adjusted HR
 (95% CI)
Female 11,628 (48.7)
0.92 
(0.85-0.99)
1.04 
(0.96-1.11)
9,419 
(47.9)
0.99 
(0.93-1.06)
1.13 
(1.06-1.21)
Age (per year 
increase)
23,824 
(99.8)
0.97 
(0.97-0.97)
0.98 
(0.97-0.98)
19,647 
(99.9)
0.97 
(0.97-0.97)
0.97 
(0.97-0.98)
Pacemaker type
VVI 19,122 (80.1) Ref Ref
8763 
(44.6) Ref Ref
VVIR 725 (3.0)
2.64 
(2.27-3.08)
2.10 
(1.80-2.46)
3296 
(16.8)
2.9 
(1.89-2.32)
1.86 
(1.68-2.26)
DDD 2946 (12.3)
4.00 
(3.69-4.34)
3.05 
(2.79-3.33)
3472 
(17.7)
2.26 
(2.05-2.49)
1.80 
(1.62-1.99)
DDDR 49 (0.2)
8.00 
(5.58-11.46)
5.32 
(3.60-7.84)
2004 
(10.2)
2.68 
(2.41-2.98)
2.02 
(1.81-2.26)
AAI 577 (2.4)
3.63 
(3.08-4.27)
2.75 
(2.31-3.27)
424 
(2.2)
2.63 
(2.14-3.23)
2.07 
(1.67-2.56)
AAIR 52 (0.2)
3.14 
(1.93-5.12)
2.09 
(1.19-3.65)
316 
(1.6)
4.07 
(3.36-4.94)
2.97 
(2.43-3.63)
VDD 17 (0.1)
2.04 
(0.66-6.33)
0.88 
(0.27-2.87)
648 
(3.3)
2.40 
(2.03-2.83)
2.08 
(1.75-2.47)
VDDR 1 (<0.1)
22.59 
(21.16-24.12)
21.38 
(19.55-23.39)
191 
(1.0)
4.26 
(3.40-5.34)
3.47 
(2.75-4.39)
CRT 13 (0.1)
3.89 
(1.59-9.57)
1.74 
(0.60-5.05)
4 
(<0.1)
0.00 
(0.00-0.00)
0.00 
(0.00-0.00)
Unknown 368 (1.5)
1.66 
(1.26-2.19)
1.52 
(1.15-2.01)
541 
(2.8)
1.76 
(1.43-2.17)
1.49 
(1.20-1.84)
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1996-2000
n (%)
Number of first 
implantations 22,694
Number of 
explantations 4015 (17.7)
Number of 
deaths 5457 (24.0)
n  (%) Crude HR (95% CI)
Adjusted HR
  (95% CI)
Female 10,569 (46.6)
0.96 
(0.90-1.02)
1.07 
(1.00-1.14)
Age (per year 
increase)
22,690
(~100.0)
0.97 
(0.97-0.97)
0.98 
(0.97-0.98)
Pacemaker type
VVI 3250 (14.3) Ref Ref
VVIR 4843 (21.3)
1.66 
(1.43-1.93)
1.53 
(1.31-1.78)
DDD 3606 (15.9)
2.80 
(2.42-3.24)
2.41 
(2.08-2.80)
DDDR 7575 (33.4)
3.16 
(2.76-3.62)
2.55 
(2.22-2.93)
AAI 238 (1.0)
3.10 
(2.28-4.21)
2.38 
(1.74-3.24)
AAIR 562 (2.5)
5.43 
(4.48-6.58)
3.74 
(3.06-4.58)
VDD 1404 (6.2)
2.36 
(1.98-2.82)
2.30 
(1.92-2.77)
VDDR 593 (2.6)
2.51 
(2.01-3.14)
2.32 
(1.85-2.92)
CRT 74 (0.3)
5.31 
(3.40-8.30)
4.20 
(2.67-6.59)
Unknown 549 (2.4)
3.91 
(3.16-4.83)
3.33 
(2.69-4.13)
  
Table A1 (continued from previous page).
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Therefore, this observation needs to be inter-
preted with caution. 
When time-to-event analysis methods to com-
pare the service time of several types of pace-
makers with 7 years of follow-up were applied
after the second, third and following implanta-
tions the outcome did not change, reason why
only data of the analysis of the first implanta-
tions is presented in Table A1. Furthermore, it 
should be noted here that for 10% of the re-
ported deaths no date of death was provided, 
hence for these records no follow-up time could 
be calculated; these records were excluded 
from the time-to-event analysis.
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Abstract
Background 
We aimed to investigate trends over time in longevity and reasons for replacement or extraction of 
pacemaker leads after first implantation. 
Methods 
Data collected between 1984 and 2006 in the national Dutch pacemaker registry were used. 
This registry covered 84.0% of sold leads. The time interval of, and reason for, replacement or 
extraction of leads implanted with a first pacemaker generator were analysed. A 7-year follow-up 
interval after first implantation was used to analyse changes over time.
Results 
During 22 years of data collection 138.225 leads were implanted with a first pacemaker generator. 
Within a mean 5.4 (SD 4.5) years 8849 leads (6.4%) were replaced or extracted, the majority for 
insulation failures (14.7%), infection (11.8%), displacement (7.1%) or for elective reasons (10.2%). 
The number of insulation failures peaked during 1991-1995. 
Conclusion 
Despite improvements in pacing techniques and experience with cardiac devices, we found that 
insulation and conductor failures, and complications such as infections did not diminish over the 
20 years of the registry. Continuing attention in clinical practice for the evaluation of these unde-
sired outcomes and maintaining quality registries is warranted, whereas manufacturers should 
use this information to further improve their devices. 
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C
ardiac implantable electronic de-
vices (CIED) rely on implantable 
pacing leads to exert their benefit 
for many patients worldwide. Al-
though new developments towards leadless 
pacemakers are underway,[1] the vast major-
ity of devices that are currently in situ trans-
fer the electronically generated pulses to the 
heart and receipt of cardiac and external sig-
nals through leads. In the early days of cardi-
ac pacing lead longevity seemed long-lasting 
but this finding was merely caused because 
problems with pulse generators occurred be-
fore any failures with leads could be ascer-
tained.[2-3] However later, the pacing lead was 
considered the ‘weakest link’ of the pacing 
system.[4]  
The materials and shape of the conductors 
and insulation, the diameter and the polar-
ity of the lead all play a crucial role in lead 
longevity.[3-5] Because of problems of any of 
these components, history shows that vari-
ous lead types were particularly prone to 
failure and needed to be replaced following 
either abandonment or extraction.[5-9] For ex-
ample in the 1980s and 1990s some specif-
ic bipolar leads were known to show a poor 
5-year longevity rate.[9]
To identify CIED failures, a registry was set 
up in the Netherlands in the early 1980’s; 
the Central Pacemaker Patients Registration 
(CPPR) from the Netherlands Pacemaker 
Registry Foundation (CPPR-SPRN).[10-11] This 
registry collected data over 25 years and al-
lows for analysis of trends over time regard-
ing the duration of service time or longevity 
of leads after first implantation.[12-13] For this 
paper, the reasons for replacement or ex-
traction of leads were studied. We anticipated 
that because of growing experience, guide-
lines and clustering of treatment facilities, 
service time of the leads would increase, and 
complication and failure rates would gradual-
ly diminish over several decades of cardiac 
pacing. 
Patients and Methods
Setting
Data were retrieved from the Central Pacemak-
er Patients Registration (CPPR) from the Neth-
erlands Pacemaker Registry Foundation (CP-
PR-SPRN).[12] In brief, in 1982, CPPR-SPRN 
was established and the computerized reg-
istration was started. Cardiologists and allied 
professionals were invited to voluntarily regis-
ter data of each patient, pacemaker generator, 
and leads on the former European pacemaker 
card. Data on symptoms, indication and diag-
nosis, brand of pacemaker and leads, type, fol-
low-up visits, explantation, hospital transfer and 
death were registered according to European 
Registry Guidelines established from 1982 on-
ward.[12-13]
Monitoring and validation of data
Until 1989, data was centrally registered by 
mailing a carbon copy of the European pace-
maker card to the registry. From 1989 onwards, 
a digitalized registration was used with au-
tomatic communication between the central 
registration center and the local implanting 
center. During the daily conversions into the 
database multiple checks were performed on 
missing data, conformation with already stored 
information and plausibility.[10] Additionally, data 
was periodically returned to the clinics for cor-
rection and verification purposes. A validation 
process to obtain better insight into the quality 
of the database was performed in 1997. A total 
of 84.0% of the sold leads could be retrieved in 
the central registry when compared to patient 
files of participating hospitals and sales data 
from manufacturers.[11]
Cohort and outcome definition
Patients admitted for implantation of the first 
pacemaker between January 1, 1984 and Jan-
uary 1, 2006 were included in this study. A total 
of 452 implantations were excluded because 
of inconsistencies in the registered data, e.g. a 
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new implantation was registered after the sup-
posed date of death of a patient, or the same 
pacemaker was registered more than once with 
different explantation dates. This resulted in a 
cohort with 96,900 patients having a first pace-
maker implanted with 138,225 leads. The years 
2006 and 2007 were used for follow-up only. 
Exposure
The primary interest was the number of lead 
Implantation period Total study period
1984-1990 1991-1995 1996-2000 2001-2005 1984-2005
Mean age at first implantation, 
years (SD)a 72.7 (13.0) 73.0 (13.0) 72.9 (13.2) 73.1 (12.9) 72.9 (13.0)
Female gender, n (%)b 11,628 (48.7) 9419 (47.9) 10,569 (46.6) 14,045 (45.8) 45,661 (47.1)
Follow-up duration (range), years 17-23 12-16 7-11 2-6 2-23
Total study 
period
1984-1990 1991-1995 1996-2000 2001-2005 1984-2005
No. of first pacemaker generators, 
(% of total # implanted 
first pacemaker generators during 
study period)
23,870 (24.6) 19,659 (20.3) 22,694 (23.4) 30,677 (31.7) 96,900 (100.0)
Lead implantations, n (% of total 
# implanted leads 
during study period), of which:
27,030 (19.6) 25,479 (18.4) 34,374 (24.9) 51,342 (37.1) 138,225 (100.0)
Number of leads per first 
pacemaker, 
n= # of pacemakers (% of 
first pacemaker):  1 20,668 (86.6) 13,788 (70.1)c 10,869 (47.9)c 9475 (30.9)c 54,800 (56.6)
2 3161 (13.2) 5839 (29.7)c 11,641 (51.3)c 19,166 (62.5)c 39,807 (41.1)
3 12 (0.1) 3 (<0.1) 73 (0.3)c 1177 (3.8)c 1265 (1.3)
4 1 (<0.1) 1 (<0.1) 1 (<0.1) 1 (<0.1) 4 (<0.1)
Unknown 28 (0.1) 28 (0.1) 110 (0.5)c 858 (2.8)c 1024 (1.1)
Lead position: Ventricular, n (%) 23,120 (85.5) 18,772 (73.7)c 21,698 (63.1)c 30,338 (59.1)c 93,928 (68.0)
Atrial, n (%) 3824 (14.1) 6694 (26.3)c 12,628 (36.7)c 20,993 (40.9)c 44,139 (31.9)
Unknown, n (%) 86 (0.3) 13 (0.1)c 48 (0.1)c 11 (<0.1)c 158 (0.1)
Table 1. Baseline characteristics of patients and leads in the nation-wide
CPPR-SPRN database, the Netherlands 1984-2005 
a For 60 patients, data on age was missing 
b For 75 patients, data on gender was missing
c Significantly different compared to previous time interval (p=0.001) 
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replacements or extractions and the reason for 
this intervention. For this study ‘service time’ is 
defined as the time between lead implantation 
and replacement or extraction of the lead. Rea-
sons for end of service time were categorized 
in several forms of technical failure of the lead 
itself (i.e. insulation or conductor failure) and 
infection.
Analysis
First, analyses of explantations and replace-
ments were performed on the entire cohort of 
patients (n=96,900) having a first implantation 
during the study period irrespective of avail-
able duration of follow-up. Next, analyses were 
repeated on three strata (a total of n=66,223 
patients) to identify changes over time. Each 
implantation in these strata was followed for 
a maximum of 7 years or until explantation, 
whichever came first. For this purpose, first im-
plantations during the years 1984-2000 could 
be used, while data from 2001-2007 were used 
for follow-up only. We chose a 7-year follow-up 
period because the mean duration of follow-up 
for explanted pacemaker generators falls within 
this time interval.[14-15]
Descriptive data are presented as mean (stan-
dard deviation, SD), median (interquartile 
range, IQR), or frequencies (%) as appropriate. 
Characteristics were compared using indepen-
dent sample t-tests for continuous variables 
and 2 tests for categorical variables, as ap-
propriate. A 2-sided p-value ≤0.001 was con-
sidered as statistically significant. We used the 
SPSS version 20.0.0, statistical package (IBM, 
Armonk, NY, USA) for all analyses.
Results 
A total of 52.9% of the patients were men and 
the mean age at time of first implantation was 
72.9 years (SD 13.0) (Table 1). Depending on 
Implantation period Total study period
1984-1990 1991-1995 1996-2000 2001-2005 1984-2005
Replacements/extractions of leads 
implanted in this period, n (%) 2958 (10.9) 2627 (10.3) 1958 (5.7)
a 1306 (2.5)a 8849 (6.4)
Mean duration of service time 
for replaced/extracted leads, years (SD) 7.6 (5.1) 5.9 (3.8) 4.1 (3.2) 1.5 (1.7) 5.4 (4.5)
Median duration of service time 
for replaced/extracted leads, years (IQR) 7.1 (3.7-10.9) 5.8 (3.2-8.7) 4.2 (0.8-6.9) 0.6 (0.1-2.4) 5.1 (1.3-8.2)
replacement/extraction <3 years, n 
(% of extracted leads)
(% of implanted leads)
628 
(21.2) 
(2.3)
625 
(23.8) 
(2.5)
821 
(41.9)a 
(2.4)
NA
3126 
(35.3) 
(2.3)
replacement/extraction <5 years, n 
(% of extracted leads)
(% of implanted leads)
981 
(33.2) 
(3.6)
1067 
(40.6)a 
(4.2)a
1099 
(56.1)a 
(3.2)a
NA
4384 
(49.5) 
(3.2)
replacement/extraction <7 years, n 
(% of extracted leads)
(% of implanted leads)
1456 
(49.2) 
(5.4)
1613 
(61.4)a 
(6.3)a
1505 
(76.9)a 
(4.4)a
NA
5875 
(66.4) 
(4.3)
Table 2. Lead replacements and duration of service time in the nation-wide 
CPPR-SPRN database, the Netherlands 1984-2005
NA: Not applicable, only 2-6 years of follow-up available
a Significantly different compared to previous time interval (p=0.001) 
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the year of implantation, patients were followed 
for 2 to 23 years after implantation.
The percentage of pacemakers implanted with 
a single lead diminished after 1990. However, 
the percentage of pacemakers implanted with 
both atrial and ventricular leads increased from 
13.2% in 1984-1990 to 62.5% in 2001-2005 
(p≤0.001). Furthermore, pacemakers implanted 
with 3 leads for cardiac resynchronization ther-
apy increased to 3.8% over the years (p≤0.001). 
More than two thirds of the leads were ventric-
ular leads. However, the percentage of atrial 
leads increased over time (p≤0.001). Missing 
information about lead insertion remained lim-
ited over the years: 0.1 to 0.5%, but increased 
after 2000 (Table 1).
For 8849 leads (6.4%) a replacement or ex-
traction was registered. The mean duration of 
service time for explanted leads was 5.4 years 
(SD 4.5). Approximately two thirds of these 
leads (n=5875, 66.4%) were replaced or ex-
planted within 7 years after implantation and 
nearly half (n=4384, 49.5%) was replaced or ex-
Implantation period Total Total all replaced/ explanted leadsa 
1984-1990 1991-1995 1996-2000 1984-2000 1984-2007
Displacement 50 (3.4) 120 (7.4)b 184 (12.2)b 354 (7.7) 626 (7.1)
Exit block 29 (2.0) 78 (4.8)b 61 (4.1) 168 (3.7) 296 (3.3)
Undersensing 32 (2.2) 42 (2.6) 31 (2.1) 105 (2.3) 195 (2.2)
Insulation failure 214 (14.7) 395 (24.5)b 94 (6.2)b 703 (15.4) 1297 (14.7)
Conductor break 54 (3.7) 59 (3.7) 62 (4.1) 175 (3.8) 327 (3.7)
Other failure (e.g. connector 
failure) 10 (0.7) 16 (1.0) 18 (1.2) 44 (1.0) 103 (1.2)
Infection 162 (11.1) 170 (10.5) 261 (17.3)b 593 (13.0) 1046 (11.8)
Other complication (e.g. erosion, 
perforation) 15 (1.0) 3 (0.1) 54 (3.6)
b 72 (1.6) 254 (2.9)
Elective replacement 133 (9.1) 165 (10.2) 143 (9.5) 441 (9.6) 905 (10.2)
Sealed 0 (0.0) 0 (0.0) 12 (0.8) 12 (0.3) 65 (0.7)
Reason unknown or unspecified 772 (53.1) 565 (35.0)b 585 (38.9) 1922 (42.0) 3735 (42.2)
Total replaced or extracted 1456 (100.0) 1613 (100.0) 1505 (100.0) 4574 (100.0) 8849 (100.0)
Table 3. Reason for replacement or extraction of leads within 7 years after 
implantation in the nationwide CPPR-SPRN database, the Netherlands 1984-2007
n (% of total replaced/extracted leads in corresponding implantation period)
a Regardless duration of follow-up
b Significantly different compared to previous time interval (p=0.001)
Next page:
Table 4. Simultaneous replacement of 
first pacemaker generators and leads in 
the nationwide CPPR-SPRN database, 
the Netherlands 1984-2007
Simultaneous replacement for 7 most frequently 
registered generator replacement reasons
EOL: end of life
a The denominator for the percentages in this row is 
the total number of replaced and permanently removed 
first pacemaker generators: n=22,410
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planted within 5 years after implantation (Table 2).
When comparing the three implantation pe-
riods, the percentage of leads that were re-
placed or explanted within 3, 5, or 7 years de-
creased with later implantation years (p≤0.001) 
(Table 2). The most recent implantation period 
2001-2005 could not be included because the 
available follow-up time was too short.
Reasons for lead replacements 
and extractions
In general, lead replacement was most fre-
quently registered because of insulation fail-
ures (14.7%), infection (11.8%), and displace-
ment (7.1%). Elective replacement, without 
further specification, was reported for 10.2% 
of the extractions (Table 3). Other failures 
and complications included conductor breaks 
(3.7%), exit block (3.3%), and undersensing 
(2.2%). For more than 40% the reason was 
unknown or unspecified (Table 3).
Analysis of implantation periods with 7 years 
of follow-up available showed that for 4574 
leads a replacement or explantation was 
registered (Table 3). The percentage of ex-
tractions or replacements following infections 
increased over time from 10-11% for leads 
implanted between 1984 and 1995 to 17% 
for leads implanted between 1995 and 2000 
(p≤0.001). Also, extractions because of lead 
displacement increased during the study pe-
riod. Replacement or extraction for insulation 
failures (mean 14.7%) increased to nearly 
25% for leads implanted between 1991 and 
1996 (p≤0.001), but dropped to 6.2% for 
leads implanted during the era 1996-2000 
(p≤0.001). Other complications such as exit 
block, undersensing failure, conductor break, 
erosion, perforation, and other technical lead 
failures had a low prevalence in the succes-
sive periods with percentages below 4%. The 
number of uncoded reasons for lead failures 
remained large over the successive periods, 
approximately 42% of all replaced or explant-
ed leads (Table 3). 
Reasons for simultaneous replacement
of pacemaker generators and leads
For 13.0% of the replaced or explanted leads 
(n=1153) no pacemaker generator replacement 
was registered, whereas for 15,918 pacemak-
ers (71.0%) only the generator was replaced 
without replacement of the leads. However, it 
also occurred that generators and leads were 
replaced independently of each other: 1620 
leads (18.3%) were replaced with a mean of 
4.3 years (SD 3.4) later than the generator. Ad-
ditionally, 563 leads (6.4%) were replaced be-
fore the generator with a mean difference of 5.2 
years (SD 3.3), (data not shown).
More than 62% of the leads were simultane-
ously replaced with replacement of the pace-
maker generator (data not shown). Registration 
of simultaneous replacement occurred most of-
ten in case of infections. In those cases, 83.4% 
of the leads were also extracted. For 92.1% 
of these leads the reason for concomitant re-
placement was also classified as infection (Ta-
ble 4). Infected systems were replaced within 
1 year after implantation in 62.1% of the cas-
es and within 3 years in 84.2% of the cases 
(Table 4). Secondly, simultaneous replacement 
of pacemaker generators and leads frequently 
occurred when electrode problems were reg-
istered as reason of pacemaker generator re-
placement. In these cases, 73.4% of the leads 
were replaced together with the generator. For 
44.9% of these leads an insulation failure was 
registered (Table 4). 
In case a pacemaker generator was replaced 
for premature ‘end of life’, for hemodynamic 
reasons, or a recall, 18.5%, 10.9% and 5.6% 
of the respective corresponding leads were si-
multaneously replaced. When pacemaker gen-
erators were replaced for normal ‘end of life’ or 
because of elective system change, 9.8% and 
15.8% of the respective corresponding leads 
were also replaced. In those groups, insulation 
failures or elective replacement were most fre-
quently registered as reason for lead replace-
ment (Table 4).
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Discussion
This large long-term follow-up study analysed 
the number and reasons of pacemaker lead 
replacements or explantation, and provides a 
comparison between three implantation pe-
riods with 7 years of follow-up. Registered re-
placements or explantations were highest in 
the first two periods. Insulation failures, con-
ductor breaks and connector failures account-
ed for more than 19% of the registered lead 
explantations or abandonments within 7 years 
after implantation in our study. Furthermore, 
displacement and infections were common 
complications leading to lead extraction with 
7 years after insertion. Both increased towards 
the end of the study period. Finally, explanta-
tions for elective reasons and for other failures 
remained stable over time. 
Technical lead problems
Purely technical lead problems such as break 
of the insulation and of conductors and other 
failures of the lead constituted in approximately 
20% of the cases the reason for registered lead 
replacement or explantation. In case of regis-
tered simultaneous replacements of pacemaker 
generators and leads, particularly insulation fail-
ures were a cause for lead replacement. Insula-
tion defects have previously been described as 
regular causes of lead failure.[9, 14, 16] These tech-
nical failures can be attributed to material char-
acteristics as well as to implantation techniques 
and lead fixation methods, bending of the lead 
in the pocket, site of insertion and so forth. In 
the 1980s and 1990s polyurethane insulated 
leads appeared to be more prone to defects due 
to metal ion oxidation or environmental stress 
cracking. [2, 5, 9, 14, 16] Another type of lead, the 
J-shaped lead, was prone to fractures of a reten-
tion wire. [5, 17] Lead failure is expected to occur 
in approximately 2-4% of implantations after an 
average of 5 years. Some studies reported fail-
ure percentages of up to 7 to 16%.[5] Hauser et 
al. found a median time to failure for all leads of 
7.2 (SD 5.2) years. Despite differences in study 
design, we believe that our findings are similar to 
the described literature.[14]
Displacement
Lead displacement accounted for approximate-
ly 7% of lead replacement or explantation over 
the entire follow-up period. This figure varied be-
tween 3.4 and 12.2% over the years. However, 
lead dislodgement might have occurred more 
often when problems such as exit block (mean 
3.3% over the entire period) and undersensing 
(mean 2.2% over the entire period) are consid-
ered manifestations of lead displacement. This 
includes that overall lead displacement should 
be considered in approximately 20% of regis-
tered lead replacement or explantation. With the 
preference towards active-fixation leads, also in 
the Netherlands, lead dislodgement is expect-
ed to have decreased during later years.[18-19]
However, this is not yet visible during the peri-
ods covered by our study. A recent prospective 
Dutch study, performed in a subpopulation of 
the one described here, found lead dislodge-
ment to be the most frequent lead-related 
complication that often occurred shortly after 
implantation, but was also not uncommon as a 
late problem.[20]
Infections
Infections of the pacing system consisting of 
pocket infection, migration along the leads and 
endocarditis resulted in approximately 12% of 
the replacements. In this condition pacemaker 
generator and lead(s) were most often simulta-
neously replaced. With 83.4% of the leads re-
placed, infection was the largest indication for 
simultaneous explantation. Complete device 
removal, including leads, is indeed the advised 
therapy in case of infection.[5, 21] Johansen et al. 
reported the highest infection rates at the earli-
est period in a registry comparable to ours but 
the prevalence of registered device infections 
in our survey clearly did not change over the 
years.[22] Procedure-related factors, such as 
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size of the implanting centre, the complexity 
of the procedure and the number of leads ap-
peared not to be associated with infection rates 
in the Danish study.[22] The prospective FOL-
LOWPACE study confirmed this outcome and 
were unable to demonstrate any relationship 
between increasing age and complication rate.
[20] Infections do not necessarily manifest them-
selves shortly after implantation, but may oc-
cur also at long-term follow-up.[23] In our study 
nearly two thirds of the explantations of the 
entire pacemaker system occurred within one 
year and within 7 years more than 95% of the 
infected systems were explanted. 
Limitations
For approximately 70% of the leads no end-
point was registered, while for those that were 
registered more than 40% of the lead ex-
tractions, replacements and abandonments the 
reason for and date of replacement or remov-
al remained unknown. We are aware that up 
to 60% of deaths have not been registered in 
SPRN.[15] Therefore, it is expected that a large 
proportion of patients may have died during 
follow-up. Furthermore, we hypothesize that at 
replacement of the pacemaker generator, old 
leads are re-connected to the new generator. 
However, the voluntary nature of the registry is 
likely to have caused underreporting of relevant 
endpoints. 
Variables such as polarity, fixation mechanism, 
insulator material, and implantation route were 
not recorded at all. Therefore, we were not 
able to assess the influence of these relevant 
variables on the explantation and longevity of 
leads.
Implications
We anticipated that because of technical im-
provements, growing experience, guidelines 
and clustering of treatment facilities, the ser-
vice time of the leads would increase, and 
complication and failure rates would gradually
diminish over several decades of cardiac pacing. 
However, the percentage of complications and 
failures was higher than expected. Considering 
that extraction of leads has a relatively high 
incidence of serious complications,[5, 24-25] high 
percentage of lead failures and complications 
such as infections and displacement is cause 
for concern. Type and rate of complications are 
important indicators for the quality of health 
care and should contribute to the evaluation of 
protocols by health care professionals. Further-
more, for improvement of their devices, manu-
facturers are obliged to collect post-marketing 
surveillance information. For both purposes, 
device registries can be an important tool.
Conclusions 
We expected a gradual decrease of lead com-
plications requiring replacement or explanta-
tion over the 20 years of registry because of 
technological improvements, enhanced experi-
ence and training, and emergence of detailed 
clinical practice guidelines. However, lead dis-
placement and infection (largely operator de-
pendent complications) did not diminish and 
rates of registered explantation due to insula-
tion and conductor failures (largely manufac-
turer dependent complications) were consid-
erable. Further reduction of complications and 
failures is warranted. 
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 Abstract
Background 
It has been suggested that a higher procedure volume is associated with less complications after 
hip arthroplasty. In order to investigate the incidence of serious negative outcomes and a possible 
association with procedure volume, we performed a retrospective nationwide cohort study on total 
hip replacements in all Dutch hospitals. 
Methods 
All total hip replacements (n = 50,080) that were identified as primary intervention in all general 
and university medical centers between January 1, 2002 and October 1, 2004 were included. Pri-
mary endpoints of follow-up were mortality and complications during admission, and re-admission 
within 3 months due to complications. Variables that were assessed as potential risk factor were 
age, sex, duration of (preoperative) admission, specific diagnosis, acute/non-planned admission, 
comorbidity, and hospital procedure volume.
Results 
Age, sex, and comorbidity were associated with complications and mortality. Additionally, acute 
admission was a risk factor for mortality but not for complications. There was no linear trend indi-
cating that decreasing volume led to an increasing number of complications, and no statistically 
significant effect for mortality was found.
Conclusion 
After adjustment for several risk factors, we found that the hospitals performing most hip pro-
cedures every year had fewer complications during index admission, but that they did not have 
a lower mortality than groups performing fewer procedures. The lack of a linear trend may be 
explained by the fact that almost all Dutch hospitals perform a high number of hip arthroplasties 
each year.
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A 
pproximately 20,000 total hip re-
placements are performed in Dutch 
general and university hospitals 
each year.[1] It is expected that this 
number will increase to more than 30,000 in 
2030 and to more than 50,000 in the longer 
term.[2] Mortality, significant blood loss, post-
operative infections, deep venous thrombosis 
(DVT), dislocations of the prosthesis, and insta-
bility are the most common early complications. 
Risk factors for complications are the type of in-
tervention (hemiarthroplasty, total hip replace-
ment, revision, trauma surgery), age, sex, and 
other patient-related factors such as obesity.[3]
Furthermore, several studies have shown an 
association between complications on the one 
hand and experience of the surgeon and the 
hospital on the other, expressed as annual 
number of hip arthroplasties.[4-15]
Most studies have been performed in the Unit-
ed States, and due to differences in healthcare 
systems, it is not clear whether these results 
can be generalized to other countries. The aim 
of our retrospective nationwide cohort study 
was to gain insight into the incidence and risk 
of several serious complications of hip arthro-
plasty, both during the index hospitalization 
period and within the first 3 months after sur-
gery. In addition, we assessed the importance 
of risk factors for complications such as the 
experience of the hospital, expressed as the 
number of interventions performed annually 
and corrected for several patient-related fac-
tors such as age, sex, co-morbidity, and diag-
nosis.
Patients and methods 
Setting
Data were retrieved from a nationwide com-
puter database of hospital discharge records, 
with complete coverage of all admissions in all 
general and university hospitals in the Nether-
lands (which has 16 million inhabitants). None 
of these hospitals is private. The university hos-
pitals are owned by the government and the 
general hospitals are independent foundations, 
financed by public money. Private clinics did not 
perform THAs. The database includes (among 
other information) basic patient characteristics, 
date of admission and discharge, the main in-
tervention (coded), the medical specialist (cod-
ed), and the main and secondary diagnoses 
at discharge, based on the ICD-9-CM coding 
system.[16] Characteristics of hospitalizations 
are registered by treating medical specialists 
or residents and coded by professional code 
clerks on the basis of hospital discharge letters. 
For every admission, one main diagnosis or di-
agnosis at discharge (mandatory) and up to 9 
secondary diagnoses (optional) are registered. 
The coding is independent of reimbursement 
of the hospital or specialist. In addition, hospi-
tals remain anonymous with the use of unique 
codes, instead of name and address data. All 
diagnoses are submitted in the same format, 
mostly electronically.
Cohort and outcome definition
All patients admitted for a first total hip arthro-
plasty between January 1, 2002 and October 1, 
2004 were included in this nationwide cohort 
study (n = 50,080). This was the most recent 
dataset available, with sufficient power due 
to the large number of records. Each cohort 
member was followed only once from the day 
of the hip arthroplasty (index hospitalization) 
until the earliest of one of the following events: 
death during index admission, a complica-
tion, or end of the follow-up time of 3 months, 
whichever came first. Patients with an ICD-9 
code indicating certain non-fatal complica-
tions related to the implant, such as mechan-
ical loosening, dislocation, or infection of the 
implant during the index hospitalization were 
excluded since these complications may have 
been related to an earlier intervention and not 
to the index intervention that was performed 
during the study period. All interventions with 
codes indicating removal or revision of hip 
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implants were excluded from the database, 
except when such removals or revisions oc-
curred within 3 months after the index oper-
ation, as they may have indicated a compli-
cation. 
In the total population, we identified 82,582 ad-
missions for hemiarthroplasty and total hip ar-
throplasty in the period 2002-2004. After exclu-
sion of patients who were admitted in 2001 but 
discharged in 2002, admissions later than Sep-
Figure 1. Schematic representation of exclusion of patients from study population
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tember 30, 2004 to ensure at least 3 months 
of follow-up, patients discharged with codes 
indicating a complication from an earlier proce-
dure, and patients with certain types of malig-
nancies, fractures, and hemiarthroplasties, the 
study cohort consisted of 50,080 admissions 
for primary total hip arthroplasty. 
In the Netherlands, most patients with a hip 
fracture have a hemiarthroplasty procedure, 
while patients with osteoarthrosis receive a 
total hip replacement. Patients with a fracture 
are clinically different from patients with os-
teoarthrosis. Thus, we excluded patients with 
fractures from the study cohort. Additionally, 
patients with osteoarthrosis or another diagno-
sis that was not fracture were excluded if they 
had hemiarthroplasty (see Figure). 
We assessed the proportion of deaths and 
complications that occurred during the index 
hospitalization and the proportion of re-admis-
sions as a result of a selected set of potential 
complications within 3 months of the index hos-
pitalization. We searched the original database 
records over the period of April 1, 2002 to Janu-
ary 1, 2005 for admitted patients with the same 
date of birth, sex, postal code of their home 
address, and hospital identification code, as 
we found that almost all patients were re-admit-
ted to the same hospital. Complications were 
identified based on the ICD-9 codes of the 
main discharge diagnoses and on literature.[4-5]
As complications during index hospitalization 
we considered ICD-9 codes describing pulmo-
nary embolism, specific complications affecting 
specified body systems such as cardiac, vascu-
lar, respiratory, or urinary complications, com-
plications of procedures, and complications of 
medical care. Reasons for re-admission that 
were considered as complications were: sev-
eral types of infection, dislocation, vascular 
complications, and complications due to the 
procedure or implant. For this, we used a spe-
cific list, which was described earlier by Kreder 
et al. and Katz et al.[4-5] In addition, removal or 
revision of hip arthroplasty within 3 months of 
the index operation was also considered to be 
an indication of a complication and was there-
fore included as an endpoint.
Hospital volume
During the study period, the Netherlands had 
88 general hospitals and 8 university medical 
centers. 2 of the 96 hospitals only performed 
hemiarthroplasties; therefore, 94 hospitals re-
mained in the study. Some hospitals have more 
than one location, but for the purpose of our 
research they were considered as one organi-
zation. The Netherlands is a densely populated 
country with a relatively old population. The av-
erage number of hip procedures per hospital 
may therefore be higher than in other countries. 
Only 13 hospitals performed less than 100 to-
tal hip arthroplasties annually during the study 
period. When hemiarthroplasties and fractures 
were also considered, this number was even 
lower. 
We divided the hospitals into 5 volume groups 
based on the mean number of total hip arthro-
plasties performed per year. The lowest volume 
group performed less than 100 procedures a 
year and the highest volume group performed 
more than 400 procedures a year. The number 
of patients in each of these groups (see Tables 
3 and 4) is the number of patients from the total 
cohort who were in that group during the study 
period of 2.75 years. 
Our data did not allow us to distinguish between 
individual surgeons. Orthopedic surgeons per-
formed almost all of the total hip replacements 
(99.9%).
Covariables
As covariables, the following variables were 
considered for inclusion in the models: age and 
sex, surgical procedure volume per hospital, 
and co-morbidity in the year prior to the inter-
vention that was severe enough for hospitaliza-
tion and diagnosis. In order to assess co-mor-
bidity a year before surgery, we searched the 
original database records over the period Jan-
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uary 1, 2001 to January 1, 2005 for admitted 
patients who had the same date of birth, sex, 
and postal code. We classified co-morbidity ac-
cording to the Charlson co-morbidity index as 
adapted by Deyo et al. for ICD-9 databases.[17-18]
Furthermore, we considered the diagnosis, 
whether admission was acute and unplanned, 
duration of admission before surgery and total 
duration of admission.
Validation
We performed validation of procedures, compli-
cations, and mortality in a sample of our study 
material by linking it to the Rotterdam Study, a 
prospective population-based cohort study of 
chronic diseases in the elderly who live in the 
Ommoord district of the city of Rotterdam.[19]
By matching according to date of birth, sex, 
and postal code of the home address, we iden-
tified 68 patients from the study cohort in the 
Rotterdam Study. These 68 patients had been 
admitted to 3 hospitals in Rotterdam and sur-
rounding area. For 40 patients, the original 
file including the original discharge letter was 
available for review. For 17 other patients, in-
formation from their general practitioner could 
Table 1. Baseline characteristics of the study cohort (n=50,080)
a Complication during index admission and/or re-admission to 3 times within 3 months of surgery
Characteristics Primary Total Hip Replacement All admissions(n=50,080)
Males
(n=14,966, 
29.9%)
Females
(n=35,114, 
70,1%)
Mean age, years (SD) 68.7 (10.6) 65.9 (11.0) 70.0 (10.1)
      Median age, years (range) 70 (15-99) 67 (15-99) 71 (15-99)
Median duration of admission, days (range) 9 (1-137) 8 (1-137) 9 (1-133)
Median duration of pre-operative admission, days (range) 1 (0-80) 1 (0-80) 1 (0-76)
Acute, non-planned admission, n (%) 504 (1.0) 132 (0.9) 372 (1.1)
Any co-morbidity, n (%) 3423 (6.8) 1164 (7.8) 2259 (6.4)
Specialist:
      Orthopedic surgeon, n (%) 50,038 (99.9) 14,956 (99.9) 35,082 (99.9)
      General surgeon, n (%) 34 (0.1) 9 (0.1) 25 (0.1)
      Other surgeon, n (%) 8 (<0.1) 1 (<0.1) 7 (<0.1)
Died during admission (all causes), n (%) 114 (0.2) 42 (0.3) 72 (0.2)
Complication during admission, n (%) 1115 (2.2) 350 (2.3) 765 (2.2)
Readmitted at least once within 3 months with a complication 1765 (3.5) 595 (4.0) 1170 (3.3)
Any unfavorable outcomea 2880 (5.8) 947 (6.3) 1933 (5.5)
Diagnosis
      Osteoarthritis, n (%) 48,313 (96.5) 14,260 (95.3) 34,053 (97.0)
      Aseptic bone necrosis, n (%) 937 (1.9) 419 (2.8) 518 (1,5)
      Congenital deformity of hip, n (%) 141 (0.3) 37 (0.2) 104 (0.3)
      Rheumatoid arthritis, n (%) 121 (0.2) 31 (0.2) 90 (0.3)
      Other, n (%) 568 (1.1) 219 (1.5) 349 (1.0)
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be accessed digitally, and no information was 
available for the other 11 patients. 
Of all the procedures, diagnoses, and compli-
cations, 91% (CI: 84–99), 90% (CI: 82–97), and 
80% (CI: 45–115), respectively, were confirmed. 
The remainder was missing and could not be 
judged. However, no procedures, diagnoses, or 
complications were false-positive.
Analysis
Descriptive analyses were conducted using 
SPSS software version 15.0. Statistical com-
parison of means and proportions consisted 
of independent samples t-tests (Student’s), 
and chi-square tests. Because the precise 
delay between hip arthroplasty and complica-
tions during the index hospitalization was not 
available in the database, we used logistic re-
gression analysis with the first occurrence of 
a complication as endpoint instead of a Cox 
proportional hazards model. Covariables that 
were considered as risk factors in the literature 
were tested in a univariable logistic regression 
analysis in order to obtain crude odds ratios. 
The final multivariable models were fitted by 
backward elimination regression based on 
the maximum likelihood ratio.[20] The effect 
of a variable on the risk of complication was 
expressed as an odds ratio with a 95% confi-
dence interval (CI).
First
n=4364
Second
n=759
Third
n=167
n % (95% CI) n % (95% CI) n % (95% CI)
2nd total hip replacement 423 9.7 (8.8; 10.6) 25 
3.3 
(2.0; 4.6) 3 
1.8 
(-0.2; 3.8)
Complication during index admission 156 3.6 (3.0; 4.1) 34 
4.5 
(3.0; 6.0) 6 
3.6 
(0.8; 6.4)
Readmission was acute/not planned 2534 58.1 (56.6; 59.5) 397 
52.3 
(48.8; 55.9) 72 
43.1 
(35.6; 50.6)
Mortality during readmission 83 1.9 (1.5; 2.3) 9 
1.2 
(0.4; 2.0) 5 
3.0 
(0.4; 5.6)
Readmission was due to complication 1765 40.4 (39.0; 41.9) 322 
42.4 
(38.9; 46.0) 70 
41.9 
(34.4; 49.4)
Complications specified: 1765 100 322 100 70 100
   Mechanical complication of device 892 50.5 (48.2; 52.9) 212 
65.8 
(60.7; 71.0) 43 
61.4 
(50.0; 72.8)
   Infection 526 29.8 (27.7; 31.9) 73 
22.7
(18.1; 27.2) 20 
28.6 
(18.0; 39.2)
   Dislocation 47 2.7 (1.9; 3.4) 10 
3.1 
(1.2; 5.0) 0 
0.0 
(0.0; 0.0)
   Pulmonary embolism 58 3.3 (2.5; 4.1) 5 
1.6 
(0.2; 2.9) 1 
1.4
 (-1.4; 4.2)
   Deep venous thrombosis 61 3.5 (2.6; 4.3) 4 
1.2 
(0.03; 2.5) 1 
1.4 
(-1.4; 4.2)
   Other 180 10.2 (8.8; 11.6) 18 
5.6 
(3.1; 8.1) 5 
7.1 
(1.1; 13.2)
Table 2. Characteristics of first three readmissions within three months after surgery
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Early mortality during index admission
Crude OR (95% CI) Adjusted OR (95% CI)
Hospital volume as # of total hip proceduresa/yr 
>400 (nh=7 / np=8,813)
b ref ref
300-400 (nh=12 / np=10,260) 0.94 (0.52; 1.70) 0.80 (0.44; 1.47)
200-300 (nh=20 / np=12,413) 1.15 (0.67; 1.98) 1.05 (0.60; 1.83)
100-200 (nh=42 / np=16,196) 0.91 (0.53; 1.56) 0.76 (0.44; 1.32)
<100 (nh=13 / np=2,398) 0.18 (0.02; 1.30) 0.17 (0.02; 1.24)
Female sex 0.73 (0.50; 1.07) 0.58 (0.39; 0.86)
Age (quartiles of # of patients)
     <65 ref ref
     66-72 1.80 (0.81; 4.01) 1.97 (0.88; 4.42)
     73-79 5.61 (2.81; 11.19) 5.83 (2.88; 11.80)
     80< 10.92 (5.52; 21.63) 10.87 (5.36; 22.07)
Co-morbidityc
Score 0 ref ref
Score 1 3.86 (2.32; 6.43) 2.69 (1.59; 4.61)
Score 2 6.80 (3.13; 14.76) 4.16 (1.86; 9.30)
Score 3 11.68 (4.70; 29.10) 5.99 (2.27; 15.85)
Diagnosis
Osteoarthritis ref ref
Aseptic bone necrosis 3.31 (1.45; 7.57) 3.22 (1.37; 7.59)
Congenital deformity of hip - -
Rheumatoid arthritis 4.28 (0.59; 30.91) 2.32 (0.29; 18.30)
Other 12.02 (6.69; 21.59) 7.91 (4.09; 15.32)
Acute, non-planned admission 6.51 (3.02; 14.06) 3.03 (1.23; 7.22)
Duration of index admission 1.04 (1.02; 1.05) 0.97 (0.95; 1.00)d
Duration of pre-operative admisison 1.06 (1.03; 1.10) -e
Complication during index admission 17.61 (11.66; 26.62) 13.23 (8.36; 20.93)
Table 3.  Adjusted associations of all risk factors with mortality per hospital group  
Cut-off p≤0.05, odds ratios in bold font are significant
a Fractures and hemiarthroplasties excluded
b nh = no. of hospitals in group / np = no. patients in group
c Charlson comorbidity index, adapted by Deyo et al. for ICD-9 databases
d Results with 3 decimals: 0.972 (0.947; 0.999)
e Not in final multivariable model
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Results 
Approximately half of the patients were older 
than 70 years, with a mean age of 69 years
(SD 11), and about 70% were women. The me-
dian duration of admission was 9 days, with a 
median preoperative stay of 1 day. Most patients 
were admitted with a diagnosis of osteoarthritis 
(97%) and 7% had one or more co-morbidities. 
About 1% (n = 504) of the admissions were 
not planned. Most of these patients (n = 408, 
81%) had osteoarthritis as the main diagnosis, 
9.5% (n = 48) had other bone defects such as 
aseptic bone necrosis and malunion/nonunion 
of fracture, and another 9.5% (n = 48) had a 
variety of other diagnoses; 11 of the patients 
of this group had osteoarthritis as secondary 
diagnosis. The reason for these admissions be-
ing acute/unplanned was not mentioned. The 
mortality rate during the index admission was 
0.2% (n = 114), and 2.2% (n = 1,115) of the pa-
tients had one or more complications. Including 
re-admissions during the 3 months after sur-
gery, 5.8% (n = 2,880) of the patients had a 
complication, either during the index admission 
or after re-admission for that reason (Table 1). 
Almost 9% (n = 4,364) of the patients were 
re-admitted at least once within 3 months of 
surgery. About 40% (n = 1,756) were readmit-
ted with a complication of the procedure, most 
of which involved a mechanical complication of 
the device (51%, n = 892) or an infection (30%, 
n = 526). The second and third re-admissions 
within the same time frame showed a simi-
lar picture (Table 2). Of these 4,364 patients, 
about 10% were admitted for a second hip re-
placement. 
Table 3 shows the univariable and multivari-
able analyses of all risk factors associated 
with mortality during the index admission. Age, 
male sex, co-morbidity, and certain diagnoses 
appeared to be associated with mortality. Fur-
thermore, a complication during the index ad-
mission was a risk factor for mortality, with an 
adjusted odds ratio of 13 (CI: 8–21). Hospital 
groups performing fewer procedures appeared 
to be associated with a lower risk of mortality 
than the hospital group that performed most 
interventions. However, the odds ratios did not 
reach statistical significance. 
Table 4 shows the univariable and multivariable 
analysis of several risk factors with complica-
tions during the index admission and the first 3 
re-admissions within 3 months of surgery. 
Age, male sex, co-morbidity, and diagnosis 
(aseptic bone necrosis and other) were sta-
tistically significantly associated with both 
endpoints. Hospital volume appeared to be 
associated with complications during the in-
dex admission, as all lower-volume groups had 
higher odds ratios than the high-volume group. 
However, it did not show the linear trend that 
would have been expected. For re-admissions 
due to complications, this association was not 
apparent.
Discussion
In this study, we found that during the index ad-
mission for total hip replacement, the percent-
age of complications was 2.2%. Almost 9% of 
the patients in the study cohort who were ad-
mitted between January 1, 2002 and October 1, 
2004 for THA were re-admitted for any cause at 
least once within 3 months of surgery. However, 
40% of these re-admissions were due to a com-
plication that could be related to the implanta-
tion. Altogether, approximately 6% of the cohort 
of patients studied experienced a complication 
during index admission and/or within 3 months 
after the implantation. Acute admission appeared 
to be a risk factor for complications during index 
admission in the unadjusted analysis, but it was 
not selected as a risk factor in the final model. 
This may have been caused by adjustment for 
co-morbidity and diagnosis, variables that may 
confound the effect of acute admission. 
The mortality during admission was 0.2% for 
patients with a total hip replacement. A compli-
cation during index hospitalization was strongly 
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Table 4. Crude and adjusted associations of all risk factors with complications 
during index admission and re-admissions 
Cut-off p≤0.05, odds ratios in bold font are significant
a Fracturers and hemiarthroplasties excluded
b nh = no. of hospitals / np = no. of patients in that group
c Charlson comorbidity index, adapted by Deyo et al. for ICD-9 databases[25,26]
d Not in final multivariable model 
e Results with 3 decimals: 1.103 (1.095; 1.110)
f Results with 3 decimals: 1.004 (0.996; 1.012)
g Results with 3 decimals: 0.986 (0.977; 0.995)
Complication during index admission Readmission due to complication
Crude OR
 (95% CI)
Adjusted OR 
(95% CI)
Crude OR 
(95% CI)
Adjusted OR 
(95% CI)
Hospital volume as # of total hip 
proceduresa/yr 
>400 (nh=7 / np=8,813)
b ref ref ref ref
300-400 (nh=12 / np=10,260)
b 2.19 (1.74; 2.75) 2.15 (1.70; 2.72) 1.25 (1.08; 1.45) 1.25 (1.07; 1.45)
200-300 (nh=20 / np=12,413)
b 2.01 (1.61; 2.52) 1.93 (1.53; 2.43) 1.04 (0.89; 1.20) 1.02 (0.88; 1.19)
100-200 (nh=42 / np=16,196)
b 2.03 (1.63; 2.52) 1.83 (1.46; 2.29) 0.96 (0.84; 1.11) 0.94 (0.82; 1.09)
<100 (nh=13 / np=2,398)
b 2.31 (1.69; 3.16) 1.88 (1.35; 2.61) 1.11 (0.88; 1.41) 1.10 (0.87; 1.39)
Female sex 0.93 (0.82; 1.06) 0.78 (0.68; 0.90) 0.83 (0.75; 0.92) 0.79 (0.71; 0.87)
Age (quartiles of # of patients)
     <65 ref ref ref ref
     66-72 1.34 (1.13; 1.60) 1.22 (1.01; 1.46) 1.06 (0.93; 1.21) 1.12 (0.98; 1.28)
     73-79 2.00 (1.69; 2.36) 1.51 (1.27; 1.80) 1.50 (1.33; 1.70) 1.61 (1.42; 1.83)
     80< 2.63 (2.21; 3.15) 1.53 (1.26; 1.86) 1.71 (1.49; 1.96) 1.88 (1.63; 2.18)
Comorbidityc
Score 0 ref ref ref ref
Score 1 2.08 (1.70; 2.54) 1.67 (1.34; 2.07) 1.53 (1.28; 1.83) 1.39 (1.15; 1.68)
Score 2 2.51 (1.72; 3.67) 1.80 (1.20; 2.70) 1.72 (1.21; 2.44) 1.54 (1.08; 2.19)
Score 3 3.14 (1.85; 5.31) 1.89 (1.04; 3.41) 1.97 (1.18; 3.28) 1.77 (1.06; 2.95)
Diagnosis
Osteoarthritis ref ref ref ref
Aseptic bone necrosis 2.11 (1.53; 2.90) 1.82 (1.29; 2.57) 1.78 (1.36; 2.33) 1.83 (1.40; 2.41)
Congenital deformity of hip - - 0.19 (0.03; 1.37) 0.22 (0.03; 1.57)
Rheumatoid arthritis 1.17 (0.37; 3.69) 0.60 (0.16; 2.20) 2.98 (1.64; 5.42) 2.57 (1.38; 4.81)
Other 3.87 (2.83; 5.29) 2.46 (1.71; 3.52) 1.75 (1.23; 2.48) 1.75 (1.23; 2.50)
Acute, non-planned admission at 
index admission 1.83 (1.17; 2.87) -
d 0.81 (0.49; 1.36) -d
Duration of index admission 1.10 (1.09; 1.10) 1.10 (1.10; 1.11)e 1.00 (1.00; 1.01)f 0.99 (0.98; 1.00)g
Duration of pre-operative 
admission 1.04 (1.02; 1.06) 0.87 (0.84; 0.91) 0.99 (0.96; 1.03) -
d
Complication during index 
admission NA NA 1.99 (1.56; 2.52) 1.91 (1.49; 2.45)
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associated with mortality. However, as might be 
expected, mortality could not be entirely related 
to the intervention, since age, co-morbidity, and 
acute admission (i.e. trauma) were also associ-
ated with it. The high-volume group had a high-
er risk of mortality than 3 of the lower-volume 
groups. This may be explained by the fact that 
complicated total hip replacements are usually 
referred to high-volume centers. However, we 
did not find that higher hospital volume was 
associated with lower mortality, as found in 
previous studies.[12, 14] Furthermore, we must 
note here that the data came from the Dutch 
National Medical Registration, which records 
all hospital admissions until discharge. Thus, 
only mortality during admission is registered in 
this database, and we were unable to monitor 
mortality after discharge. SooHoo et al. found a 
mortality rate of 0.7% and a complication rate 
of 3.8% within 90 days.[15] It is possible that the 
mortality rate is higher and shows more dif-
ferences between volume groups when mor-
tality that occurs after discharge is taken into 
account. Mortality within 3 months of surgery 
may still be related to the procedure, although 
the rate is rather low due to modern advances 
in surgery, anesthesia, and rehabilitation— and 
despite early discharges, operations on older 
and more fragile individuals, and earlier reha-
bilitation.[21-22]
In the past decade, several studies have been 
performed on the incidence of complications 
following surgery and the effect of hospital and 
surgical procedure volume.[4-5, 7-14] Many of these 
studies had a follow-up time of 3 months after 
surgery, since it appeared that the largest pro-
portion of complications manifests itself within 
that time period, an extensive proportion of which 
occurred within a few days of surgery.[4-5, 23-24]
Primary endpoints were mortality, infection, dis-
location and/or instability, deep vein thrombosis, 
and pulmonary embolism. In our study, we in-
vestigated the occurrence of any complication, 
including the above-mentioned outcomes, and 
infection, dislocation, deep vein thrombosis, and 
pulmonary embolism separately. 
Although hospital groups performing a lower 
number of THRs were more strongly associ-
ated with complications during the index ad-
mission than the highest-volume group, our 
study did not show a trend towards a lower 
proportion of complications when the number 
of interventions per hospital increased. Fur-
thermore, there was no association between 
volume groups and re-admissions within 3 
months. As the average number of hip arthro-
plasties per hospital was high in our study, this 
may have removed the potential difference be-
tween high-volume and low-volume hospitals. 
However, as in another study that did not find 
an effect of hospital volume on outcome,[25] and 
according to privacy legislation, our adminis-
trative data did not allow us to identify the sur-
geons who performed the intervention. Several 
other studies showed that a higher volume of 
hip arthroplasties resulted in a lower incidence 
of complications, and suggested that proce-
dure volume per surgeon is the most important 
determinant.[7-8, 12-13, 26] This was questioned in 
other studies, where the authors concluded 
that hospital volume is an important factor.[9]
It was also found that in patients who were 
operated by higher volume surgeons, higher 
hospital volume was independently associated 
with lower early failure rates but specializa-
tion of the hospital may also play a role.[7, 11]
Furthermore, it has been suggested that the 
volume effect reaches a plateau and does not 
improve further regardless of increasing vol-
ume.[27] Thus, hospital volume may still be an 
appropriate indicator of quality.[28]
Finally, there may have been residual confound-
ing caused by factors that could not be adjusted 
for in our analysis, such as type of prosthesis 
used, facilities in the operating room, and so on. 
As far as we know, our study is the first nation-
wide study in which all primary total hip replace-
ments have been included, and involves a high 
average number of hip procedures per hospital 
in a densely populated country. Also, validation 
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of a sample showed that the quality of the regis-
try is good. Furthermore, it is unlikely that there 
was selection bias, since Dutch inhabitants in 
need of hip arthroplasty are generally admit-
ted to a Dutch hospital. Information bias due to 
knowledge of the research question was also 
unlikely, as the admissions were registered pro-
spectively. However, false-negative misclassifi-
cation of cases could be an issue because we 
only had access to data about mortality during 
hospitalization. Although a median length of stay 
of 9 days is rather long for this type of procedure, 
it is still likely that some mortality related to the 
procedure occurred after discharge. Additional-
ly, although trained code clerks register hospital 
admissions, mistakes in coding and deviations 
between employees and hospitals cannot be 
excluded. However, given the high concordance 
between registered determinants and complica-
tions and medical records in our validation sam-
ple, we think that this is unlikely. 
At least one additional diagnosis was men-
tioned in only 25% of the admissions. Possible 
complications may not have been registered 
because such registration is optional and only 
registration of the main diagnosis is mandato-
ry. This may have led to underestimation of the 
number of complications. 
In conclusion, in contrast with results from USA 
hospitals, volume does not fully explain the 
differences in mortality and complications be-
tween hospitals in the Netherlands. This might 
be explained in part by the fact that the aver -
age number of hip arthroplasties per hospital is 
high. This might mean that under such circum
stances, other determinants become more im-
portant in explaining differences—such as vol-
ume per surgeon or technical considerations 
such as type of prosthesis, surgical technique, 
use of cement, conditions in the operating 
rooms, or patient related factors. Other options 
that may be interesting for further investigation 
are (1) the degree of orthopedic specialization 
of hospitals, as an association between this 
parameter and favorable outcome has been 
shown in a recent study,[29] and (2) the impor-
tance of standardization of the process, which 
was found to be strongly associated with better 
patient outcomes and more efficient use of re-
sources in another study.[14]
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Abstract
Background 
Non-traumatic subarachnoid haemorrhage (SAH) is a devastating disorder and in the majority 
of cases caused by rupture of an intracranial aneurysm. No actual data are available on the inci-
dence of non-traumatic SAH and aneursymal SAH (aSAH) in the Netherlands and little is known 
about treatment patterns of aSAH. Our purpose was therefore to assess the incidence, treatment 
patterns, and case-fatality of non-traumatic (a)SAH within the Dutch general population.  
Methods 
Two population based data sources were used for this retrospective cohort study. One was the 
nationwide hospital discharge registry (LMR). Cases were patients hospitalized for SAH (ICD-9-
code 430) in 2001-2005. The second source was IPCI, a medical record database allowing for 
case validation. Cases were patients with validated (a)SAH in 1996-2006. Incidence, treatment, 
and case-fatality were assessed.
Results 
The incidence rate (IR) of non-traumatic SAH was 7.12 per 100,000 PY (95%CI: 6.94-7.31) and in-
creased with age. The IR of aSAH was 3.78 (95%CI: 2.98–4.72). Women had a twofold increased 
risk of SAH; this difference appeared after the fourth decade. Non-traumatic SAH fatality was 30% 
(95%CI: 29-31%). Of aSAH patients 64% (95%CI: 53-74%) were treated with a clipping procedure, 
and 26% (95%CI: 17-37%) with coiling.
Conclusion 
Non-traumatic SAH is a rare disease with substantial case-fatality; rates in the Netherlands are 
similar to other countries. Case-fatality is also similar as well as age and sex patterns in incidence.
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N 
on-traumatic subarachnoid hae-
morrhage (SAH) is a devastat-
ing event, with a case-fatality of 
around 30%.[1-2] Incidence rates 
have been assessed in many countries and 
two patterns can be distinguished: countries 
with high incidence of around 20 per 100,000 
person years (PY), such as Finland and Japan, 
and countries with low incidence of approxi-
mately 5-10 per 100,000 PY.[3]
Approximately 85% of non-traumatic SAH is a 
result of rupture of an intracranial aneurysm 
(IA), although it is not clear whether this per-
centage is the same over different age and 
sex categories.[1] Causes of spontaneous SAH 
from other origins include among others oth-
er vascular lesions, inflammatory and non-in-
flammatory lesions, tumours, and drug or sub-
stance use.[1, 4]
The diagnosis of SAH is primarily based on 
CT imaging and lumbar puncture, eventually 
followed by angiography; not only to identify 
an aneurysm as potential cause of the haem-
orrhage, but also to study the anatomical and 
morphological configuration of the aneurysm 
in relation to adjoining arteries, which allows 
optimal treatment selection.[1] Treatment of an-
eurysmal SAH (aSAH) consists mainly of either 
neurosurgical clipping or endovascular coiling. 
Other less frequently used treatment modal-
ities comprise wrapping, stenting, or balloon 
occlusion.[5-7]
Given the fact that no recent data on age and 
sex specific incidence of non-traumatic SAH 
and aSAH in the Netherlands are available, 
we assessed the incidence of both conditions 
in the general Dutch population. Moreover, we 
studied case-fatality, and treatment modalities 
applied to aSAH patients. This was done in two 
population based databases; a national dis-
charge database (LMR, Landelijke Medische 
Registratie) and a smaller medical record da-
tabase (IPCI, Integrated Primary Care Informa-
tion) which allowed for assessment of the pres-
ence of an aneurysm and treatment modality.
Materials and methods
LMR database
Hospital discharge diagnoses were obtained 
from the national registry of hospital admis-
sions, the National Medical Registration (LMR), 
containing information on all admissions in 
general and academic hospitals throughout the 
Netherlands (base population: approximately 
16.5 million subjects). The International Clas-
sification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM) was used to classify 
hospital admissions in the Netherlands during 
the study period. Data used include hospital 
code, patient sex and age, ICD-9-CM coded 
discharge diagnosis, up to 9 diagnostic or ther-
apeutic procedures (coded according to the 
LMR Classification of Diagnostic, Therapeutic, 
and Surgical Acts), and discharge destination 
(‘home’, ‘old people’s home’, ‘nursing home’, or 
‘died in hospital’).
Non-traumatic SAH cases were all admissions 
with a primary discharge diagnoses (ICD-9-
CM) 430 (subarachnoid haemorrhage) during 
the years 2001 through 2005. Case-fatality was 
defined as dying in the hospital during hospital-
ization for SAH.
The denominator for the incidence calculation 
was the annual mid-year population size as 
obtained from Statistics Netherlands (CBS, ac-
cessed through http://www.cbs.nl, as of 7 June 
2010).
IPCI database
The Integrated Primary Care Information (IPCI) 
database is a general practice research data-
base with electronic medical record data cur-
rently comprising more than one million pa-
tients throughout the Netherlands. The patient 
population is representative of the Dutch pop-
ulation regarding age and sex.[8] Details of the 
database have been described elsewhere.[9]
The system complies with the European Union 
guidelines on the use of medical data for re-
search and has been proven valid for epide-
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miological studies.[9] The Scientific and Ethical 
Advisory Group of the IPCI project approved 
the study (Project No. 07/02). The database 
allows for validation of disease by requesting 
additional information from the general practi-
tioner by questionnaire and copies of original 
specialist letters.
Potential cases of n on-traumatic SAH and 
aSAH were identified from the IPCI database 
using an extensive narrative search; we identi-
fied potential cases in the computerized records 
by searching for International Classification of 
Primary Care (ICPC) codes of ‘cerebrovascular 
accident’ (K90), ‘other diseases of peripheral 
arteries’ (K92), or ‘other diseases of the circu-
latory tract’ (K99), and by free text searches on 
‘intracranial’, ‘aneurysm’, ‘subarachnoid’, ‘hae-
morrhage’, or ‘nimodipine’. In the Netherlands, 
nimodipine is exclusively prescribed as prophy-
laxis for delayed cerebral ischemia after aSAH. 
To further validate the diagnosis of SAH, a 
short questionnaire was mailed to the GPs. 
The questionnaire was used to confirm wheth-
er the person, according to the GP’s judgment, 
indeed suffered from (aneurysmal) SAH, and 
whether the patient had been seen and diag-
nosed by a specialist. Copies of all specialist 
letters were requested. Specialist letters usu-
ally provide information about history, physical 
examination, lumbar puncture, and reports on 
imaging of the patient. 
All cases were validated by manual review of 
the electronic medical record and subsequent-
ly by review of a questionnaire and specialist 
letters that were obtained from the GP for each 
case. The validity of the diagnosis was judged 
by a medical doctor (R.R.) and a neurologist 
(D.W.J.D. or F.K.). The judgment of the neurolo-
gist was decisive. Case-fatality was defined as 
dying within a period of 30 days after the date 
of onset of SAH (index date).
The denominator for the incidence calculation 
was the number of person years in the IPCI da-
tabase during the study period (January 1996–
September 2006).
Statistical analysis
The incidence rate of non-traumatic SAH and 
aSAH was calculated by dividing the number of 
incident cases (numerator), by the total number 
of accrued person years (IPCI) or persons (LMR) 
in the study population (denominator). Incidence 
rates (IR) were calculated in age and sex cate-
gories. Confidence intervals (95% CI) for each 
estimate were based on the Poisson distribution. 
To estimate case-fatality of aSAH in the IPCI da-
tabase, Kaplan-Meier survival analysis was used. 
Incidence rates were used to calculate rate ratios 
of SAH and aSAH between females and males. 
All analyses were performed using SPSS soft-
ware version 15.0 (Chicago, Ill., USA).
Literature review
To compare our Dutch findings with the existing 
literature on this topic, we performed a system-
atic review of the literature from October 2005 
onwards, adding to the review of De Rooij and 
co-workers on the same topic, which ended in 
October 2005.[3] A similar Medline search was 
used: (“Stroke”[Mesh] OR “Subarachnoid Hae-
morrhage”[Mesh]) AND (“Epidemiology”[Mesh] 
OR “Population”[Mesh] OR “Incidence”[Mesh]) 
for the time period from October 2005 to May 
2009. The papers thus obtained were abstract-
ed manually by one researcher (R.R.). Our 
inclusion criteria were: (1) study population is 
representative of the population in general; and 
(2) for studies about stroke in general, SAH 
should be considered as a separate entity. We 
excluded papers reporting incidence rates in 
Finnish and Japanese populations, since these 
rates are consistently higher than in other pop-
ulations and therefore add little to the compari-
son with our findings.[1]
Results 
LMR: SAH
In the period 2001 to 2005 a total of 5,769 pa-
tients (64% female) were admitted to Dutch 
hospitals with discharge diagnosis ‘non-trau-
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Figure 1. Sex Specific Incidence Rates of SAH in 5-year age bands in LRM data. Solid lines are estimated rates, 
dashed lines the 95% confidence bands; grey line for women, black line for men
Figure 2. Non-traumatic SAH and aSAH incidence rate by age (IPCI database)
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matic subarachnoid haemorrhage’. The over-
all nationwide incidence rate of non-traumatic 
SAH was 7.12 per 100,000 person-year (PY) 
(95% CI: 6.94-7.31) (Table 1). The incidence 
rate rapidly increased with age (Table 1, Figure 1).
The overall incidence rate ratio (IRR) of SAH 
for women compared to men was 1.72 (95% CI: 
1.63-1.81). This differential risk occurred grad-
ually and was most pronounced in the fourth 
and fifth decade (Table 1, Figure 1). Case-fa-
tality for SAH during hospitalization was 30% 
(95% CI: 29-31%), and increased with age, 
but did not differ between males and females
(Table 1).
IPCI database: non-traumatic 
SAH and aSAH
In the initial source population of 488,118 per-
sons, 107 incident cases of non-traumatic SAH 
(70% female) were identified after validation 
(Table 1). Based on these data the observed 
crude rate was 5.53 per 100,000 PY (95% CI: 
All Female Male All
1st author Year IR 95% CI IR 95% CI IR 95% CI case-fatality 95% CI
De Rooij[3] 2007 9.1 8.8-9.5 - - - - - -
2007a 10.5 9.9-11.2 11.5 10.6-12.6 9.2 8.4-10.2 - -
Benatru[19] 2006 2.12f,g 1.04–3.21 - - - - 26.1c 10.6–55.5
Feigin[20] 2006 10 8.0-12.0 10 7.0-13 10 7.0-13 - -
Jiang[21] 2006 1.6d 0.8–4.1 1.5d 0.6–6.7 1.6d 0.6–6.5 - -
Johansen[22] 2006 9 - 10 - 6 - 27.5c 25.5-29.5b
Labovitz[23] 2006 9.7 7.5–12.0 10.4 - 9 - 26.0c 16-40b
Engberg[24] 2007 13.6 - - - - - 22.7e 19.8-25.8b
Kozak[25] 2007 27 26-28 33 32-35 20 19-21 26.7 25.2-28.3
Smeeton[26] 2007 6h 5.0-8.0 - - - - - -
Ishikawa[27] 2008 - - 54.4 - 25.6 - - -
Islam[28] 2008 7f 4.0–12.0 7 3.0–15 7 3.0–16 25c 0.5–49.5
Koffijberg[17] 2008 12.4 12.2-12.6 14.4 14.2-14.7 10.3 12.2-12.6 31.7c 30.9-32.5b
Vaartjes[29] 2008 7.9b 7.4-8.3b 9.9 9.2–10 5.7 5.2–6.3 - -
EROS[30] 2009 - - 3.3g 0.7-9.2 4.8g 1.5-11.4 - -
Sridharan[31] 2009 4.2i 2.2-6.1 - - - - - -
Table 2. Published incidence rates of non-traumatic SAH, overall and in sex strata 
a Subset of 18 studies, reporting incidences for men and women separately
b Calculated from data in article
c Case-fatality within 28 days
d Beijing population only
e Case-fatality within 14 days
f Most recent period only
g Standardized to EU population
h White population only
i Age adjusted
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4.56–6.66) (Table 1), which translates to a rate 
of 6.48 per 100,000 PY in the Netherlands af-
ter standardization to the Dutch age and sex 
distribution. The incidence rate increased with 
age and was similar to the LMR rates up until 
64 years; rates were lower after that (Table 1). 
In 68% of all IPCI derived non-traumatic SAH 
cases (n=73) an aneurysm had been diag-
nosed (95% CI: 59-76%). The proportion of 
aneurysms as cause of non-traumatic SAH 
diminished with age, although the trend is not 
statistically significant (Figure 2). 
The crude observed incidence rate of aSAH 
was 3.78 per 100,000 PY (95% CI: 2.98–4.72), 
which would imply a rate of 4.26 per 100,000 
for the Dutch population (age and sex stan-
dardized). Of the patients with an aneurysm 
the majority was treated by means of a neuro-
surgical clipping procedure (64%, 95% CI: 53-
74%) and 26% (95% CI: 17-37%) by means of 
endovascular coiling. Five patients (7%) did not 
receive any treatment because of rapid deterio-
ration and death. In the remaining 3% we could 
not find information on procedures. 
Kaplan-Meier survival analysis showed that 
26% of SAH patients died within 30 days (95% 
CI: 17-34%) (Table 1). Case-fatality in aSAH pa-
tients was 5.6% (95% CI: 0.31-10.9) (Table 1). 
Risks could not be estimated in separate treat-
ment groups due to low numbers.
Discussion 
We used two different population based data-
bases: a hospital discharge database and an 
electronic medical record database to assess 
the occurrence, treatment, and case-fatality of 
non-traumatic SAH and aSAH in the Nether-
lands. We used both sources to profit from the 
size in the LMR and the quality of information 
and validation opportunities in the IPCI data-
base. By using these data, we revealed various 
important observations: first, the crude national 
incidence rate of SAH was between 5 and 7 
cases per 100,000 PY, putting the Netherlands 
in the low incidence countries. Second, about 
70% of non-traumatic SAHs were of proven 
aneurysmal origin and this varied slightly by 
age (lower in high ages). Third, case-fatality 
of non-traumatic SAH was high: around 26% 
within one month and this increased with age. 
Fourth, a striking age and gender pattern was 
observed in the incidence rates. The incidence 
rates increased rapidly after age 40, but most-
ly so for women. Fifth, the incidence rates for 
aSAH increased less rapidly with age than for 
non-traumatic SAH overall, suggesting a differ-
ence in the percentage of aneurysms by age. 
Sixth, the majority of persons with an aSAH 
underwent surgical clipping. 
Our findings on the rates and case-fatality 
were similar to previously published popula-
tion-based studies from other countries. How-
ever, often the rates for aSAH are not available. 
The assumption that 85% of non-traumatic 
SAH is based on aneurysms, may therefore not 
hold true and certainly not for all age categories. 
Some of the previous studies have investigated 
sex specific rates and age-gender interaction, 
and also reported higher rates in women; how-
ever, the age dependent change in incidence 
for women compared to men was reported few 
times. The reasons for the overall higher inci-
dence in women are not clear, but hormonal 
factors would be a first logical option.[10-11] Our 
finding that the preponderance of women be-
comes evident around the menopause, during 
which changes in oestrogen levels take place, 
further supports this suggestion. Previously, an 
increase in cardiovascular risk among women 
after menopause has been recognized,[12] for 
which declining endogenous oestrogen levels 
have been held responsible.[13] Declining levels 
of oestrogen might lead to impaired activation 
of nitric oxide,[14] which is hypothesized to be an 
important factor in the aetiology of SAH through 
its effects on the vascular endothelium.[15-16]
Being based on observational data the results 
of our study should be interpreted in the light 
of potential limitations, such as selection bias 
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and information bias. Selection bias in assess-
ment of rates and case-fatality is negligible in 
this study since we used population based da-
tabases. Selection may have occurred because 
validation of the discharge diagnoses for the 
LMR was done only in our hospital. Results of 
this validation may not be generalizable to all 
other centres. Thus, the most important limita-
tion is misclassification of the outcome. For a 
patient to be considered a case in our study, 
the diagnosis non-traumatic SAH had to be 
made. Patients who died before reaching medi-
cal care were not included in the LMR estimate 
and it is highly likely that they were also missed 
in the IPCI database due to lack of a proper 
diagnosis and specialist information. Previous 
studies have estimated the percentage of per-
sons dying outside hospitals to be between 
11 and 13%.[17-18] This means that the true in-
cidence is potentially 10% higher than in our 
estimations (up to 8 per 100,000 PY). Another 
potential limitation is the accuracy of the regis-
tered diagnosis in the LMR database. Valida-
tion of discharge diagnoses in our own hospital 
showed that 10% of the cases were false pos-
itive (data not shown). Inclusion of these false 
positive cases in incidence estimates would 
lead to overestimation. In the IPCI database, 
false positives were unlikely, since cases were 
validated. In both databases, false negative 
misclassification has not been quantified. We 
think it is limited in the IPCI database as we ap-
plied a very sensitive search on codes and free 
text to identify potential cases and reviewed all 
potential cases manually. 
Misclassification of mortality was an issue in 
the LMR database. Since the database only
captures data during hospitalizations and is 
not linked to a death registry, it is not possible 
to obtain mortality data of patients once they 
are discharged from the hospital. We therefore 
chose to report on the mortality during hospital 
admission only. Nonetheless, the case-fatality 
is comparable to the case-fatality as estimat-
ed from the IPCI database that does capture 
follow-up and mortality data. This implies that 
most cases die often immediately and mostly 
during hospitalization. Case-fatality of aSAH pa-
tients is remarkably low and may not represent 
true fatality of an aneurysmal SAH (Table 1).
Severe cases may have died before undergo-
ing imaging; in that case an aneurysm could 
not be proven. Less severe cases will probably 
have survived the 30-day period.
The strength of this study is that two sepa-
rate databases were used to address not only 
non-traumatic SAH but also aSAH. Both are 
observational and our study showed that they 
can be used complementary. Discharge data-
bases are large which allows for fine stratifi-
cation, but medical record databases allow for 
depth and more clinical insight. Together they 
have provided thorough insight in the occur-
rence, case-fatality, and treatment of non-trau-
matic (a)SAH.
Conclusion
In this study, we showed non-traumatic SAH 
incidence in the Netherlands is in the range of 
the low-incidence countries. We demonstrated 
that the incidence for both SAH and the sub-
group of aSAH depends highly on age and sex 
but the patterns for aSAH might be slightly dif-
ferent than for non-traumatic SAH overall.
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Abstract
Background 
Invasive procedures for treatment of trigeminal neuralgia (TGN) include percutaneous radiofre-
quency thermocoagulation (PRT), partial sensory rhizotomy (PSR) and microvascular decom-
pression (MVD). Using a nationwide discharge registry from the Netherlands, we assessed the 
frequency of use, patient characteristics and evaluated treatment failure for each patient undergo-
ing PRT, PSR or MVD from January 2002 through December 2004. 
Methods 
Only patients without a procedure in the year prior were included. Primary outcome was read-
mission for repeat procedures for TGN or known complications within one year. Comparability 
of patient populations was assessed through propensity scores based on hospital, age, sex and 
comorbidity. Conditional logistic regression matched on propensity score was used to calculate 
relative risks (RR) with 95% confidence intervals (95% CI) for repeat procedures or complications. 
Results 
During the study period, 672 patients with TGN underwent PRT, 39 underwent PSR and 87 un-
derwent MVD. Hospital type was the predominant determinant of procedure type; age, sex and 
comorbidity were weak predictors. The RR for repeat procedures for PSR was 0.21 [95% CI: 0.07; 
0.65] and for MVD 0.13 [95% CI: 0.05; 0.35] compared to PRT (RR 1). For complications, the RR 
of PSR was 5.36 [95% CI: 1.46; 19.64] and of MVD 4.40 [95% CI: 1.44; 13.42]. 
Conclusion 
Sex, urbanization and comorbidity did not influence prognosis but hospital and surgical volume 
did. In conclusion, although PSR and MVD are associated with a lower risk of repeat procedure 
than PRT, they seem to be more prone to complications requiring hospital readmission.
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T
rigeminal neuralgia is a severe 
form of facial pain presenting with 
paroxysmal, unilateral pain in one 
or more branches of the fifth cranial 
nerve.[1] It has an estimated annual incidence 
of 12.6 per 100,000 person-years.[2] It can be 
either idiopathic or secondary to diseases such 
as tumors, infarction and multiple sclerosis.[3]
Idiopathic trigeminal neuralgia is currently hy-
pothesized to be caused by neurovascular 
contact between an aberrant vein or artery and 
the fifth cranial nerve at the root entry zone.[4] 
The three most common invasive modalities for 
the treatment of idiopathic trigeminal neuralgia 
are microvascular decompression (MVD), par-
tial sensory rhizotomy (PSR) and percutane-
ous radiofrequency thermocoagulation (PRT). 
During MVD a teflon patch is placed between 
the nerve and vascular structure using an open 
brain surgical approach.[5] Partial sensory rhi-
zotomy and PRT are both destructive tech-
niques aiming to destroy a part of Gasserians 
ganglion by respectively a neurosurgical or a 
minimal invasive röntgen-guided approach.[6]
Other possible procedures include glycer-
ol injections, gamma-knife radiosurgery and 
balloon decompression. All procedures lack 
evidence of efficacy in randomized controlled 
trials.[7]
Partial sensory rhizotomy is sometimes used 
as an alternative for MVD if arterial contact 
cannot be found, but it is also an open neu-
rosurgical procedure with risks comparable to 
those of MVD.[8] Although guidelines exist sug-
gesting a longer duration of pain freedom after 
MVD compared to PRT, this advice should be 
regarded as an expert opinion.[9-10] A literature 
study describing long term outcomes of indi-
vidual treatment modalities indicate that MVD 
has a better effectiveness than PRT, but also 
a higher rate of adverse events.[11] Studies in-
cluded in this review concerned mainly cohort 
studies of individual procedures with more than 
five years of follow-up. These studies, however, 
have not been performed in one data source 
and therefore do not allow for a direct compari-
son of procedures. 
At present the frequency of use of the individ-
ual invasive treatment modalities for trigeminal 
neuralgia in daily practice is not known and 
comparisons of the safety and effectiveness of 
the different treatment modalities on a popula-
tion-based scale are lacking. Direct compari-
sons between the treatment modalities using 
one data source have not been reported. Fur-
thermore, reports on prognostic factors for the 
success rate of individual treatment modalities 
remain contradictory.[12] To describe the fre-
quency of use of MVD, PSR and PRT and to 
compare the complication and failure rate of 
these modalities on a nationwide scale, we per-
formed a cohort study using a database with 
hospital discharge diagnoses with complete 
coverage of the population in the Netherlands.
Materials and methods 
Source population
Data were retrieved from a nationwide electronic 
database with hospital discharge records, that 
covers admissions in all general and university 
medical centers in the Netherlands (Landelijke 
Medische Registratie). The database includes, 
among others, demographics, date of admis-
sion and discharge, main intervention (coded), 
medical specialist (coded) and the main and 
secondary diagnoses at discharge, based on 
the ICD-9-CM coding system.[13] Characteris-
tics of hospitalizations are recorded by medi-
cal specialists or residents and coded by pro-
fessional code clerks on the basis of hospital 
discharge letters. For every admission, one 
discharge/main diagnosis (mandatory), and up 
to nine secondary diagnoses (optional) are reg-
istered. This is done similarly for interventions. 
The coding is independent of reimbursement 
of hospital or specialist. Patients and hospitals 
are anonymized to allow for secondary use and 
processing of the data. All diagnoses are sub-
mitted in the same format, mostly electronically. 
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The database used for this study comprised 
data from 1 January 2001 up to and including 
31 December 2005. More recent data are not 
available due to a change in the registration 
system in the Netherlands, which has resulted 
in incompleteness of the registry after 2005.
Cohort definition
For incidence rate calculations, the study base 
comprised the entire population of the Neth-
erlands during the study period between 1 
January 2002 and 31 December 2004. For all 
other analyses, we generated a cohort of pa-
tients admitted for MVD (ICD-9 codes: 5-014.0), 
PSR (intervention code (ICD-9 codes): 5-014.1, 
5-014.2) or PRT (ICD-9 codes: 5-043.2) all with 
trigeminal neuralgia as main diagnosis during 
the study period. Patients who had one of the 
procedures in the year prior to study entry were 
excluded from the cohort. Each cohort mem-
ber was followed until the earliest of one of the 
following events: admission for a complication, 
repeat procedure (any of the three studied) or 
end of a one-year follow-up period, whichever 
came first. 
Outcome definition
The primary outcome parameters in this study 
were frequency of use, plus complications and 
treatment failure leading to hospital readmis-
sion within one year of the initial admission. 
Complications included hospitalizations for 
hearing loss, dysaesthesia, persistent neuro-
logical deficit, death, cerebrospinal fluid leak-
age, facial hypaesthesia, meningitis, ataxia, 
heamatoma, infarctions, pulmonary embolisms, 
herpes labialis, vertigo, tinnitus, an- or hypacu-
sis, facial spasms, trochlear and acoustic palsy, 
facial paresis, severe brain damage, keratitis, 
sensory loss, corneal hypaesthesia, arterio-
venous fistula, bleeding, loss of sight, corne-
al anesthesia, facial asymmetry and all ICD-9 
codes specifically specifying complications of 
procedures (appendix 1).[5, 8, 11, 14-20] Complica-
tions were identified based on the ICD-9 codes 
of the main or secondary diagnoses. Treatment 
failure was defined as a readmission for one of 
the studied procedures for treatment of trigemi-
nal neuralgia or for other reasons (e.g. pharma-
cological treatment) with trigeminal neuralgia 
mentioned as primary or secondary diagnosis. 
The index date for complications and failure 
was the date of hospital admission. 
In addition to readmission rates for first com-
plication or repeat procedure, we examined 
the duration of hospital stay of the initial pro-
cedure (index hospitalization) and in-hospital 
mortality of the index hospitalization as sec-
ondary outcomes. To evaluate complications 
and treatment failure after discharge, patients 
were linked by patient number (same hospital) 
and gender, date of birth and postal code (oth-
er hospitals). 
Covariates
We considered the patient related (age, sex, 
urbanization level, comorbidity, specialism per-
forming the procedure) and hospital related 
variables (surgical procedure volume per hos-
pital, type of hospital) as potential confounders 
and prognostic factors. These factors might be 
related to treatment choice and outcome based 
on either clinical judgment or literature. Urban-
ization was chosen since it might reflect the ac-
cessibility to health care providers in the direct 
neighbourhood. The year prior to the index hos-
pitalization was used to assess the presence 
of comorbidity (leading to hospital admission) 
on the basis of discharge diagnoses during that 
year. Comorbidity was categorized according 
to the Charlson comorbidity index adapted for 
ICD-9 CM.[21, 22] During the study period, there 
were 105 hospitals in the Netherlands, of which 
eight were university medical centers. To com-
pare the experience with a specific procedure 
between hospitals we classified the surgical 
volume (i.e. number of procedures performed) 
for each procedure in each hospital into quin-
tiles. Quintiles were based on the distribution of 
surgical volumes in the population. A surgical 
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volume category of one meant that the hospital 
belonged to the 20% hospitals with the lowest 
surgical volume in a certain procedure (includ-
ing zero procedures). A score of five meant 
that the hospital belonged to the group of 20% 
hospitals with the highest surgical volume. The 
scores related to the three different procedures 
were then added together in one overall score 
ranging from 3 to 15, under the assumption that 
all types of procedures add to the experience of 
hospitals and surgeons.[14] Urbanization of the 
home address was evaluated using postal code 
data from Statistics Netherlands.[23] Very urban 
indicated more than 2500 houses per squared 
kilometer. Moderately urban is between 1500 
and 2500, normal between 1000 and 1500, 
moderately rural between 500 and 1000 and 
very rural below 500 houses per squared ki-
lometer.
Analysis
For each treatment modality, we calculated the 
incidence rate by dividing the number of proce-
dures by the total Dutch population for that year 
according to Statistics Netherlands.[23]
Failure and complication risks were calculated 
for each type of intervention at 1 month, 1-2 
months, 2-3 months and 3-12 months after the 
initial hospitalization by Kaplan-Meier analysis. 
Rates of failure and complication were calcu-
lated by dividing the number of readmissions 
by the total number of person years (patients 
could count multiple times). 95% Confidence 
intervals (95% CI) were calculated based on a 
binomial distribution.
To study whether we could compare outcomes 
between treatment groups we calculated pro-
pensity scores for each procedure with PRT as 
reference category.[24] Overlapping propensity 
scores of different procedures would indicate 
comparable treatment groups allowing for cal-
culation of relative risks for complications and 
repeat procedures. Propensity scores were 
calculated for each procedure separately. The 
following variables were included in the model: 
the Charlson comorbidity score, sex, age and 
the type of treating hospital using logistical re-
gression analysis. The final propensity score in-
cluded all of these covariates for all procedures. 
Since we expected the treating hospital to be a 
very large predictor for type of procedure, we 
calculated a second propensity score model 
including age, sex and chronic disease score. 
Conditional logistic regression with matching 
on propensity score (including age, sex and co-
morbidity within bins of 0.1) was used to yield 
relative risks (RR) for PSR and MVD. Percuta-
neous radiofrequency thermocoagulation was 
taken as reference category. A Cox proportional 
hazards model was used to analyze prognostic 
factors for treatment failure. 
A sensitivity analysis was performed includ-
ing only specific complications described in 
literature (all of the above except the ICD-9 
codes specifically specifying complications of 
procedures).[5, 8, 11, 14-20] Furthermore, to ensure 
complications were due to the index hospital-
ization and not due to other interventions after 
the index hospitalization a sensitivity analysis 
was performed in patients without hospitaliza-
tions between the index hospitalization and 
the first complication. Further sensitivity anal-
yses included only patients operated in 2004, 
taking into account only complications and 
readmissions stated as primary discharge di-
agnosis (not as additional diagnoses). Hos-
pitalization data only provide information on 
in-hospital death and death may impact on the 
failure rates. Therefore, we conducted a surviv-
al analysis with imputed survival data to take 
into account deaths occurring during follow-up. 
Survival data was imputed using the age and 
gender specific mortality data of the general 
Dutch population from 2003 as provided by Sta-
tistics Netherlands (CBS).[23] Imputation of sur-
vival data was done using R (version 2.7.12) (R 
Development Core Team, Vienna, Austria).[25]
Five possible dates of death were imputed 
based on age and gender. The Kaplan Meier 
analyses were redone using this imputed sur-
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Figure 1B. Incidence rate per calendar year. The y-error bars display the 95% confidence interval. The incidence 
rate of most treatment modalities is more or less stable over time. PRT, percutaneous radiofrequency thermocoag-
ulation; PSR, partial sensory rhizotomy; MVD, microvascular decompression.
Figure 1A. Incidence of individual treatments. The incidence per 1000,000 people per age category in The 
Netherlands. Treatments are applied more in older people, which is to be expected because the incidence of 
trigeminal neuralgia increases with age. Neurovascular treatment is not used after the age of 80. 
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vival data. In compliance with the method of 
multiple imputations the rates and the standard 
errors were averaged.[26] All statistical analyses 
were conducted in SPSS 15.0 (SPSS, Inc, Chi-
cago, IL,USA).
Results
Incidence
Between 1 January 2002 and 31 December 
2004, 87 MVD, 39 PSR and 672 PRTs were per-
formed. The incidence rate of the three studied in-
vasive procedures for trigeminal neuralgia in the 
Dutch population was 16.4 per million persons 
per year (95% CI: 15.3; 17.6) (Table 1). The rates 
were highest between the age of 70 and 79 for all 
procedures and the rate remained more or less 
stable over calendar time (Figure 1A and B).
Baseline characteristics
Patients undergoing an intervention for trigem-
inal neuralgia during the study period were on 
average 65.8 years of age (SD 13.4) and a 
minority was male (43%) (Table 1). Patients 
were generally healthy with a mean Charlson 
comorbidity index of zero. The average num-
ber of procedures performed per hospital per 
year was 5.54 (SD 8.94). Percutaneous ra-
diofrequency thermocoagulation was the most 
widely applied procedure with a high average 
relative surgical volume level compared to that 
of PSR and MVD (1.17, 0.44 and 0.31 proce-
dures per hospital respectively). Finally, pa-
tients undergoing PRT were on average older 
and had a shorter hospital stay than patients 
admitted for the other procedures. There were 
large differences in hospital and physician 
characteristics between the three procedures 
(Table 1).
Complications / therapeutic failure
In total, 33.8% of patients were readmitted for 
a repeat procedure (2.4%) or a complication 
(31.6%) within one year following the initial 
procedure (Table 2). The one-year readmission 
risk derived from Kaplan-Meier analysis was 
34% (95% CI: 30% to 37%) for all procedures 
together. The one-year readmission risk was 
lowest with MVD (9%, 95% CI: 3% to 15%) and 
highest for PRT (38%, 95% CI: 34% to 42%) 
(Table 2, Figure 2).
Most complications occurred within the first 
month (31.6%) after the initial procedure. The 
risk of complications was lowest for PRT (2% 
vs 8% and 6%). The majority of complica-
tions were unspecific procedure complication 
codes (61%). Specified complications includ-
ed Bell’s palsy (11%), infections (5%), ana-
phylactic shock (6%), hemiplegia (6%), aspi-
ration (6%), hematoma (6%) and respiratory 
complications (6%). Most repeat procedures 
took place between the third and ninth month 
(36.5%) after the initial procedure. 
Figure 2. Survival curve. Of the 3 studied treatment 
modalities, the percutaneous radiofrequency thermo-
coagulation had the highest risk of readmission. PRT, 
percutaneous radiofrequency thermocoagulation; 
PSR, partial sensory rhizotomy; MVD, microvascular 
decompression.
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A propensity score model based on hospital, 
age, sex and comorbidity could accurately 
predict which treatment was given (c statis-
tic 0.99). There was, however, poor overlap. 
If hospital was excluded from the propensity 
score the model performed worse (c-statis-
tic 0.70) but there was considerable overlap 
showing that actually the hospital was im-
portant for the decision which treatment to 
perform and not so much the patient. After 
matching on propensity score (not consid-
ering hospital), the relative risk of PSR for 
readmission (both complications or repeat 
procedures) was 0.40 [95% CI: 0.18 to 0.90], 
5.36 [95% CI: 1.46 to 19.64] for complications 
and 0.21 [95% CI: 0.07 to 0.65] for repeat 
procedures. Microvascular decompression 
had a relative risk of 0.25 [95% CI: 0.12 to 
0.52] for total readmission, 4.40 [95% CI: 1.44 
to 13.42] for complications and 0.13 [95% CI: 
0.05 to 0.35] for undergoing a repeat proce-
dure. Most people undergoing a PRT under-
went a PRT as repeat procedure, whereas 
most people undergoing a PSR underwent 
this procedure again as repeat procedure. In 
contrast, after MVD most people had a PRT 
as second procedure (Table 2). 
Sensitivity analyses considering only patients 
operated in 2004, or only healthy patients 
(Charlson comorbidity index of zero), or only 
in literature specified complications, or only 
main diagnoses or using imputed survival data 
showed that the results and conclusions did not 
materially change (p>0.05).
Concerning our secondary outcomes; the ad-
mission duration of the index hospitalization 
was 2.62 days (SD 3.38). No patients died 
during hospital stay (95% CI: 0.0% to 0.4%). 
Table 2. Characteristics of readmissions following initial procedure for trigeminal neuralgia
This table displays the prevalence and type of readmission within one year according to type of initial procedure 
for trigeminal neuralgia
PRT, Percutaneous radiofrequency thermocoagulation
PSR, Partial sensory rhizotomy
MVD, Microvascular decompression
a There is one patient admitted for both a repeat procedure and a complication
b Admission for trigeminal neuralgia without a specific intervention listed. A reason for readmission without 
intervention can be drug treatment
c Calculated by using Kaplan-Meier analysis with days from discharge until readmission as follow-up time. 
Between square brackets are the 95% confidence intervals. SD = standard deviation
PRT PSR MVD Total
Readmission total (%) 256 (100%) 6 (100%) 8 (100%) 270 (100%)
   Complication (%) 11 (4.3%) 3 (50.0%) 5 (62.5%) 19 (7.0%)
   Repeat procedure (%) 245 (95.7%) 3 (50.0) 4 (37.5%)a 252 (93.0%)a
Repeat procedure
   Percutaneous Radiofrequency Thermocoagulation (%) 196 (80.0%) 0 (0.0%) 2 (50.0%) 198 (78.6%)
   Partial Sensory Rhizotomy (%) 2 (0.8%) 2 (66.7%) 1 (25.0%) 5 (2.0%)
   Microvascular Decompression (%) 6 (2.4%) 0 (0.0%) 1 (25.0%) 7 (2.8%)
   Other or unspecified (%)b 41 (16.7%) 1 (33.3%) 0 (0.0%) 42 (16.7%)
One-year readmission riskc 38 [34-42] 15 [4-27] 9 [3-15] 34 [30-37]
   One-year complication riskc 2 [1-3] 8 [0-16] 6 [1-11] 3 [2-4]
   One-year risk for repeat procedurec 37 [33-41] 8 [0-17] 5 [0-9] 32 [29-35]
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Prognostic factors
Sex, age, comorbidity, surgical volume, urban-
ization and hospital (aggregated) were evalu-
ated as prognostic factors for treatment failure. 
Cox regression analysis, stratified by the type 
of first procedure showed surgical volume and 
type of hospital to be associated with failure 
(Table 3). Only the second and fifth group of 
surgical volume were associated with an in-
creased risk of failure (OR: 1.54 (95% CI: 1.10 
to 2.16) and 1.53 (95% CI: 1.07 to 2.20) respec-
tively). However, no clear volume-success rela-
tionship (i.e. dose-effect) could be shown. Be-
ing treated in a general hospital was associated 
with an increased risk of failure (OR: 4.81 (95% 
CI: 2.47 to 9.34) compared to being treated in 
Table 3. Prognostic factors
In bold are the statistically significant predictors of treatment failure
Ref is reference category, NA is not available (no cases in that group)
PRT, Percutaneous radiofrequency thermocoagulation
PSR, Partial sensory rhizotomy
MVD, Microvascular decompression
PRT PSR MVD Total
Age 0.92 [0.72-1.18] 1.30 [0.24-7.08] 7.18 [0.88-58.39] 1.01 [0.79-1.28]
Sex 1.01 [1.00-1.02] 0.96 [0.00-1.02] 1.00 [0.95-1.05] 1.01 [1-1.02]
Comorbidity index
   0 Ref NA Ref Ref
   1 1.21 [0.62-2.36] NA 0.05 [0.00-∞] 1.33 [0.68-2.58]
   2 4.19 [1.34-13.12] NA 0.05 [0.00-∞] 2.92 [0.94-9.13]
   3 0.73 [0.18-2.92] NA NA 0.85 [0.21-3.4]
Hospital
   University Ref Ref Ref Ref
   General 4.56 [1.13-18.32] 0.03 [0-32.85] 10.35 [1.27-84.12] 4.81 [2.47-9.34]
Surgical volume
   1 Ref NA Ref Ref
   2 1.49 [1.06-2.08] Ref 98257.15 [0.00-∞] 1.54 [1.1-2.16]
   3 0.76 [0.33-1.78] 0.85 [0.05-13.68] 86540.31 [0.00-∞] 0.8 [0.38-1.68]
   4 0.94 [0.60-1.48] NA NA 0.99 [0.63-1.56]
   5 1.50 [1.04-2.15] 1.42 [0.15-13.64] NA 1.53 [1.07-2.2]
   6 0.49 [0.23-1.02] 0.19 [0.01-3.05] 15163.02 [0.00-∞] 0.29 [0.17-0.52]
Urbanization
   Very urban Ref Ref Ref Ref
   Moderately urban 0.97 [0.66-1.44] 0.59 [0.08-4.20] 0.70 [0.10-4.99] 0.94 [0.64-1.36]
   Normal 0.84 [0.55-1.29] 0.43 [0.04-4.80] 0.86 [0.14-5.16] 0.82 [0.54-1.22]
   Moderately rural 0.88 [0.59-1.31] 0.68 [0.06-7.55] 0.20 [0.02-2.19] 0.82 [0.56-1.2]
   Very rural 0.89 [0.59-1.33] NA 0.00 [0.00-∞] 0.8 [0.54-1.19]
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a university hospital. There was no relationship 
between the comorbidity index, gender, age 
and being admitted for complications. 
Discussion
This study showed that PRT was the most 
frequently applied invasive procedure for tri-
geminal neuralgia with 13.8 procedures per 
1 million person-years per calendar year. 
The rate of invasive procedures did not ma-
terially change over time. Given an estimat-
ed prevalence of trigeminal neuralgia in the 
Netherlands of 1600 per 1 million persons 
approximately 1% of persons with trigeminal 
neuralgia undergo a first invasive procedure 
each year.[27] The type of procedures per-
formed were strongly hospital, age and spe-
cialist dependent. Partial sensory rhizotomy 
and MVD were more likely to be carried out in 
specialized centers than PRT. Percutaneous 
radiofrequency thermocoagulation was most-
ly performed by anesthesiologists while PSR 
and MVD were almost exclusively carried out 
by neurosurgeons. One MVD procedure was 
performed by an ear/nose/throat specialist, 
although this might have reflected a coding 
error. One would expect the duration of stay 
to be similar for PSR and MVD since they are 
both neurosurgical procedures. The differ-
ence might be due to a lower efficacy or less 
familiarity of the treating specialist (or hospi-
tal) with the procedure. This latter might be 
reflected by the considerable difference in the 
absolute number of operation performed. An-
other noteworthy finding was the high degree 
of patients readmitted for unspecified repeat 
procedures. These might reflect patients being 
admitted for drug treatment. One would expect 
less PSRs being performed since these are 
usually reserved for patients in which no neu-
rovascular contact could be shown. These op-
erations might be performed in patients who 
underwent a previous destructive procedure 
thus lowering the success rate of MVD. This 
is less likely since we selected patients who 
were treatment naïve in the year preceding 
the index hospitalization. Alternatively, these 
patients might be selected based on absence 
of neurovascular contact. Given the spread in 
estimates of the presence of this contact, this 
might be plausible.[28-30]
Microvascular decompression had the lowest 
relative risk for readmission (either compli-
cations or repeat procedures), mainly be-
cause of a lower risk for repeat procedures. 
Microvascular decompression had, however, 
a higher complication risk compared to PRT. 
Readmission was not associated with sex, 
urbanization and comorbidity, which is in 
line with previous reports.[31] It was, howev-
er, positively associated with surgical volume 
(low and high) and receiving treatment in a 
general hospital. A previous paper reported a 
higher complication rate in hospitals and sur-
geons with a lower caseload.[32] Our finding 
that a lower caseload is associated with read-
mission is in line with this study. The associa-
tion between a higher caseload and readmit-
tance might occur because more severe or 
complicated patients are referred to the hos-
pitals with a high caseload. Our finding that 
younger patients more frequently underwent 
MVD is in line with current practice.[33] This is 
presumably due to the allegedly longer effect 
of MVD and presence of comorbidity in old-
er patients which makes it difficult to conduct 
that intervention.[33]
Percutaneous radiofrequency thermocoagu-
lation showed the lowest absolute complica-
tion rate but the highest failure rate which is 
in line with recent reviews.[11-12, 20, 34- 35]  One 
study compared MVD to PRT and reported 
an equal effect but a lower long-term com-
plication rate for MVD.[36] Our study shows 
a difference in effect, but this may be be-
cause we only assessed serious complica-
tions requiring a readmission, which do not 
represent the total range of adverse events. 
Assuming that neurosurgical interventions 
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have a higher percentage of adverse events 
requiring hospitalization, this will lead to a 
selective underestimation favoring PRT. The 
high failure rate of PRT might have several 
reasons. Compared to MVD which is usually 
performed by experienced neurosurgeons, 
PRT is also performed by less experienced 
doctors. Furthermore, to avoid anesthesia 
dolorosa, doctors will be careful to apply too 
much coagulation. They prefer to conduct the 
operation in two stages instead of risking 
adverse events. The low complication rate of 
PRT is especially noteworthy since it is more 
often performed in high risk (older) patients.
Limitations
Being an observational study using a hospi-
tal registry we must consider the influence of 
potential misclassification and confounding. 
There are several sources of misclassification. 
Firstly, the failure rate may be an underesti-
mation, since not every failure requires read-
mission as some recurrences may be treated 
conservatively. Our study did not focus on 
failure that could be addressed in an outpa-
tient setting. Furthermore, it could be higher 
since patients dissatisfied after a procedure 
might not undergo a repeat procedure. Giv-
en the lower effectiveness of PRT, this might 
give rise to an underestimation of the relative 
risk for readmittance. Secondly, admission for 
complications after the intervention may have 
been the result of other hospitalizations during 
follow-up, this issue was explored by exclusion 
of patients with other hospitalization during 
follow-up. This did not change the results sub-
stantially. Thirdly, since the database only cap-
tures in-hospital deaths and not the outpatient 
deaths, people dying the year after readmis-
sion are lost to follow-up and cannot count in 
the numerator which may lead to an underes-
timation of risks. Due to differences in age, this 
is less likely to happen for MVD and more for 
the other interventions. People undergoing a 
MVD are younger and thus less likely to die 
out of the hospital. To minimize this bias, we 
imputed age and gender specific survival data 
from the general Dutch population, the relative 
risk estimated did not change substantially. 
The fourth limitation of our study is the low 
number of prognostic variables and the 
lack of specific prognostic factors such as 
disease severity. We evaluated the type 
of hospital (university or general) as a 
proxy for disease severity, duration of pain 
etc., under the assumption that the pa -
tient population of university hospitals (tertia-
ry centers) would differ from those of general 
hospitals (secondary centers). Previous de-
structive surgery, a known risk factor for an 
unfavorable outcome of MVD and PSR, could 
not be considered in our analyses since we 
only had one year of history available.[5, 8] Pa-
tients undergoing a destructive procedure in 
that year were excluded from the analysis to 
minimize possible confounding. To further limit 
residual confounding due to the fact that we 
had limited prior history data we performed a 
sensitivity analysis amongst people undergo-
ing a procedure in 2004. For these persons, 
we had three years of prior history, the results 
in these patients were consistent with the 
main analysis showing that residual confound-
ing due to a short availability of information 
is limited. Several factors are known to be 
prognostic factors for failure of (neurosurgical) 
procedures for trigeminal neuralgia. These in-
clude having a clear-cut and marked vascular 
compression at surgery, type of vessel com-
pressing, duration of complaints, involvement 
of all three branches and postoperative pain 
relief.[8, 20, 31, 37-38] Unfortunately these could not 
be evaluated given the nature of our database. 
Despite its limitations the results of our study 
are unique in that they capture a large nation-
wide study sample which provides a compre-
hensive overview of the application of invasive 
procedures for trigeminal neuralgia in daily 
practice. The study further gives a valid esti-
mate of the absolute and relative risks (com-
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plications requiring admission) and effective-
ness (re-admission for repeat procedure) of 
individual surgical procedures in patients with 
trigeminal neuralgia. Previous reports showing 
a higher success rate of MVD compared to 
PRT have now been confirmed in a single data 
source. Finally, we have shown that the choice 
for a certain treatment modality is, at least in 
the Netherlands, largely institutionalized prac-
tice and not based on a nationwide consensus.
Appendix
ICD-9 Complication
389  Hearing loss 
34981  Cerebrospinal fluid rhinorrhea 
7820  Disturbance of skin sensation 
38861  Cerebrospinal fluid otorrhea 
322  Meningitis of unspecified cause 
321  Meningitis due to other organisms 
320  Bacterial meningitis
047  Meningitis due to enterovirus
7813  Lack of coordination
368  Visual disturbances
998  Other complications of procedures, 
 NEC
997  Complications affecting specified
 body systems, not elsewhere
 classified 
996  Complications peculiar to certain
 specified procedures
054  Herpes simplex
7804  Dizziness and giddiness
3883  Tinnitus
3510  Bell’s palsy
37853  Fourth or trochlear nerve palsy 
3885  Disorders of acoustic nerve
78194  Facial weakness
854  Intracranial injury of other and
 unspecified nature
370  Keratitis
9961  Mechanical complication of other 
 vascular device, implant, and graft
37181  Corneal anesthesia and hypoesthesia 
V410  Problems with sight
E870  Accidental cut, puncture, perforation, 
 or hemorrhage during medical care
E871  Foreign object left in body during 
 procedure
E878  Surgical operation and other surgical 
 procedures as the cause of abnormal
 reaction of patients, or of later
 complication, without mention of 
 misadventrue at the time of operation
E879  Other procedures, without mention of 
 misadventure at the time of procedure,
 as the Cause of abnormal reaction of 
 patient, or of later complication 
9954  Shock due to anesthesia
9950  Other anaphylactic shock
C2939  Unspecified transient mental disorder 
 in conditions classified elsewhere
C3209  Meningitis due to unspecified bacterium
C3229  Meningitis, unspecified
C3429  Hemiplegia, unspecified 
C3682  Diplopia
C3899  Unspecified hearing loss
C4340  Cerebral thrombosis
C5070  Due to inhalation of food or vomitus
C5990  Urinary tract infection, site not specified
C9973  Respiratory complications 
C9981  Hemorrhage or hematoma or seroma
 complicating a procedure
C9985  Postoperative infection 
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A 
n estimated number of 500,000 
different medical devices are avail-
able on the European market, of 
which over 900 different types of 
implants.[1-2] However, as Europe is considered 
one internal market, individual countries are 
not always informed on the type and number 
of implants available on their national markets.
[3] In Europe, medical devices have to comply 
with the Council Directive on Medical Devices, 
93/42/EEC and active implantable devices with 
Council Directive on Active Implantable Medical 
Devices, 90/385/EEC.[4-5] Both will be replaced 
by a new Regulation on Medical Devices, which 
entered into force in May 2017 and will fully ap-
ply in 2020.[6] The European legislation estab-
lishes essential requirements for design, pro-
duction, clinical investigation and evaluation, 
risk assessment, conformity assessment and 
post-market surveillance. Implants are consid-
ered high risk medical devices and in Europe 
must undergo a conformity assessment proce-
dure by a notified body which includes audits 
of the production facilities, an evaluation of the 
technical file, a design examination, appraisal 
of the clinical evidence, and assessment of the 
risk analysis.[4-6] These steps in the life cycle of 
medical devices are depicted in Figure 1.
Before market-entry a manufacturer shall as-
sess what the expected performance of an im-
plant will be. Depending on the type of implant, 
these include characteristics such as expect-
ed longevity, wear and tear, calculated risks, 
foreseen complications and in case of active 
implants also available ancillary functions, pro-
gramming, battery longevity, et cetera. Compli-
ance to essential requirements for safety and 
performance must be substantiated by clinical 
evidence, which can comprise of a critical ap-
praisal of available literature, bench testing, 
animal testing, clinical investigation or a com-
bination of these activities.[7] These Directives 
not always require clinical trials; if substantial 
equivalence to a previously approved device 
can be proven, a critical appraisal of literature 
may suffice. However, for implantable devices 
and class III devices (highest risk class) clinical 
investigation is required, unless it is duly justi-
fied to rely on existing data.[4-5] 
Contrary to medicinal products, regulatory 
oversight of medical devices puts more em-
phasis on post-market surveillance than on 
pre-market clinical studies. This has several 
reasons. There is a large number of medical 
devices on the market, which are more com-
plex than drugs, more diverse and product 
development is more iterative combined with 
a relatively short product life cycle. In addi-
tion, there is a learning curve associated with 
technology adoption.[8-11] Even more important, 
clinical trials may not identify all risks and com-
plications with implants, especially when they 
are rare or occur after several years of usage. 
This requires a larger group of study subjects 
than generally available in order to reach suf-
ficient statistical power. Additionally, such stud-
ies tend to be expensive and would take many 
years, time that is not available for innovative 
technologies.[12-13] Other disadvantages are that 
investigators may be well trained and familiar 
with the device’s characteristics and applica-
tion. Trials are often conducted in an idealized 
physical environment and in a carefully select-
ed population that can deviate from the popula-
tion in which the device is actually used in the 
post-marketing phase. Additionally, physicians 
may use devices for other indications than 
those for which the clinical evaluation has been 
performed.[9-10, 14, 18] Therefore, clinical investiga-
tions have limitations and ongoing clinical eval-
uation and collection of post-market data after 
market-entry is essential. 
Results from the analysis of post-market sur-
veillance information should be used as feed-
back in a continuous cycle of improvement of 
the device, providing input for design improve-
ments, risk analysis updates and adjustments 
of the instructions for use.[19] As some risks be-
come apparent only after regular and/or long 
term clinical use, any unexpected malfunctions 
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may require more regular follow-up or even 
premature explantation. Legislation therefore 
requires manufacturers to actively follow their 
products during the post-market phase, inves-
tigate any unexpected events and report mal-
functions to competent authorities in several 
countries. However, besides the mandatory re-
porting of incidents, legislation does not clearly 
describe which and how post-market surveil-
lance activities should be performed.
A well-functioning post-market surveillance 
process depends on information sharing. How-
ever, the Dutch Health Care Inspectorate has 
observed that health care professionals and in-
stitutions are – often by order of their lawyers – 
reluctant to provide information or return defec-
tive medical devices to the manufacturer when 
they are involved in a litigation procedure, or the 
threat thereof. This hampers the PMS-process, 
which in the end is not beneficial for patients.
Recent major incidents with ICD leads, met-
al-on-metal hip implants, breast implants and 
vaginal mesh have led to a focus on device 
safety by media, politics and patients. Recur-
ring questions in that context are: how many 
patients have received an involved implant and 
how to prevent such events in the future. This 
information is also relevant for competent au-
thorities overseeing the medical devices field 
and regulations. In many countries, including 
the United States of America and Canada, ini-
tiatives were taken to improve the post-market 
surveillance of devices.[14-15, 20-22] In Europe, it is 
part of the revised legislation.[6] Meanwhile and 
pending the transitional phase from old to new 
legislation, an action plan has been established 
to strengthen the current legislative system. 
Following the major incidents in recent years 
the importance of maintaining registries is in-
creasingly recognized. Establishing these im-
plant registries is part of the joint action plan.[23] 
National device registries may contain relevant 
data to identify products with a lower than ex-
pected reliability and allows immediate identi-
fication of patients treated with specific mod-
els of implants in case of alerts or recalls from 
manufacturers, as was proven in Denmark for 
pacemakers and electrodes and Sweden re-
garding several orthopaedic implants.[12, 24] As 
such, the output of device registries is import-
ant for the quality chain of medical devices on 
one hand and for tracking and tracing purposes 
of patients on the other hand, notably when in-
adequate implants are involved. That is why ef-
forts are being made by national governments 
to establish registries on implantable medical 
devices.
The main objective of this thesis is to examine 
the usability of a number of currently available 
and accessible registries for information on 
implant performance and complications of im-
plant therapy. The current chapter first summa-
rizes the main findings of the studies described 
in this thesis. Second, several methodological 
issues related to the studies are discussed, fol-
lowed by a discussion of the role of registries 
in (post-)marketing surveillance of implantable 
medical devices. The chapter finalizes with fu-
ture perspectives and concluding remarks.
Main findings
CPPR-SPRN – utilization and follow-up 
of implantable pacemakers
Duration of service time, cause of death, rea-
sons for replacement and complications of 
pacemakers provide valuable information for 
both cardiologists and manufacturers. When 
these malfunctions are registered in the im-
plant registry, this allows for trend analysis on 
the performance of the devices, and as such 
provides input for continuing improvement of 
implants. A study that performed a meta-anal-
ysis on several registries, showed that they 
proved very useful to assess pacemaker and 
ICD malfunctions.[25] Therefore, we aimed to as-
sess service time and reasons for explantation 
of pacemakers and leads in the Dutch registry 
for pacemakers.
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In chapter 2 we described the results of the 
analyses on the Central Pacemaker Patients 
Registration from the Netherlands Pacemaker 
Registry Foundation (CPPR-SPRN). This reg-
istry started in 1982 and contained data col-
lected for more than 20 years. In chapter 2.1 
we analysed pacemaker implanted between 
1984 and 2006, which showed an increase in 
number of pacemakers used and an extension 
of the diagnosis for which pacemaker therapy 
is chosen. However, the implantation ratio in 
the Netherlands was below the European av-
erage. Furthermore, it showed that during the 
mid-1990s adaptive pacing frequencies with 
dual chamber systems (DDD(R) devices) were 
increasingly used. Around the millennium year, 
cardiac resynchronization therapy (CRT) was 
introduced, for which the data show an obvious 
increase in use.
In chapter 2.2 we aimed to investigate the 
trends in duration of service time of pacemak-
er generators and the reasons for explantation. 
We found that during the study period 22,134 
patients (22.8%) had at least one pacemaker 
generator replacement or removal and 4350 
patients (4.5%) had more than one. For approx-
imately 1 in 5 pacemaker generators a replace-
ment was registered. The mean duration of fol-
low-up to pacemaker generator replacement or 
removal (service time) during the whole study 
period was 6.3 (SD 3.3) years. Nearly 20% of 
the explantations occurred following technical 
failures or complications, with insulation fail-
ures and infections being most abundant. Dou-
ble chamber systems were significantly more 
often explanted than single chamber systems 
and they were also significantly more often ex-
planted for normal ‘end of life’ within 5 and 7 
years after implantations than single chamber 
systems. 
Leads can be an important source of failures 
and complications of pacemaker therapy. 
Therefore, in chapter 2.3, we also studied the 
percentage of and reasons for explantations 
of leads as registered in the database. These 
analyses showed that 138,225 leads have 
been implanted with 96,900 first pacemakers, 
of which 8849 (6.4%) have been replaced or 
explanted. Main registered reasons for explan-
tation were insulation failures, infections and 
displacements. Generally, in case of pace-
maker generator replacement, the leads were 
not replaced. However, when simultaneous 
replacement of generator and leads occurred, 
this was most frequently done because of in-
fections.
In general, the results from these chapters 
demonstrate that also with the older and now 
discontinued pacemaker registry, important in-
formation can be generated on the quality of 
medical devices. 
LMR – national hospital discharge 
records database
The national hospital discharge records da-
tabase was initially established for research 
purposes. Main advantages of this database 
are that it includes all admissions to Dutch ac-
ademic and general hospitals and is indepen-
dent of reimbursement.[26] As such, it provides 
a rich source of information on characteristics 
of hospital admissions. Since only a limited 
number of databases is available on medical 
devices and implants, we aimed to investigate 
treatment patterns and re-admissions for sev-
eral implant-related therapies using this hospi-
tal admissions database.
In the study described in chapter 3.1 we in-
vestigated re-admissions following total hip ar-
throplasty (THA). A majority of the 50,080 pa-
tients admitted for THA had osteoarthritis as 
main diagnosis. Approximately 9% (n=4364) 
of the patients were re-admitted at least once 
within 3 months after the surgery, 40% of them 
for complications. More than half of the com-
plications concerned mechanical problems 
and for another 30% an infection was rea-
son for re-admission. A lower hospital proce-
dure volume appeared to be associated with 
complications during index admissions, but 
117General discussion Chapter 4
no such relation was found for re-admissions 
due to complications. Mortality during index 
admission was 0.2% and was higher during 
consecutive re-admissions. Having a compli-
cation appeared to be a risk factor for mortality 
during re-admission. Unfortunately, we did not 
have data on mortality of patients after they 
were dismissed from hospital. Therefore, the 
actual mortality within 3 months after surgery 
is unknown. Furthermore, we did not have in-
formation on the type of implant that was used 
or to what extent a complication was related to 
the implant itself.
In chapter 3.2 we studied the incidence and 
treatment of non-traumatic subarchnoid hem-
orrhage (SAH), a devastating event with high 
morbidity and mortality.[27-28] Based on the LMR 
data we found that 5769 patients were admit-
ted to hospital for SAH as discharge diagnosis 
between 2001 and 2005. This corresponds to 
an incidence of 7.2 per 100,000 person-years 
(95% CI: 6.94-7.31). The main treatment op-
tions are clipping or coiling of the aneurysm. 
The first being an invasive neurosurgical pro-
cedure, while the latter is a less invasive en-
dovascular procedure that can be performed 
by radiologists.[29] In the LMR data it appeared 
that coiling procedures could not be regis-
tered as such. Therefore, we were unable to 
compare treatment modalities based on these 
data. However, the Integrated Primary Care In-
formation (IPCI) database, a general practice 
research database with electronic medical re-
cord data which we used for comparison, did 
contain information on treatment. In the initial 
source population of 488,118 persons, 107 in-
cident cases of non-traumatic SAH were iden-
tified after validation. Analysis of these data 
showed that nearly two thirds (64%, 95% CI: 
53-74%) of the patients was treated by clipping 
procedure and 26% (95% CI: 17-37%) were 
treated by endovascular coiling. The low num-
bers in each treatment group did not allow us to 
estimate the risk of mortality in each treatment 
group.
Finally, chapter 3.3 describes the results of 
our study on three most common invasive 
treatments for trigeminal neuralgia (TGN); 
microvascular decompression (MVD), partial 
sensory rhizotomy (PSR), and percutaneous 
radiofrequency thermocoagulation (PRT). We 
compared readmissions for repeat procedures 
and complications after these operations. TGN 
is a severe form of facial pain in one or more 
branches of the fifth cranial nerve.[30] During 
MVD a Teflon patch is introduced between the 
nerve and vascular structure that is in con-
tact with the nerve, the other treatments are 
aimed at destruction of (part of) the nerve. In 
the LMR database we found 672 patients treat-
ed with PRT, 87 with MVD and 39 with PSR 
between January 1, 2002 and December 31, 
2004. One third of the patients was readmitted 
within one year after surgery for either a com-
plication (31.6%) or a repeat procedure (2.4%). 
The one-year readmission risk was lowest for 
MVD, whereas the risk for complications was 
lowest for PRT. After MVD most people had a 
PRT as repeat procedure, whereas for PSR 
and PRT the same procedure was performed 
again. The choice for procedure type appeared 
to be hospital dependent. Furthermore, Cox re-
gression analysis, stratified by the type of first 
procedure, showed that surgical procedure vol-
ume and type of hospital were associated with 
failure. However, the relationship with volume 
only applied to the second and fifth groups of 
surgical procedure volume, there was no clear 
‘dose-effect’ for the volume-success relation-
ship.
Use of nationwide hospital admissions data 
proved useful for studying several types of im-
plant-related procedures. It provides relevant 
information on re-admissions following com-
plications and repeated procedures. Strengths 
are the nationwide coverage of the data and 
the coding of procedures and complications 
that is independent of reimbursement. Our in-
stitute also used the LMR database for several 
studies on adverse drug reaction-related hospi-
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talizations.[31-34] However, analysis of these data 
proved to be most useful when other (external) 
data were available for linking or comparison, 
providing a denominator for calculating the 
ADR-hospitalization ratio. This data is not al-
ways available for implants and when it is, the 
utility depends on the availability of reliable pa-
rameters which can be used for linkage. For our 
studies, this appeared to be a major limitation. 
Furthermore, several of the ADR-studies iden-
tified the same limitations we found in our LMR 
based studies on implants: deaths may have 
occurred outside of the hospital, and adverse 
events may not have been recognized or were 
treated outside of the hospital.[31, 33-34] Finally, a 
limitation is that the LMR data do not contain 
any information on the implant that was used. 
This prevented us from studying associations 
of implant characteristics on re-admissions for 
complications and re-operations. 
Methodological considerations
In general, the effects of medical interven-
tions can be studied in two different ways: by
(1) randomized, (double-)blind clinical trials or 
by (2) observational studies. In the first case, 
the investigators assign the treatment blinded 
and at random, whereas for the latter study 
type normal clinical practice is observed.[35] In 
case of clinical investigation of implants, ran-
domized and blinded clinical trials are not al-
ways feasible or possible or may even be un-
ethical. In such cases, observational studies 
are an important tool for studying the effects of 
devices and device therapy on disease. In the 
past decades, pharmaco-epidemiological stud-
ies focusing on the adverse effects of drugs 
have gained essential insight into the causes 
of adverse effects. Comparable studies with 
(implantable) medical devices are much more 
uncommon. 
The epidemiological studies described in this 
thesis used data from two large registries: The 
Central Pacemaker Patients Registration from 
the Netherlands Pacemaker Registry Founda-
tion (CPPR-SPRN) and the national hospital 
discharge records database (LMR). Both reg-
istries have been described in more detail in 
the respective studies and the introduction to 
this thesis. In this chapter, the methodological 
aspects of these databases and studies are 
discussed in more depth.
Study setting and design CPPR-SPRN
The SPRN-database was established to gen-
erate an overview of patient and implant char-
acteristics; trends in types of pacemakers and 
leads; and the annual number of implants per 
clinic and nationwide. Additionally, the registry 
also served a purpose to warn hospitals in case 
of quality issues with pacemakers or leads.[36-38] 
We used the database to study the utilization 
of pacemakers and leads, and the service time 
and reasons for explantation of these devices.
Methodological strengths include the long peri-
od of follow-up of more than 20 years. Further-
more, the registry was nearly nationwide with 
most of the hospitals participating. Data was col-
lected before and irrespective of the outcome, 
reducing the risk of information bias. A validation 
process to obtain better insight into the quality 
of the database was performed in 1997. 96% of 
pacemaker generators and 84% of the leads 
could be retrieved in the central registry when 
compared to patient files of participating hospi-
tals and sales data from manufacturers.[37]
Available patient characteristics include date of 
birth, sex, symptoms of heart disease, diagno-
sis for pacemaker implantation, aetiology, date 
and reason of explantation of the pacemaker 
generator, and date and reason of death (volun-
tarily recorded). Additionally, several character-
istics on the implanted pacemaker generators 
were available. Due to agreements made with 
manufacturers at the start of the registry we 
could not use brand names, therefore only the 
pacemaker type according to the North Amer-
ican Society of Pacing and Electrophysiology 
(NASPE) coding; VVI/VVIR, DDD/DDDR, AAI/
AAIR, etc.,[39] could be included in our analyses.
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Limitations of the data included the large pro-
portion of loss to follow-up of the patients. 
Deaths were registered voluntarily. A validation 
study using data from the Rotterdam Study 
showed that approximately 60% of the deaths 
was not registered in SPRN. Age at death and 
implanted pacemaker type did not statistically 
significantly differ between the group of patients 
that was registered as deceased in SPRN and 
the group that was not. Furthermore, informa-
tion on aetiology, reason of explantation, and 
diagnosis for implantation was unknown in the 
majority of cases, sometimes as high as 75% 
(aetiology). This reduced the usability of the 
data for more complex statistical analyses.
We performed three studies using the 
SPRN-data. Most of which had a descriptive 
study design. We also performed a cohort 
study to investigate the Cox proportional haz-
ard rate for explantation of first pacemakers 
within 7 years of follow-up, between different 
pacemaker types with VVI-mode as reference 
type. This analysis calculates an accurate es-
timate of the relative risk with adjustment for 
available relevant confounding factors and 
competing risk of death. Selection bias is un-
likely with this design, as all different exposure 
types were derived from the same prospective 
population-based cohort study.
Competing risks
We calculated the hazard ratio for pacemaker 
replacement adjusted for the competing risk 
of death as described by So et al.[40] Because 
deceased patients are no longer at risk for ex-
plantation, they cannot be considered as cen-
sored as the assumption that the censoring 
mechanism is independent of the probability of 
the outcome of interest (i.e. explantation), is no 
longer met.[41] However, as validation of mortal-
ity using the Rotterdam study showed that only 
an estimated 40% of deaths was registered in 
the SPRN-registry, the hazard ratio of pace-
maker replacement is expected to be an under-
estimation of the true ratio because those who 
deceased without being censored are kept in 
follow-up until the end of the study period while 
reasons for explantation might also be causes 
of death.
Study setting and design LMR
The national hospital discharge records data-
base was established in 1963. The purpose of 
the registry was to provide medical-administra-
tive information regarding hospital care in the 
Netherlands to support governmental and hos-
pital policy. Additionally, it could provide bench-
mark information to hospitals and medical spe-
cialists, but also serve research purposes.[42]
Registered data include date of admission, 
coded main discharge diagnosis for admission 
(mandatory), up to 9 coded secondary diagno-
ses (optional), coded intervention, type of spe-
cialist who performed the intervention, date of 
birth of the patient, sex, and date of discharge. 
The diagnoses were coded using the ICD9 
coding system,[43] whereas the intervention was 
coded using a national system. The strength 
of this registry is the nationwide coverage of 
admissions, as all hospitals provided informa-
tion. The LMR was replaced by another sys-
tem in 2005. At that time, reimbursed medical 
interventions were not yet performed in private 
clinics. Therefore, information on discharge di-
agnosis, type of intervention and outcome was 
available for each patient admitted to hospital.
We used this database for studies on three 
types of interventions: total hip arthroplasty 
(THA), non-traumatic subarachnoid haemor-
rhage (SAH) and trigeminal neuralgia (TGN) 
and assessed the incidence of the intervention 
and/or condition, and for the THA and TGN 
studies we also assessed re-admission due to 
complications within 3 months and 1 year re-
spectively. We identified patients based on the 
intervention code (THA) or the discharge di-
agnosis (SAH and TGN). As interventions and 
discharge diagnoses are recorded similarly for 
each hospital and irrespective of reimburse-
ment, data was collected before and irrespec-
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tive of the outcome and thus not prone to in-
formation bias. Patient details are anonymized, 
and therefore re-admissions due to complica-
tions were linked based on date of birth, sex 
and postal code of the patient for the THA and 
TGN studies.
Anonymization of patient and hospital details 
had the disadvantage that validation of the 
data is cumbersome, or even impossible. For 
the SAH study we could only validate cases 
from our institution. This showed that for 10% 
the cases were false positive. For the THA 
study we used the Rotterdam Study by linking 
cases based on date of birth, sex and postal 
code. This validation showed that none of the 
procedures, diagnoses or complications were 
false-positive. Of the procedures, diagnoses 
and complications respectively 91%, 90% and 
80% could be confirmed.
An additional disadvantage was that only death 
during admission could be included in the anal-
yses. Furthermore, information on co-morbidity 
was scarcely available. We used the Charlson 
co-morbidity index to include co-morbidity in 
our analyses for the THA and TGN studies. 
This is a weighted index that takes the number 
and seriousness of co-morbidity into account. 
It was developed based on the 1-year mortality 
from an inception cohort study of 604 patients 
admitted to a New York hospital.[44] Diseases 
were assigned a weight based on their calcu-
lated relative risk for death within one year. The 
index appeared to be a significant predictor of 
1-year survival. It was later adapted and vali-
dated for research based on databases using 
ICD-9-CM codes.[45] The co-morbidity index 
was added to the dataset as a variable, based 
on the ICD-9 codes provided for the secondary 
diagnoses fields. However, only co-morbidity 
for which hospitalization was required could be 
included as secondary diagnosis. As registra-
tion of these diagnoses was optional, informa-
tion on co-morbidity was not always available.
The studies based on LMR-data are retrospec-
tive cohort studies. The THA study compared 
different groups of hospitals grouped by yearly 
volume of interventions and the effect this vol-
ume has on the occurrence of complications. 
As the time between the intervention and the 
complication during index admissions was un-
known, we used logistic regression to calculate 
odds ratios. Similarly, the TGN study compared 
three treatment groups and their failure rates by 
analysing the re-admission rate after interven-
tion. Prognostic factors were calculated using 
Cox regression analysis. Finally, the SAH study 
is a descriptive study, calculating the incidence 
and case-fatality rates of patients admitted to 
hospital for subarachnoid haemorrhage. 
Bias and confounding
Contrary to randomized clinical trials, expo-
sure in observational studies is decided on 
by doctors. Due to the lack of randomization, 
several (potentially) interfering factors are not 
controlled for. By choosing the correct study 
design and adjusting for the potentially interfer-
ing factors during the statistical analyses, the 
influence of these factors on the association 
found can be reduced. 
The main biases that can be introduced in ob-
servational studies include selection bias, infor-
mation bias and confounding. Bias undermines 
the internal validity of research.[46] Selection bias 
occurs when selection of patients in the groups 
that are compared coheres with the exposure 
or outcome. For cohort studies, this bias occurs 
when follow-up information is less likely to be 
collected on subjects who have better (or worse) 
outcomes.[47-48] This bias is considered negligi-
ble for the studies based on the SPRN-registry 
because of the population-based nature of the 
data. Nearly all patients receiving a pacemak-
er were included in the database. Contribution 
to the LMR-registry was obligatory for all Dutch 
hospitals. The completeness of the data is one 
of the main advantages of this registry. Exposure 
nor outcome is related to inclusion in both CP-
PR-SPRN and LMR registries, because registra-
tion depended on having a pacemaker implanted
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(CPPR-SPRN) or being admitted to hospital 
(LMR). 
Information bias arises when collection of data 
on exposure and/or outcome is different for cas-
es and controls. Examples of information bias 
are observer-bias, recall-bias, response-bias, 
classification-bias or measurement-bias.[46-47] 
It results from incorrect determination of expo-
sure or outcome, or both and can be attributed 
to imperfect definition of a study variable or a 
flawed data collection procedure.[46, 48] Infor-
mation on outcome should be collected in the 
same way for those exposed and those un-ex-
posed (cohort studies) and data on exposure 
should be obtained in the same way for cases 
and controls (case-control studies).[46] Infor-
mation bias can occur as differential or sys-
tematic misclassification or as non-differential 
or random misclassification. In the first case, 
the bias is one-directional which can lead to an 
over- or underestimation of the effect, whereas 
in the latter case misclassification is multi-di-
rectional and can obscure an association that 
is present.[46]
Our studies based on the CPPR-SPRN-data 
may contain information bias, because some 
hospitals did not contribute to the registry, or did 
not contribute during the entire study period. If 
these hospitals used other pacemaker types, 
our exposure of interest, than the hospitals in-
cluded in the registry, this may have caused a 
bias. However, we believe that it is unlikely that 
the pacemaker types in these hospitals differed 
to a great extent. Furthermore, we do not be-
lieve that participation in the registry was relat-
ed to the outcome of interest: replacement of 
the pacemaker generator and/or leads. There-
fore, any misclassification is considered to be 
non-differential. Misclassification of outcome is 
non-differential if outcomes are assessed inde-
pendently of exposure and patient co-morbidi-
ty.[47, 49] Furthermore, information bias does not 
apply to objective outcomes such as whether 
a patient with a pacemaker or hip implant re-
quired revision surgery.[48]
Information bias may have occurred in the 
studies based on the LMR-data. In our study 
on non-traumatic subarachnoid haemorrhage 
(SAH), we also studied case-fatality. By using 
the hospital discharge registry, we could only 
include those fatalities that occurred during 
hospital admission, whereas SAH-patients who 
died after discharge were not counted. In this 
case the bias may have been small, as com-
parison with the Integrated Primary Care Infor-
mation (IPCI) database, which contains com-
plete information on mortality, showed a similar 
case-fatality rate. In the total hip arthroplasty 
and trigeminal neuralgia studies we investigat-
ed complications during admission and re-ad-
missions as primary outcomes. Complications 
that were not severe enough or led to death 
outside of hospital, were not included and may 
thus have affected incidence ratios and odds 
ratios. These ratios may have been an under-
estimation as we believe that the misclassifica-
tion is random, because it is not related to the 
exposure.
Confounding occurs when the studied effects 
of exposure on the outcome of interest are 
altered by or blurred with the effects of other 
risk factors. A confounding variable is associ-
ated with both the exposure and the outcome, 
but is not a factor in the causational relation-
ship between exposure and outcome.[46-48] 
Confounding can be controlled for by several 
methods before or after the study took place. 
Multivariate modelling by performing analysis 
using logistical or Cox proportional hazards 
regression analyses is one of these meth-
ods,[46] which has been mainly used to ad-
just for confounding in the studies described 
in this thesis. A pre-requisite is that potential 
confounding factors are known. Age and sex 
are two very common confounders, that are 
almost always included in multivariate statisti-
cal models. When information on such factors 
is available, they can be tested for their con-
founding effect by univariate analysis. When 
the point estimate changes by 10%, the factor 
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is considered to be a confounder by conven-
tion.[50]
In both the CPPR-SPRN and LMR databases 
only a limited number of potential confounders 
were available. Age and sex were known and 
included in studies on both databases. Howev-
er, information on co-morbidity of patients, drug 
use and data on the applied implant were often 
not available. For example, the indication for 
which a pacemaker was implanted was regis-
tered and could be included in the multivariate 
analysis. However, several pacemaker settings 
were not available, whereas they are known 
to affect pacemaker longevity. In the LMR-da-
tabase we derived co-morbidity from the sec-
ondary diagnoses of which up to nine could 
be registered. Registration of secondary diag-
noses was optional, however, and not every 
hospital provided this information. Additionally, 
only the co-morbidity which led to (previous) 
hospital admissions were registered. There-
fore, we were unable to completely control for 
confounding in the described studies, which 
may have affected the generalizability to other 
populations and thus the external validity of the 
studies.
Role of registries in post-market
surveillance
Post-market surveillance (PMS) can pro-
vide information on the performance of a de-
vice in actual clinical care and identify risks 
and complications that have not yet been 
identified during pre-market clinical investi-
gations. Professional societies, the medical 
device industry and national authorities for 
medical devices each have a role to play in 
establishing successful post-market sur-
veillance.[51-52] Manufacturers must use in-
formation collected via PMS to update their 
risk analyses, product designs and clinical 
evidence.[7] Multiple sources for signalling 
of previously unidentified risks, hazards and 
complications are available and include:
(1) post-market clinical follow-up studies,
(2) (serious) adverse event reporting by health 
care professionals and voluntary adverse 
event reporting by patients, (3) annual perfor-
mance reports by manufacturers, and (4) reg-
istries. However, each source of PMS has sev-
eral serious challenges which are discussed 
below. We will pay particular attention to the 
usability of registries as a source for PMS.
Performing post-market clinical follow-up stud-
ies (PMCF) is a legal requirement. These are 
studies with CE-marked devices and intend-
ed for information collection on clinical safety 
and performance, including residual risks of 
a device which is used in accordance with its 
approved labelling. The objective is to confirm 
the clinical performance and safety throughout 
the expected lifetime of the device, the accept-
ability of identified risks and to detect emerging 
risks on the basis of factual evidence.[7] Lim-
itations of clinical studies, such as relatively 
small samples and short follow-up, have been 
discussed previously. 
The second source of PMS information is re-
porting of incidents. Manufacturers have the 
legal obligation to report incidents that have led 
or could have led to harm or death.[7] In gen-
eral, reporting by health care professionals, 
either to competent authorities or to manufac-
turers, is voluntary. In the Netherlands, only 
those adverse events leading to serious harm 
or death are mandatory for health care profes-
sionals to report to the Dutch Health and Youth 
Care Inspectorate.[53] Less severe events and 
near-misses can be reported voluntarily. Struc-
tured follow-up on the performance of implants 
via reporting of incidents requires physicians to 
report malfunctions to the manufacturer of the 
device. Deaths and severe harm attributable 
to device malfunctions, but also device-related 
user failures, should be reported to both the 
manufacturer and the competent authority for 
medical devices in the country where the death 
or harm occurred. 
Following the severe incidents with met-
al-on-metal hip prostheses and pelvic floor 
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repair systems containing mesh, the Inspec-
torate called for a facility where patients could 
report side-effects and adverse events that 
may be related to their implant.[54-55] In July 2017, 
a reporting and expertise centre on side-ef-
fects of implants has been established.[56]
The purpose of this centre is to collect infor-
mation on side-effects and complications that 
may be related to implants, and identify trends 
as early as possible. Both health care pro-
fessionals and patients are invited to report. 
Results of the analyses are shared simulta-
neously with the Inspectorate and the public. 
This allows the Inspectorate to take regulatory 
measures when necessary, whereas health 
care professionals and manufacturers are also 
able to benefit from the information for their 
daily clinical practice and for PMS data collec-
tion respectively.[56]
While important, reporting has several lim-
itations, the main of which is underreporting. 
Health care professionals are not always in-
formed on what to report, consider the process 
to be burdensome, fear the consequences or 
are discouraged by a lack of feedback.[14, 18, 20, 22]
Furthermore, statistical analysis and the deter-
mination whether reports represent a true safe-
ty signal or merely reflect an increase in reports 
from users are restricted because a reliable de-
nominator – the number of implanted devices –
is usually lacking.[20]
Third, information related to reporting of mal-
functions that can provide a denominator is 
included in annual performance reports on im-
plantable devices which the US FDA requires 
manufacturers to submit.[25, 57] These reports 
contain information on the number of implant-
ed and explanted devices, and device malfunc-
tions during the reporting period. This provides 
insight into malfunctions and trends in device 
reliability. While these reports without a doubt 
provide useful information on device perfor-
mance and malfunction, they depend on health 
care professionals returning the device, which 
may not always happen.[58] When replacement 
of devices takes place under warranty, under-
reporting may be lower, because the device 
must be returned in order to receive a new de-
vice from the manufacturer.[59] Furthermore, the 
analyses of these reports do not always allow 
to account for explantations for other reasons 
than malfunction, such as infections, upgrades 
or recalls as they were not uniformly reported 
by manufacturers.[57] Moreover, devices are 
rarely evaluated after death of a patient with a 
device.[60] A study that investigated 415 pace-
makers and 556 leads post-mortem for defects, 
revealed that 3.8% of the pacemakers had a 
life-threatening malfunction like a defect, bat-
tery exhaustion, ventricular lead failure, infec-
tion or bipolar sense with unipolar ventricular 
lead. Covering a study period of 4 years, the 
investigators calculated an annual complica-
tion rate of 0.95%.[61] Additionally, they found 
that 3.7% of the pacemakers had a potentially 
life-threatening malfunction such as an infec-
tion, a missing notch in ventricular leads or 
an indifferent screw that was not tightened. It 
appeared that lead defects were more frequent 
than generator defects.[61] Therefore, it seems 
feasible to undertake such studies for the 
purpose of collecting information on possible 
causal relationships between implant failures 
or complications and death.
The fourth source for PMS information and 
main focus of this discussion are registries, 
which present more opportunities for proce-
dure and device-related outcomes data, and 
importantly: provide a denominator.[8, 20, 62] That 
clinical registries and remote monitoring data-
bases have proven their added value has be-
come clear with the recall of the Riata leads 
from St. Jude Medical,[52] but also international 
orthopaedic registries such as the Scandina-
vian and the Australian arthroplasty registers 
have successfully identified several product 
failures within a relatively short period of time. 
The Swedish arthroplasty register was the 
first to be established and is considered 
exemplary.[12, 63-64] Arthroplasty registers are 
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one of the most common types of registries in 
Europe, after registries in the field of cardiac 
implants.[63] In 2015 there were 11 registered 
nationwide arthroplasty registries worldwide.[12]
However, the actual number may even be 
higher, since the successive Dutch cardiac im-
plant registries were not included in this over-
view, and presumably other registries may not 
have been either. 
Registries serve to inform several stakeholders 
like manufacturers, health care professionals, 
insurers and policy-makers, but can also be used 
for benchmarking purposes and improvement 
of patient management. Collaboration between 
these stakeholders is important for the devel-
opment and maintenance of registries.[16, 62-63]
Regardless of the advantages that registries 
have for post-market surveillance of devices, 
existing registries have not always served their 
purpose. For example, the breast implant reg-
istry in the UK took a lot of time and energy to 
initiate and maintain. When it came to interro-
gating the data, it was discovered that the data-
set was so poor that no real benefit could be 
derived from it.[65] There are also disadvantages 
for several stakeholders. Besides functioning 
as a benchmarking tool, health care profes-
sionals may feel they are controlled. Further-
more, maintaining a registry adds to the admin-
istrative burden. Finally, registries may provide 
insight into the market shares of manufacturers 
and a ranking of their devices, which they often 
consider to be proprietary information.[63] 
The usefulness of registries depends on the 
nature, size and extent of the details that are re-
corded. Many existing and past registries have 
been limited in size or limited in the number of 
participating centres, or were run by manufac-
turers individually without nationwide coverage 
or the ability to pool data, making it difficult to 
identify rare outcomes.[14-15, 66-67] Furthermore, 
outcomes are not only influenced by the de-
vice, but also by the surgical technique and by 
patient related factors.[65] Also, the purpose with 
which a registry was implemented may limit its 
use for other goals; a registry set up for tracking 
and tracing purposes or for measuring a par-
ticular outcome may not be suitable for other 
quality analyses.[65] Even cultural differences 
and differences in market shares of manufac-
turers between countries influence the gener-
alizability of analyses on registries.[12] 
Despite these drawbacks it is expected that the 
number and extent of registries will increase, 
partly due to the new European regulation.[64] 
In the United States, registries are considered 
to play a unique and prominent role in medical 
devices surveillance and the FDA believes that, 
within the boundaries of privacy protection, reg-
istries in selected product areas combined with 
routinely collected electronic health information 
containing unique device identification should 
serve as the foundation of a national medical 
device post-market surveillance system.[11] 
Recognizing the strength of pooling data 
from smaller national registries, a plan was 
launched by the FDA in 2010: The International 
Consortium of Orthopedic Registries (ICOR). 
The purpose of ICOR is to provide a robust 
infrastructure to facilitate evidence-based de-
cision-making on the performance of medical 
devices, by aligning several national registries 
and thus add to the knowledge of implant per-
formance in order to support clinicians, device 
regulators, insurers, patients and industry.[8, 68] 
The Nordic Arthroplasty Register Association 
(NARA) is a major contributor to ICOR. This ini-
tiative compares registries from Norway, Swe-
den, Denmark and Finland. It pooled the data 
from the available national registries, which 
allowed comparison of different treatment strat-
egies because of different treatment traditions 
among the countries. By combining the regis-
tries, numbers are high enough to compare im-
plants and techniques.[69]
The data holders participating in ICOR remain 
owner and maintain full control of their data. 
They can contribute to studies they select by 
harmonizing data definitions and the process-
es for data collection and storage. Such inter-
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national collaborations require agreements on 
data definitions, data collection procedures, 
and methods for making comparisons between 
interventions and overcome the limitations of 
individual registries. Particularly the device 
capture and classification at a level that allows 
device evaluation and assessment is critical. 
The minimum data set for device data col-
lection is based on a unique device identifier 
(UDI). ICOR identified different stages at which 
collaboration with decentralised approaches is 
possible.[8, 68] 
Some of the registries contributing to ICOR 
work together with their regulatory authorities, 
such as the Australian regulators, the MHRA 
in the UK and the FDA in the US. The integra-
tion of work of the registries into the regulato-
ry process is considered helpful for advancing 
regulatory science.[8] Based on the ICOR ini-
tiative a similar international collaboration in 
the field of cardiovascular device evaluation 
and surveillance was considered for tran-
scatheter aortic valve replacement (TAVR). 
The Dutch TAVR register is one of the partic-
ipants.[70] The importance of registries in the 
field of medical devices is underlined by the 
International Medical Device Regulators Fo-
rum (IMDRF), a global co-operation in which 
several international markets are represented, 
including Europe. IMDRF drafted a proposed 
document on the essential principles of pa-
tient registries.[71] They define a registry as: 
“An organized system with a primary aim to 
improve the quality of patient care that contin-
uously collects relevant data, evaluates mean-
ingful outcomes and comprehensively covers 
the population defined by exposure to partic-
ular device(s) at a reasonably generalizable 
scale (e.g. international, national, regional, and 
health system)”.[71] 
IMDRF envisages international collaboration 
to undertake medical device safety and perfor-
mance evaluations, based on strong registries 
and collaborative distributed data consortia. 
International experience with devices can be 
brought together by various participating coun-
tries, while all countries may benefit from the 
results. Furthermore, IMDRF sees an essential 
role for regulators to initiate the engagement of 
their national registries.[71]
Future perspectives
Major device failures and recalls have highlight-
ed the need for registries for 1) tracking and 
tracing of implants to a patient level, and 2) for 
quality assessment and performance data. For 
the first purpose, the Dutch government has 
set up an implant registry in cooperation with 
professional societies in the areas of orthopae-
dics, cardiology, plastic surgery and gynae-
cology. During the course of 2018, health care 
professionals and institutions will be obliged by 
Dutch legislation to cooperate with this govern-
mental national implant registry.[72-73] However, 
as this registry serves tracking and tracing of 
implants following recalls or serious failures 
alone,[74-75] it is not intended nor suitable as a 
quality registry.
The current implant registries from the pro-
fessional societies of four major health care 
specialties are more suitable for that pur-
pose. Besides for traceability, they have been 
established for monitoring implant use, and 
complication registration. They include regis-
tries for cardiac implantable electronic devices 
– the National Cardiavascular Data Registry 
(NCDR);[75-76] orthopaedic implants – the Dutch 
Arthroplasty Register (Landelijke Registratie 
Orthopedische Implantaten – LROI);[75, 77] gy-
naecological implants such as mesh for pelvic 
organ prolapse – POMT; [72, 78] and breast im-
plants – Dutch Breast Implant Registry (DBIR), 
which is also part of the international ICOBRA 
initiative.[75, 79] However, these registries are 
not accessible for authorities nor industry and 
some of them have only been established re-
cently following incidents. Furthermore, only a 
limited number of high risk implants is regis-
tered and although the percentage of coverage 
is high, it is not yet nationwide.[75]
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In terms of devices, the Netherlands is a rela-
tively small market. This puts forward the ques-
tion whether Dutch registries alone will obtain 
enough power to identify rare failures and 
complications for individual device types and 
models. Therefore, the Netherlands may ben-
efit form participation in international collabora-
tions and vice versa.
Furthermore, past observational studies re-
garding product use have mainly focused on 
complications of drugs, whereas such studies 
on implants have been limited. In addition to 
clinical investigations, post-market follow-up 
studies and registries, we also recommend 
that observational studies for surveillance of 
medical devices are set-up. Critical condition 
for such studies is the number of included sub-
jects in order to have enough power for statis-
tically significant associations that are clinically 
relevant. Registries may fulfil a need here as a 
source for study cohorts, while simultaneously 
providing a reliable denominator.
Finally, in several other countries such as Aus-
tralia, the United Kingdom and United States, 
regulators are engaged in registry consortia, 
as is also envisaged by the International Med-
ical Devices Regulators Forum. Whereas the 
Dutch authorities are involved in the National 
Implant Registry (LIR) aiming at tracking and 
tracing of implants, they are not involved in the 
clinical quality registries. A closer cooperation
between stakeholders would be beneficial for 
the generation and use of market surveillance 
data.
Concluding remarks
Randomised clinical trials with implants are 
not always an option for reasons described in 
this chapter. Medical registries, in particular 
those dedicated to implants, can therefore be 
a useful tool for providing information on im-
plant and patient characteristics, but also on 
clinical evidence and post-market surveillance 
data, such as safety, performance and compli-
cations. Despite the results we have obtained 
with the studies described in this thesis, the 
existing registries we have used have been 
established for other purposes. For the current 
need of information on device performance, 
these registries are no longer state-of-the-art. 
This underlines the importance of a priori defi-
nition of the purpose of the registry and data 
needed to be captured. When set-up accord-
ing to pre-defined criteria and goals, registries 
can provide sufficient data and a denominator 
needed to draw clinically relevant conclusions. 
Additionally, national registries can deliver bench-
marking information for clinicians, but since the 
Dutch market is relatively small, adherence to 
international collaborations for device evaluation 
and surveillance data is advisable. Finally, it is not 
only important that device registries are able to 
detect device problems early, but also provide the 
data that is necessary to guide patient care. 
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I
t is estimated that at this moment ap-
proximately 500,000 different medical 
devices are marketed in the Europe-
an union, ranging from devices such as 
plasters, needles, wheel chairs and surgical 
knives to blood glucose meters, MRI scanners, 
hip implants and cardiac implantable electron-
ic devices. Technological development has 
advanced in the past decades, leading to in-
creased life expectancy and improved quality of 
life. For example, implantable devices such as 
pacemakers and implantable cardioverter de-
fibrillators (ICDs) have both prolonged as well 
as improved the quality of the lives of many 
patients. However, each surgical intervention 
has a risk of complications. This is particularly 
true for implants, which by definition are foreign 
objects that are introduced into the body. In 
some cases – especially when a patient’s life 
depends on a functioning implant – failures and 
complications can be fatal. That is why implants 
are considered high risk devices and as such 
must comply with strict legal requirements and 
go through conformity assessment procedures 
before they are allowed on the market. Howev-
er, patient safety and trust in medical devices 
have taken serious blows in the recent past af-
ter some major incidents.
As described in chapter 1, and partly in chap-
ter 4, manufacturers have to provide proof 
that the device is safe and effective, and that 
it complies with the essential requirements as 
laid down in European Directives for medical 
devices. These requirements focus on a safe 
device design. Manufacturers must make an 
inventory of all possible risks that normal use 
and any reasonably foreseeable misuse of the 
device may generate. Any residual risks need 
to be mitigated preferably by alarms on the 
device itself and if this is not possible – as is 
the case for several implants – they should be 
mentioned in the instructions for use. A noti-
fied body will evaluate if the device is in con-
formity with the legal requirements. This is an 
organisation that has the expertise to assess 
medical devices and as such is appointed by 
its national authority. As part of this process, 
manufacturers have to provide clinical evi-
dence on the performance and safety of their 
device. For high risk devices (i.e. hip implants 
and pacemakers) they usually have to perform 
clinical studies. However, for several reasons, 
not all defects, failures and complications can 
be identified during such studies. Consequent-
ly, rare events and complications may only 
emerge after devices have been used for a 
longer period of time and in several thousands 
of patients. Therefore, post-market surveillance 
(PMS) is of major importance for the evalua-
tion of device performance in real-life. During 
the PMS phase manufactures must actively 
collect information on the use of their devices 
in order to implement appropriate measures for 
improvement, correct any failures when neces-
sary, and report any incidents to the competent 
authorities of European Member States. 
Competent authorities are governmental or-
ganisations responsible for market surveillance 
and law enforcement in the field of medical 
devices. Whereas marketing safe and effective 
devices, and taking every measure necessary 
in case of problems and failures, is primarily 
the responsibility of manufacturers, compe-
tent authorities are also allowed to prevent or 
suspend the marketing of devices or take oth-
er measures in case of severe (public) health 
threats. In contrast to medicinal products, reg-
ulatory oversight of medical devices puts more 
emphasis on post-market surveillance than on 
pre-market clinical studies. This has several 
reasons. There is a large number of medical 
devices on the market, which exceeds the num-
ber of registered drugs. Also, medical devices 
are more complex, more diverse and product 
development is more iterative combined with 
a shorter product life cycle. Additionally, there 
is a learning curve associated with technology 
adoption.
Accordingly, early detection of device problems 
is of great importance to authorities. They rely 
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on different sources of information regarding 
device safety. Examples are market surveil-
lance activities such as inspections of manu-
facturers and studies on products or product 
groups, but also obligatory vigilance reports 
by manufacturers, and, depending on national 
legislation, mandatory and/or voluntary reports 
by health care professionals and patients. Clin-
ical (device) registries are another important 
source of information. They may contain rele-
vant data to identify products with a lower than 
expected reliability and are able to identify pa-
tients who have been implanted with an inade-
quate implant. 
Therefore, the main objective of this thesis was 
to examine the usability of a number of cur-
rently available and accessible registries for 
information on implant performance and com-
plications of implant therapy. For the studies 
described in this thesis, existing registries have 
been used: a utilization register on pacemak-
ers (CPPR-SPRN) and a national hospital dis-
charge records database (LMR). These data-
bases are some of the few long-term registries 
available in the Netherlands.
Chapter 2 describes the studies that are 
based on the CPPR-SPRN database. The 
Netherlands Pacemaker Registry Foundation 
(CPPR-SPRN) was established in 1982 and 
at the same time the computerised Central 
Pacemaker Patients Registration was started. 
The registry aimed to collect information on 
patient and device characteristics, trends and 
annual numbers of implanted devices. Anoth-
er purpose of the registry was to inform health 
care professionals and patients about quality 
issues with pacemakers and leads. The results 
from our studies on this database showed that 
the registry provided important information on 
pacemaker therapy.
In chapter 2.1 we studied the number and 
types of pacemakers that have been implant-
ed between 1984 and 2006. The data showed 
that during this period nearly 97,000 patients 
received their first pacemaker. The number of 
first pacemakers used in the Dutch population 
gradually increased over the years: from 225 
implants per million inhabitants in 1984 to 423 
implants per million inhabitants in 2005. The 
type of pacemaker that was mainly implant-
ed changes from VVI to DDD. In case of VVI 
sensing and pacing both take place in the right 
ventricle; the pacemaker responds by inhibiting 
its activity when it detects a spontaneous heart 
signal. With DDD sensing and pacing take 
place in both the atrium and the ventricle and 
the pacemaker can respond by either inhibiting 
its activity or by triggering.
Furthermore, we studied the trends in duration 
of service time of pacemaker generators and 
the reasons for explantation as described in 
chapter 2.2. We found that during the study 
period 22.8% of the patients had at least one 
pacemaker generator replacement or removal 
and 4.5% had more than one. These explanta-
tions occurred after a mean of nearly 6.5 years 
and were done because of technical failures or 
complications in approximately 20% of the cas-
es. In addition to problems with the pacemaker 
generator, the leads that conduct the electri-
cal pulse to the heart can also be a source of 
failures and complications. In chapter 2.3 we 
therefore studied the percentage and reasons 
for explantations of leads. Our analysis showed 
that nearly 6.5% of the 138,225 leads that were 
implanted with first pacemaker generators have 
been replaced or explanted. The main reasons 
for this were insulation failures, infections and 
displacements. Infections were also the main 
reason for simultaneous explantation of the 
pacemaker generator and its accompanying 
leads. In general, it appeared that in more than 
70% of the generator replacements, the leads 
were not explanted.
For the studies described in chapter 3, we 
used the national hospital discharge records 
database (Landelijke Medische Registratie, 
LMR). This database was established for re-
search purposes and contains all admissions 
to Dutch academic and general hospitals be-
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tween 1986 and 2006. Because registry of 
interventions and diagnoses was mandatory, 
provided in codes, and independent from reim-
bursement, it provides a rich source of informa-
tion on hospital admissions. We studied three 
interventions that use medical devices and 
implants: total hip arthroplasty, clipping and 
coiling of subarchnoid haemorrhage and three 
treatments for trigeminal neuralgia.
In the study described in chapter 3.1, we in-
vestigated re-admissions following complica-
tions and/or re-operations within three months 
after total hip arthroplasty (THA). Approximate-
ly 9% of the 50,080 patients were re-admitted 
of whom 40% for complications. These consist-
ed mainly of mechanical problems and infec-
tions. Furthermore, we studied whether hos-
pital procedure volume was associated with a 
higher risk of re-admissions. A lower procedure 
volume appeared to be associated with com-
plications during index admissions, but such a 
relation was not found for re-admissions due 
to complications. We could only study mortal-
ity during admission, which was 0.2% during 
index admission and increased with each fol-
lowing re-admission. The actual mortality within 
3 months was unknown, because we did not 
have information on the number of deaths that 
occurred outside the hospital.
Chapter 3.2 describes the incidence and treat-
ment of non-traumatic subarachnoid haemor-
rhage (SAH). We found an incidence of SAH 
of 7.2 per 100,000 person-years. This type of 
haemorrhage can be treated by clipping or 
coiling of the aneurysm. The first treatment is 
an invasive neurosurgical procedure, while the 
other one is a less invasive endovascular pro-
cedure that can be performed by radiologists. 
We found that coiling procedures were not 
registered as such in the LMR data. By using 
data from the Integrated Primary Care Informa-
tion (IPCI) database, we found that 64% of the 
patients were treated by clipping of the aneu-
rysm, while 26% was treated by coiling. Due to 
the limited size of the patient groups, we could
not estimate the risk of death for each group.
Trigeminal neuralgia (TGN) is a severe form 
of facial pain in one or more branches of the 
fifth cranial nerve. In chapter 3.3 we studied 
readmissions for repeat procedures and com-
plications of the three most common invasive 
treatments of TGN. These are microvascular 
decompression (MVD), partial sensory rhizot-
omy (PSR), and percutaneous radiofrequency 
thermocoagulation (PRT). During MVD a teflon 
patch is introduced between the nerve and vas-
cular structure that is in contact with the nerve, 
the other treatments are aimed at destruction 
of (part of) the nerve. Most patients (84%) un-
derwent PRT, 11% MVD and 5% PSR. Nearly 
34% of the patients was re-admitted within one 
year primarily for complications, but also for a 
repeat procedure. The risk for readmission was 
lowest for MVD, whereas the risk for complica-
tions was lowest for PRT. After MVD most peo-
ple had a PRT as repeat procedure, whereas 
for PSR and PRT the same procedure was per-
formed again. Hospital procedure volume was 
partly associated with failure. However, this re-
lationship only applied to the second and fifth 
groups of surgical procedure volume.
Finally, chapter 4 provides a general discus-
sion of the results, including methodological 
considerations that need to be addressed with 
regard to epidemiological studies, future per-
spectives and a general conclusion. We also 
described several sources of post-market infor-
mation that are relevant for detection of compli-
cations and failure of devices. Recent failures 
and recalls of implants have highlighted the 
need for registries for the purpose of tracking 
and tracing implants to patient level, but also 
for quality assessment and performance data. 
Although several registries already existed, 
mainly in the field of orthopaedics and cardi-
ology, new registries in other fields have been 
initiated recently. They serve to inform several 
stakeholders, such as health care profession-
als, manufacturers, insurers and health author-
ities, for the benefit of patient safety and man-
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agement. Successful use of registries requires 
collaboration between these stakeholders, au-
thorities included. 
The data in our studies clearly support the vital 
role registries on implants and implant thera-
pies play in modern day health care. In addi-
tion, registries may fulfil a need as source for 
the formation of study cohorts and providing a 
reliable denominator for observational studies 
regarding implant use. In comparison to stud-
ies on drugs, such studies have been limited 
in the field of medical devices. However, the 
registries we have used were established for
other purposes and can no longer be consid-
ered state-of-the-art. An important limitation 
was that several implant characteristics rele-
vant for such analyses were not always includ-
ed in the data. This illustrates the importance of 
a priori definition of the purpose of the registry 
and the data needed to be registered. Addition-
ally, adherence to international collaborations, 
which have already been initiated in some ar-
eas, is at least advisable to be able to identify 
rare complications and failures, whereas it is 
also important that registries are able to provide 
data that is necessary to guide patient care. 
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N
aar schatting zijn er thans in 
de Europese Unie ongeveer 
500.000 verschillende medische 
hulpmiddelen op de markt. Deze 
variëren van pleisters, naalden, rolstoelen en 
chirurgische mesjes tot bloedglucosemeters, 
MRI-scanners, heupimplantaten en implan-
teerbare elektronische hulpmiddelen voor het 
hart. In de afgelopen decennia is de technol-
ogische ontwikkeling enorm toegenomen, 
waardoor zowel de levensverwachting als de 
kwaliteit van leven zijn toegenomen. Implan-
teerbare hulpmiddelen zoals pacemakers en 
implanteerbare cardioverter defibrillatoren 
(ICD’s) hebben bijvoorbeeld het leven van vele 
patiënten zowel verlengd als verbeterd. Elke 
chirurgische ingreep heeft echter een risico op 
complicaties. Dat geldt vooral voor implantat-
en, waarbij per definitie een vreemd object in 
het lichaam wordt gebracht. In sommige geval-
len – vooral wanneer het leven van een patiënt 
afhankelijk is van een functionerend implanta-
at – kunnen gebreken en complicaties fataal 
zijn. Daarom beschouwt men implantaten als 
hoogrisico hulpmiddelen en moeten ze voldoen 
aan strenge wettelijke eisen en een conformite-
itbeoordelingsprocedure doorlopen voordat 
de EU-lidstaten ze toelaten tot de markt. Als 
gevolg van enkele recente en ern stige inci-
denten zijn de patiëntveiligheid en het vertrou-
wen in medische hulpmiddelen echter ernstig 
geschaad.
Zoals beschreven in hoofdstuk 1, en deels 
ook in hoofdstuk 4, moeten fabrikanten be-
wijzen dat het hulpmiddel veilig en effectief 
is en dat het voldoet aan de essentiële eisen 
uit de Europese Richtlijnen voor medische 
hulpmiddelen. Deze eisen richten zich op een 
veilig ontwerp van het hulpmiddel. Fabrikant-
en moeten een inventarisatie maken van alle 
moge lijke risico’s die normaal gebruik en elk 
redelijk misbruik van een hulpmiddel met zich 
mee kan brengen. Elk resterend risico moeten 
ze vervolgens zoveel mogelijk inperken door 
alarmen op het hulpmiddel zelf en als dat niet 
mogelijk is – zoals bij verschillende implantaten 
– moeten fabrikanten ze vermelden in de geb-
ruiksaanwijzing. Een aangemelde (keurings)
instantie (notified body) zal evalueren of het 
hulpmiddel voldoet aan de wettelijke eisen. Een
notified body is een organisatie die de exper-
tise heeft om medische hulpmiddelen te beoor-
delen en daarvoor door zijn nationale autoriteit 
is aangewezen. Als onderdeel van deze proce-
dure moeten fabrikanten klinisch bewijs leveren 
over de geclaimde prestaties en veiligheid van 
hun hulpmiddel. Voor hoogrisico hulpmiddelen 
(bijvoorbeeld heupimplantaten en pacemakers) 
moeten zij doorgaans klinische studies uit-
voeren. Echter, om verschillende redenen is het 
niet altijd mogelijk om alle defecten, gebreken 
en complicaties tijdens zulke studies te iden-
tificeren. Als gevolg daarvan zullen zeldzame 
incidenten en complicaties pas bekend worden 
nadat hulpmiddelen voor een langere tijd en 
in enkele duizenden patiënten toegepast zijn. 
Daarom is post-market surveillance (PMS), het 
intensief volgen van hulpmiddelen nadat ze in 
gebruik genomen zijn, van groot belang voor de 
evaluatie van de prestaties van het hulpmiddel 
in het dagelijks gebruik. Tijdens de PMS-fase 
moeten fabrikanten actief informatie verzame-
len over het gebruik van hun hulpmiddelen om 
het product te verbeteren, waar nodig gebre-
ken te herstellen, en incidenten melden aan 
de bevoegde autoriteiten van de Europese 
Lidstaten.
Bevoegde autoriteiten zijn overheidsorganisa-
ties die verantwoordelijk zijn voor markttoezicht 
en handhaving op het gebied van medische 
hulpmiddelen. Fabrikanten zijn primair zelf 
verantwoordelijk voor het in de handel bren-
gen van veilige en effectieve hulpmiddelen en 
het nemen van elke benodigde maatregel in 
geval van problemen en gebreken. Dat neemt 
echter niet weg dat bevoegde autoriteiten de 
mogelijkheid hebben om de handel van hulp-
middelen te voorkomen of op te schorten, of 
andere maatregelen te nemen als die hulpmid-
delen een gevaar voor de (publieke) gezond-
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heid vormen. In tegenstelling tot geneesmid-
delen, richt het overheidstoezicht op medische 
hulpmiddelen zich meer op de fase nadat de 
producten in de handel gebracht zijn dan op 
klinische studies vooraf. Dit heeft verschillende 
redenen. Het aantal verschillende soorten me-
dische hulpmiddelen dat op de markt is, betreft 
het honderdvoudige van het aantal genees-
middelen. Daarnaast zijn medische hulpmid-
delen complexer en meer divers, en verloopt 
de productontwikkeling veel sneller gecom-
bineerd met een kortere levenscyclus dan bij 
geneesmiddelen. Daarnaast is er sprake van 
een leercurve bij het introduceren van nieuwe 
technieken. 
Als gevolg daarvan is het snel opsporen van 
problemen met hulpmiddelen van groot belang 
voor toezichthoudende autoriteiten. Ze zijn voor 
productveiligheid afhankelijk van verschillende 
informatiebronnen. Voorbeelden zijn toezichts-
activiteiten zoals inspecties bij fabrikanten en 
onderzoeken naar producten of productgroepen, 
maar ook de verplichte incidentmeldingen door 
fabrikanten en, afhankelijk van nationale wet-
geving, de verplichte en/of vrijwillige meldingen 
door zorgverleners en patiënten. Een andere 
belangrijke bron van informatie zijn de klin-
ische (hulpmiddelen) registraties. Deze kunnen 
relevante gegevens bevatten om producten met 
een lagere dan verwachte betrouwbaarheid op 
te sporen en kunnen patiënten identificeren die 
een gebrekkig implantaat hebben gekregen.
Het belangrijkste doel van dit proefschrift was 
daarom om de bruikbaarheid te onderzoeken 
van verschillende beschikbare en toegankelijke 
registraties voor informatie over de prestaties 
van en complicaties van behandelingen met im-
plantaten. Voor de studies die in dit proefschrift 
zijn beschreven, zijn bestaande registraties 
gebruikt: het kwaliteitsregister van pacemakers 
(SPRN) en de Landelijke Medische Registratie 
(LMR). Dit zijn enkele van de langetermijnreg-
istraties die in Nederland beschikbaar zijn.
Hoofdstuk 2 beschrijft de studies die geba-
seerd zijn op de SPRN-database. De Stichting 
Pacemaker Registratie Nederland (SPRN) is in 
1982 opgericht en in dat jaar is de geautoma-
tiseerde Centrale Pacemaker en Patiënten 
Registratie van start gegaan. De registratie 
had tot doel om informatie te verzamelen over 
patiënten- en pacemakerkenmerken, trends 
en het aantal pacemakers dat jaarlijks geïm-
planteerd werd. Een ander doel van de reg-
istratie was om zorgverleners en patiënten 
te informeren over kwaliteitsproblemen met 
pacemakers en leads. De resultaten van onze
studies op deze database lieten zien dat de 
registratie belangrijke informatie opleverde 
over de behandeling met pacemakers.
In hoofdstuk 2.1 hebben we het aantal en 
de typen pacemakers onderzocht die tussen 
1984 en 2006 geïmplanteerd zijn. De gegevens 
lieten zien dat in deze periode bijna 97.000
patiënten hun eerste pacemaker kregen. Het 
aantal eerste pacemakers dat artsen bij pa-
tiënten in de Nederlandse bevolking toepas-
ten, nam over de jaren geleidelijk toe: van 225 
implantaten per miljoen inwoners in 1984 naar 
423 implantaten per miljoen inwoners in 2005. 
Het meest geïmplanteerde type pacemaker
veranderde in die periode van VVI naar DDD. In 
het geval van VVI vinden het meten van hartac-
tiviteit (sensing) en het stimuleren van het hart 
(pacing) allebei in de rechter hartkamer plaats; 
de pacemaker reageert door zich in te houden 
(Inhibit) als hij een spontaan signaal van het 
hart zelf waarneemt. Bij DDD vinden sensing 
en pacing plaats in zowel de bezoem als het 
ventrikel, en kan de pacemaker afhankelijk van 
de hartactiviteit zowel een puls afgeven als in-
houden. 
Verder bestudeerden we de trends in de werk-
ingsduur van pacemaker generatoren en de 
redenen voor explantatie, zoals beschreven 
in hoofdstuk 2.2. We vonden dat tijdens de 
studie periode 22,8% van de patiënten ten-
minste één vervanging of verwijdering van de 
pacemaker heeft ondergaan en 4,5% meer 
dan één. Deze explantaties vonden gemiddeld
6,5 jaar na implantatie plaats en waren in on-
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geveer 20% van de gevallen het gevolg van 
technische gebreken of complicaties. Naast 
problemen met de pacemaker generator, kun-
nen ook de leads problemen geven. De leads 
zijn de geleidedraden die de elektrische puls 
van de pacemaker generator naar het hart 
overbrengen. In hoofdstuk 2.3 hebben we 
daarom het percentage en de redenen voor ex-
plantatie van leads onderzocht. Onze analyses 
toonden aan dat bijna 6,5% van de 138.225 
leads die met een eerste pacemaker generator 
geïmplanteerd waren, zijn vervangen of verwij-
derd. De belangrijkste redenen hiervoor waren 
gebreken aan de isolatielaag van de draden, 
infecties en ongewenste verschuiving van de 
leads. Infecties waren ook de belangrijkste re-
den voor gelijktijdige explantatie van de pace-
maker generator en de bijbehorende leads. In 
het algemeen bleek dat bij meer dan 70% van 
de vervangingen van de generator de leads 
niet verwijderd werden.
Voor de studies beschreven in hoofdstuk 3 
hebben we gebruik gemaakt van de Landelijke 
Medische Registratie (LMR). Deze database is 
voor onderzoeksdoeleinden opgezet en bevat 
alle opnames in Nederlandse academische 
en algemene ziekenhuizen tussen 1986 en 
2006. Aangezien registratie van behandelin-
gen en diagnoses verplicht was, deze vast-
gelegd werden in codes en dit onafhankelijk 
was van vergoeding, vormt de LMR een rijke 
bron aan informatie over ziekenhuisopnames. 
We bestudeerde drie behandelingen waar-
bij medische hulpmiddelen en implantaten
gebruikt werden: totale heupvervanging, clip-
pen en coilen van subarachnoïdale bloedingen, 
en drie behandelingen voor aangezichtspijn.
In de studie die beschreven is in hoofdstuk 
3.1 onderzochten we heropnames als gevolg 
van complicaties en/of heroperaties binnen 
drie maanden na een totale heupvervanging 
(total hip arthroplasty, THA). Bijna 9% van de 
50.080 patiënten werden opnieuw opgenomen, 
waarvan 40% voor complicaties. Deze beston-
den voornamelijk uit mechanische problemen 
en infecties. Daarnaast bestudeerden we of het 
aantal ingrepen per ziekenhuis geassocieerd 
was met een hoger risico op heropname. Een 
lager aantal ingrepen bleek geassocieerd te 
zijn met complicaties tijdens de indexopname, 
maar een dergelijke relatie vonden we niet 
voor heropnames als gevolg van complicaties. 
We konden alleen de sterfte tijdens opname 
onderzoeken; deze bedroeg 0,2% tijdens de 
indexopname en nam toe met elke volgende 
heropname. De daadwerkelijke sterfte binnen 
drie maanden was onbekend, omdat we geen 
informatie hadden over het aantal sterfgevallen 
buiten het ziekenhuis.
Hoofdstuk 3.2 beschrijft de incidentie en be-
handeling van niet-traumatische subarach-
noïdale bloedingen (SAH). We vonden een 
incidentie (aantal nieuwe gevallen) van SAH 
van 7,2 per 100.000 persoonsjaren. Dit type 
bloeding kunnen artsen behandelen door een 
clip op het aneurysma te plaatsen of er een 
draad in te brengen die zich opkrult (coil). De 
behandeling met een clip is een invasieve neu-
rochirurgische procedure, terwijl de andere een 
minder invasieve endovasculaire behandeling 
is die een radioloog kan uitvoeren. We vonden 
dat de behandeling met coiling niet als zodanig 
geregistreerd was in de LMR-data. Door data 
te gebruiken van de Integrated Primary Care
Information (IPCI, een database van huis-
artsen), vonden we dat 64% van de patiënten 
werd behandeld met clipping van het aneurys-
ma, terwijl 26% werd behandeld door coiling. 
Vanwege de beperkte grootte van deze patiën-
tengroepen konden we het risico op overlijden 
binnen elke groep niet berekenen.
Aangezichtspijn, of trigeminusneuralgie (TGN),
is een ernstige vorm van gezichtspijn in een
of meerdere takken van de vijfde aan-
gezichtszenuw. In hoofdstuk 3.3 hebben we 
de heropnames bestudeerd voor herhaal-
procedures en complicaties van de drie meest 
voorkomende behandelingen van TGN. Dit zijn 
microvascular decompression (MVD), partial 
sensory rhizotomy (PSR) en percutaneous 
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radiofrequency thermocoagulation (PRT). Bij 
MVD brengen artsen een teflonschijfje in tus-
sen de zenuw en het bloedvat dat de zenuw 
raakt; de andere behandelingen richten zich op 
vernietiging van (een deel van) de zenuw. De 
meeste patiënten (84%) ondergingen PRT, 11% 
MVD en 5% PSR. Bijna 34% van de patiënten 
kwam binnen een jaar terug voor heropname 
als gevolg van complicaties, maar ook voor 
herhaalingrepen. Het risico op heropname was 
het kleinst bij MVD, terwijl het risico op compli-
caties het kleinst was voor PRT. De patiënten 
die MVD hadden ondergaan, kregen het vaakst 
PRT als herhaalingreep, terwijl na PSR en PRT 
dezelfde procedure opnieuw gedaan werd. Het 
aantal ingrepen per ziekenhuis was deels geas-
socieerd met het falen van de indexingreep. Dit 
verband gold echter alleen voor de tweede en 
vijfde volumegroep van aantal ingrepen.
Tot slot bevat hoofdstuk 4 de algemene dis-
cussie van de resultaten, inclusief methodol-
ogische  overwegingen die van belang zijn bij 
epidemiologische studies, verkenningen voor 
de toekomst en een algemene conclusie. Daar-
naast hebben we verschillende bronnen voor 
PMS-informatie beschreven die relevant zijn 
voor het opsporen van complicaties en geb-
reken van hulpmiddelen. Recente gebreken 
en terugroepacties van implantaten illustreren 
de noodzaak voor registraties met als doel het 
herleiden van implantaten tot op patiëntniveau, 
maar ook voor gegevens over prestaties en ten 
behoeve van kwaliteitsbeoordeling. Ondanks 
dat er al verschillende registraties bestaan, 
voornamelijk in de orthopedie en cardiologie, 
zijn recentelijk op andere gebieden nieuwe
registraties opgezet. Zij dienen voor het in-
formeren van verschillende belanghebbenden, 
zoals zorgverleners, fabrikanten, verzekeraars 
en toezichthouders, ten bate van de veiligheid 
en behandeling van patiënten. Succesvol geb-
ruik van registraties vereist samenwerking tus-
sen deze belanghebbenden, inclusief toezicht-
houders.
De resultaten van onze studies leveren een 
duidelijke onderbouwing van de essentiële rol 
die registraties van implantaten en behandelin-
gen in de moderne gezondheidszorg spelen. 
Daarnaast blijkt dat registraties een noodzaak 
vervullen als belangrijke bron voor de vorming 
van studiecohorten en het leveren van een be-
trouwbare noemer voor observationele studies 
over het gebruik van implantaten. In vergelijking 
met studies op geneesmiddelen is het aantal 
studies op het gebied van medische hulpmid-
delen beperkt in aantal. De registraties die wij 
gebruikten zijn echter voor andere doeleinden 
opgezet en zijn niet langer state-of-the-art. Een 
beperking was dat verschillende gegevens 
over de implantaten die relevant zijn om mee te 
nemen in de analyses, niet altijd beschikbaar 
waren. Dit onderschrijft het belang om vooraf 
het doel van de registratie en de benodigde 
gegevens daarvoor te definiëren. Daarnaast is 
het op zijn minst te adviseren om aan te sluiten 
bij internationale samenwerkingsverbanden, 
die op sommige terreinen al tot stand gekomen 
zijn, om zeldzame complicaties en gebreken 
te kunnen opsporen. Tot slot is het belangrijk 
dat registraties in staat zijn om gegevens te le-
veren die nodig zijn om te adviseren over de 
zorg voor patiënten.
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ijn promotietraject heeft lang 
geduurd, daar zal ik niet om-
heen draaien. Een combinatie 
van een afwijkende construc-
tie, weinig tijd naast werk, tijdrovende databe-
werking, en niet in de laatste plaats mijn karak-
tereigenschappen. Een perfectionist die werk, 
onderzoek en relaties allemaal op het hoogste 
niveau wil uitvoeren en onderhouden, maakt 
het zichzelf niet gemakkelijk. Zo dat is eruit! 
Maar nu ligt het boekje er toch maar mooi en ik 
ben heel tevreden met het eindresultaat. Door 
eerdergenoemde constructie van een promotie 
naast een vaak veeleisende baan, voelde het 
voor mij vaak als een eenzaam traject. Echter, 
je doet zoiets nooit helemaal alleen. Daarom 
wil ik diverse mensen bedanken voor hun bij-
drage en steun. Omdat dat in de loop van de 
jaren best veel mensen zijn geweest, en ik 
zoals de meesten van jullie weten zelden kort 
van stof ben, zal dit dankwoord meerdere pagi-
na’s in beslag nemen.
In de eerste plaats wil ik prof.dr. B.H.Ch. Strick-
er en prof.dr. J.H. Kingma bedanken. Beste 
Bruno, nadat de plannen voor een promotietra-
ject begonnen uit te kristalliseren, ben ik onder 
jouw hoede gekomen. Als toch wat vreemde 
eend in de bijt, een medisch technoloog tussen 
de geneesmiddelenbewakers, schoof ik aan bij 
jouw onderzoeksgroep voor farmacovigilantie. 
Ik heb bepaald geen standaard promotietraject 
doorlopen, zelfs in vergelijking met je andere 
promovendi die zowel in Rotterdam als bij de 
inspectie werk(t)en. Ik weet ook niet of ik an-
deren deze constructie kan aanbevelen. Maar 
ik wil je bijzonder hartelijk danken dat je het al 
die jaren met me volgehouden hebt. Ik ben blij 
en dankbaar met alles wat ik van je heb geleerd 
op het gebied van epidemiologie en statistiek. 
Op momenten dat het moeizaam ging, heb je 
me altijd op het hart gedrukt om niet te stop-
pen, en hoewel dat soms een aanlokkelijke 
optie was, heb ik dat nooit serieus overwogen. 
Ik heb altijd volgehouden dat ik ‘A’ heb gezegd 
en dus ook ‘B’ zou doen. Het heeft lang gedu-
urd, maar het resultaat ligt er nu. Ik denk dat 
we daar allebei een goed gevoel over hebben. 
Prof.dr. Kingma, beste Herre, hoewel onze 
wegen nu gescheiden zijn, was deze promo-
tie er zonder jou waarschijnlijk niet gekomen. 
Gedurende je positie als Inspecteur-Generaal 
van de Inspectie voor de Gezondheidszorg wil-
de je ook enkele promovendi begeleiden. Ik wil-
de me naast mijn werk ook op dit gebied graag 
verder ontwikkelen, dus één en één was twee. 
Dank dat je dit mogelijk hebt gemaakt.
Een bijzonder woord van dank voor prof.dr. 
N.M. van Hemel is op deze plek zeker gerecht-
vaardigd. Ik ben ontzettend dankbaar voor wat 
u voor mij en mijn promotie heeft betekend. Tij-
dens het hele proces van analyseren, schrijven, 
submitten en reviseren heb ik heel veel gehad 
aan onze (veelal telefonische) overleggen. Dat 
ik zelf geen arts ben, maakte dat ik soms twi-
jfelde over de interpretatie van de resultaten en 
opmerkingen van reviewers. Onze besprekin-
gen gaven me altijd weer het vertrouwen dat 
we op de goede weg waren. Veel dank voor 
uw betrokkenheid, ook wat betreft de afronding 
van mijn proefschrift!
Graag wil ik op deze plek ook de commissi-
eleden bedanken voor het plaatsnemen in de 
commissie. Prof.dr. C. Wagner, prof.dr. J.W. 
Deckers en prof.dr. J.A.N. Verhaar in de kleine 
commissie en naast prof.dr. N.M. van Hemel 
ook prof.dr. I.P. Leistikow en prof.dr. K.G.M. 
Moons in de grote commissie.   
Prof.dr. A. Hofman, voormalig hoofd van de af-
deling epidemiologie van de medische faculteit 
van het ErasmusMC en grondlegger van de 
ERGO-studie, wil ik van harte bedanken voor 
het feit dat ik via een gastvrijheidsaanstelling 
werkzaam mocht zijn bij de afdeling. Ik heb 
enorm veel bewondering voor wat u heeft 
bereikt met ERGO. Er zijn al veel belangrijke 
wetenschappelijke inzichten en promoties uit 
deze populatiestudie voortgekomen. Daar-
naast heb ik met plezier deelgenomen aan uw 
colleges tijdens de NIHES-master. Prof.dr. A. 
Ikram, het huidige hoofd van de afdeling ep-
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idemiologie, wil ik eveneens bedanken voor 
de gastvrijheid. Arfan, hoewel we weinig met 
elkaar te maken hebben gehad, heb ik ook voor 
jou veel bewondering met wat je op jonge leeft-
ijd al hebt bereikt. Veel succes met het voortz-
etten van het belangrijke en mooie werk van 
de afdeling.
Hoewel mijn onderzoek zich niet op ERGO 
gericht heeft, heb ik voor de validatie van ge-
gevens bij enkele studies wel gebruik gemaakt 
van de ERGO-data. Daarom wil ik bij deze de 
deelnemers uit Ommoord bedanken, evenals 
de medewerkers die de ERGO-studie mogelijk 
hebben gemaakt. Speciale dank voor Jolande 
Verkroost voor de hulp bij het valideren en 
opzoeken van informatie. Jouw werk vindt wat 
meer op de achtergrond plaats, maar is o zo 
belangrijk! Nano wil ik hartelijk bedanken voor 
de ICT-ondersteuning.
Drie artikelen uit mijn proefschrift zijn geba-
seerd op de SPRN-registratie. Dat was zonder 
Carla en Arnold niet mogelijk geweest. Veel 
dank voor het beantwoorden van mijn vragen 
en het meedenken. Ik waardeer het zeer dat 
jullie een aantal keren ‘even’ vanuit Groningen 
naar Utrecht zijn afgereisd voor overleg. Verder 
ben ik alle professionals die aan SPRN hebben 
bijgedragen zeer erkentelijk.
En dan kom ik nu bij iemand die een cruciale 
rol gespeelt heeft voor zowel mijn carrière 
bij de inspectie als in de beginfase van mijn 
promotie-onderzoek: dr. J. de Koning, of ‘ome 
Han’ zoals ik u stiekem noem. Als stagiaire 
kwam ik in 2000 onder uw begeleiding bij de 
inspectie werken en na dat half jaar nam u 
me als projectmedewerker in dienst voor het 
project bloedgebruik in ziekenhuizen. Daarna 
stroomde ik door naar de afdeling medische 
technologie, waar ik nog steeds zit. In de 
beginjaren heeft u me ook begeleid bij mijn 
onderzoek. U heeft een paar keer het verhaal 
verteld over uw eigen promotietijd en het Sin-
terklaasgedicht dat sprak over die vermaledi-
jde promotie en dat vermaledijde proefschrift. 
Ik begrijp de strekking daarvan maar al te 
goed… Heel veel dank voor uw begeleiding, 
ik heb er veel van geleerd en denk nog regel-
matig terug aan de begintijd op de 13e verd-
ieping van de D-toren in de Resident! In de 
beginjaren heb ik ook begeleiding gehad van 
Prof.dr. M. Sturkenboom van de afdeling me-
dische informatica van het ErasmusMC. Beste 
Miriam, dank daarvoor. 
Van mijn leidinggevenden bij de inspectie heb 
ik altijd veel steun gehad om aan mijn onder-
zoek te werken. In de eerste jaren ook in de 
vorm van tijd. Mijn direct leidinggevenden in 
de loop der jaren ben ik hiervoor zeer erken-
telijk. Daarbij wil ik Paul ‘sr.’, Rob, Hans ter 
S., en Jos bij naam noemen. Ook de Inspec-
teurs-Generaal die na Herre Kingma kwamen, 
prof.dr. G. van der Wal en (de huidige IG) dr. 
R. van Diemen-Steenvoorde, en voormalig 
hoofdinspecteur Josée Hansen wil ik harteli-
jk bedanken, zowel voor de mogelijkheid om 
onderzoek te doen als voor de persoonlijke 
belangstelling.
Dan mijn collega’s van de inspectie. Mijn 
teamgenoten wil ik danken voor hun belang-
stelling en steun. G., met jou werk ik het meest 
samen, we hebben geregeld onze handen vol 
aan onze gezamenlijke implantatendossiers. Ik 
zeg het waarschijnlijk niet vaak genoeg, als ik 
het al een keer gezegd heb, maar ik ben heel 
blij met een collega zoals jij! Collega’s van de 
IVD-vakgroep, samen zorgen we ervoor dat er 
genoeg aandacht blijft voor de IVD’s. Het is fijn 
samenwerken met jullie, dank ook voor jullie 
belangstelling. Kees, jij in het bijzonder, fijn om 
af en toe even mijn verhaal kwijt te kunnen en 
de ervaringen uit jouw promotietraject te horen. 
Het zorgde ervoor dat ik weer even kon relati-
veren. Daarom ben ik blij dat je op 6 december 
als paranimf naast me staat!
Andere collega’s en oud-collega’s van de afdel-
ing medische technologie ook dank voor jullie 
belangstelling. Het is een eer om met zoveel 
fijne collega’s te mogen samenwerken! Voor de 
nieuwe collega’s die op het moment dat ik dit 
schrijf net de afdeling zijn komen versterken: ik 
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kijk uit naar onze samenwerking!
Ook (oud-)collega’s van andere afdelingen dan 
medische technologie wil ik bedanken voor hun 
belangstelling. Een bijzonder woord van dank 
is voor Irene H.: jou wil ik hartelijk bedanken 
omdat je mij bij professor Van Hemel geïntro-
duceerd hebt. Op een moment dat ik zoekende 
was naar de verdere richting van mijn onder-
zoek en dacht aan een studie op het gebied 
van de cardiologie, pakte jij meteen de telefoon 
en belde jouw voormalige opleider Norbert van 
Hemel. Een afspraak was snel gemaakt en het 
resultaat zit in dit boekje in de vorm van drie 
artikelen over pacemakers en leads. Ik kan dus 
wel stellen dat jij op een kruispunt in mijn pro-
motietraject een belangrijke rol hebt gespeeld! 
Dank ook voor je interesse. Beste Janneke van 
L., bedank voor de fijne samenwerking. Aan 
het begin van mijn promotie hebben we bij de 
inspectie samen onderzoek gedaan voor de 
Staat van de Gezondheidszorg. Jammer dat we 
het artikel dat daaruit voortkwam niet hebben 
kunnen publiceren. 
Van de afdeling epidemiologie en medische 
informatica van de medische faculteit Eras-
musMC, wil ik co-auteurs Maarten, Seppe en 
Roelof heel hartelijk danken voor de samen-
werking. Maarten, ik heb groot ontzag voor 
jouw kennis en inzicht. Ik vreesde stiekem de 
momenten dat ik manuscripten met jouw com-
mentaar terugkreeg, maar ze werden er (uiter-
aard) altijd beter van! Seppe, vrolijke noot bij 
medische informatica, je filmpjes voor collega’s 
die gingen promoveren zijn volgens mij legend-
arisch. Roelof, het was een plezier om met jou 
aan het SAB-artikel te werken. Het was prettig 
om af en toe even frustraties te kunnen delen. 
Dank daarvoor! Belangstelling, gezelligheid en 
een klankbord waren er in Rotterdam ook bij 
kamergenoten (waarvan sommigen tevens in-
spectiecollega’s waren).
Thuis zeggen we voor de grap weleens tegen 
elkaar “we hebben te veel vrienden”, maar we 
zijn natuurlijk gewoon geluksvogels met zoveel 
lieve mensen om ons heen! Ik wil ze allemaal 
bedanken voor hun belangstelling, steun en 
vriendschap. Jullie weten wie jullie zijn! Marit, 
wat fijn dat je mijn paranimf wilt zijn! 
Jos, ik heb jou als leidinggevende al bedankt 
voor je steun, maar naast leidinggevende bes-
chouw(de) ik je ook als mijn mentor. Ik heb veel 
van je geleerd en dat doe ik nog steeds. Na 
je vertrek bij de inspectie hebben we contact 
gehouden en ik ben blij met deze bijzondere 
vriendschap. Ik weet dat je er soms een hard 
hoofd in had, maar nu is het af. Ik weet dat je 
trots op me bent en dat betekent veel voor me. 
Ik reken op nog meer goede gesprekken in de 
toekomst!  
Mijn schoonouders, mijn zwagers en 
schoonzus, en mijn ‘schoonoma’ wil ik heel 
hartelijk bedanken voor hun belangstelling, 
steun en gezelligheid. Het was fijn om op de 
momenten dat we samen waren voor feestda-
gen, vakantieweekjes, verjaardagen of ge-
woon zomaar, even mijn gedachten te ver-
zetten. Ik ben gezegend met een schoonfamilie 
zoals jullie! Ooms en tantes, ook die uit mijn 
schoonfamilie, en de vrienden van mijn ouders 
wil ik bedanken voor hun belangstelling hoe het 
met mij en mijn onderzoek ging in de loop der 
jaren.
Lieve pap en mam, het is goed gebruik om 
de belangrijkste mensen aan het eind van 
het dankwoord te noemen. Jullie vonden het 
weleens moeilijk om te vragen hoe het met 
mijn onderzoek ging, omdat jullie wel zagen 
dat het me niet altijd gemakkelijk afging. Het 
was ook inderdaad niet altijd mijn favoriete 
gespreksonderwerp. Ik wil jullie uit het diepst 
van mijn hart bedanken voor jullie steun en 
de mogelijkheden die jullie mij geboden heb-
ben. De oma’s hebben nog meegemaakt dat 
ik hieraan begonnen ben, ze zien het me niet 
meer afmaken, maar ze zouden vast trots ge-
weest zijn op hun enige kleindochter.
Mijn allerliefste echtgenoot, vriend, klank-
bord, studiegenoot en maatje, al 22 jaar 
samen . Dat dit proefschrift er ligt is voor 
een heel groot deel aan jou te danken, en 
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niet alleen omdat je de opmaak en de cov-
er gedaan hebt (die er beiden geweldig uitz-
ien!). Gedurende dit hele traject was je mijn 
rots in de branding. Je hebt me door moeilijke 
periodes heen geholpen en stond altijd klaar 
om te helpen met praktische zaken als ik het 
druk had of tegen deadlines aan zat, of door 
er samen op uit te gaan. Ik prijs mezelf geluk-
kig met iemand zoals jij. Ik hou van je!
Het dankwoord in deze digitale versie is op 
sommige punten ingekort.
155Dankwoord Chapter 6

Chapter 7
Bibliography
Bibliography158 Chapter 7
159Bibliography Chapter 7
Manuscripts based on the studies in this thesis
Chapter 2.1
Utilisation of cardiac pacemakers over a 20-year period: Results from a nationwide pacemaker 
registry.
De Vries LM, Dijk WA, Hooijschuur CA, Leening MJ, Stricker BH, van Hemel NM.
Neth Heart J. 2017 Jan;25(1):47-55. doi: 10.1007/s12471-016-0880-0.
Chapter 2.2
Trends in service time of pacemakers in the Netherlands: a long-term nationwide follow-up study.
De Vries LM, Leening MJ, Dijk WA, Hooijschuur CA, Stricker BH, van Hemel NM.
Neth Heart J. 2017 Sep; 25:581–591. doi: 10.1007/s12471-017-1024-x. [Epub ahead of print]
Chapter 2.3
Trends in replacement and extraction of pacemaker leads in the Netherlands: a long-term 
nationwide follow-up study.
De Vries, Leening MJ, Dijk WA, Hooijschuur CA, Stricker BH, van Hemel NM.
Submitted
Chapter 3.1
Complications after hip arthroplasty and the association with hospital procedure volume.
De Vries LM, Sturkenboom MC, Verhaar JA, Kingma JH, Stricker BH.
Acta Orthop. 2011 Oct;82(5):545-52. doi: 10.3109/17453674.2011.618907.
Chapter 3.2
Incidence, treatment, and case-fatality of non-traumatic subarachnoid haemorrhage in the 
Netherlands.
Risselada R*, de Vries LM*, Dippel DW, van Kooten F, van der Lugt A, Niessen WJ, Firouzian A, 
Stricker BH, Sturkenboom MC.
Clin Neurol Neurosurg. 2011 Jul;113(6):483-7. doi: 10.1016/j.clineuro.2011.02.015.
*These authors equally contributed to this paper.
Chapter 3.3
A nationwide study of three invasive treatments for trigeminal neuralgia.
Koopman JS, de Vries LM, Dieleman JP, Huygen FJ, Stricker BH, Sturkenboom MC.
Pain. 2011 Mar;152(3):507-13. doi: 10.1016/j.pain.2010.10.049.
Other published manuscripts
IVD Classification – Proposal for a European Rule-based Decision Model.
Hollestelle M, De Bruijn A, De Vries LM, Kraus JJ.
RAJ Devices. 2007;(nov/dec):373-9.

Chapter 8
PhD portfolio
PhD portfolio162 Chapter 8
163PhD portfolio Chapter 8
Research skills
2005 – 2006: Master or Science in Clinical Epidemiology, Netherlands Institute for Health
  Sciences, Erasmus University, Rotterdam
2006:   Additional courses during the Erasmus Summer Programme
2016:   Workshop Systematic Literature Retrieval in Pubmed
2016:   Workshop Systematic Literature Retrieval in other databases (i.e. Embase)
Teaching
2006:   Supervising medical students during a NIHES course, Erasmus University
  Medical Center, Rotterdam, the Netherlands
Other
In her capacity as Inspector for Medical Technology at the Dutch Health and Youth Care 
Inspectorate, she has been involved in several activities regarding the market surveillance of 
medical devices, amongst others the following:
• Market surveillance activities and studies on implants
• Contribution to the development and implementation of the new medical devices regulations 
(2012-current)
• Member of the IVD Technical Group and its predecessor; an expert group of European 
Member States, the European Commission, industry and other stakeholders on regulatory 
issues regarding in-vitro diagnostic medical devices (2002-current)
• Manager of a project on cosmetic care (2015-current)
• Presentation on cosmetic devices and treatments at the meeting of Competent Authorities 
on Medical Devices (CAMD) in Amsterdam (2016)
• Several presentations on IVDs, medical technology and legislation for stakeholders

Chapter 9
About the author
About the author166 Chapter 9
167About the author Chapter 9
L 
aura Marieke de Vries (1977) did a 
Master’s study in medical biology at 
the Free University (VU) in Amster-
dam. Her first internship was at the 
Free University Medical Center, department of 
clinical genetics and antropogenetics, in the re-
search group of prof.dr. Hans Joenje. 
This internship was followed by a second in-
ternship at the municipal health service GGD 
Amstelland-De Meerlanden, under supervision 
of Nicole Penterman. At the GGD, she devel-
oped an educational program on public health 
screening for breast cancer aimed at women of 
Turkish and Moroccan descent. 
In her final year at the university, she followed 
the graduation course Policy & Management in 
Healthcare. Part of this course was a six-month in
ternship at the Dutch Healthcare Inspectorate. 
During this internship, she studied the reports 
on medical incidents that occurred in hospitals 
between 1993 and 2000, under supervision of 
dr. J. de Koning. 
In 2005, she also started the work described 
in this thesis, under supervision of prof.dr. Bru-
no Stricker. In the same year, she followed the 
NIHES master Clinical Epidemiology, for which 
she obtained a certificate in 2006. 
She still works at the Inspectorate (which is now 
called Dutch Health and Youth Care Inspec-
torate), currently as Coordinating/Specialist In-
spector. She is involved in market surveillance 
and law enforcement activities in the areas of 
implants and in-vitro diagnostic medical devic-
es. Additionally, she contributed to the develop-
ment, and is involved in the implementation, of 
the new regulations on medical devices.  

